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Abstract 
Sharad Ramchandra Kamble 
Title: “Molecular Interactions in Pharmaceutical Preformulation and 
Supramolecular Complexes”. 
Subtitle: ‘Structural Properties Governing Drug-Plasma Protein Binding and 
Investigation of Amino Acids Co-crystals’. 
Keywords: Drug-Plasma Protein Binding, HPLC, Linear Free Energy 
Relationship, Abraham’s descriptors, Amino acids, Co-crystallisation, Non-
Hygroscopic Effervescent Tablets. 
 
The study of pharmaceutical preformulation includes the evaluation of 
pharmacokinetic, pharmacodynamic and physicochemical properties of the drug 
molecules that aid the formulation. However, it has a limited role in determining 
drug dosage optimisation in the formulation. The study of drug-Plasma Protein 
Binding (PPB), and the lipophilicity, solubility, and ionic behaviours of the 
desired drug molecules addresses the gap and enhances our undertraining 
related to the behaviour of the drug molecules in the body. 
The High-Performance Liquid Chromatography (HPLC) technique was used in 
the current study to assess drug-PPB interaction. Using Michael Abraham’s 
‘Linear Free Energy Relationship’ (LFER) method, two major plasma proteins 
namely, Human Serum Albumin as HSA and α-1-Acid Glycoprotein as AGP, 
were used and the structural properties governing drug-plasma protein binding 
was determined. This is the first time that the effect of ionised species on PPB 
has been quantitatively evaluated. 
In addition, the molecular interactions also play a key role in the supramolecular 
complexes of co-crystals. The project also evaluated the co-crystallisation 
ii 
 
process and its effect on physicochemical properties of the drug. In the current 
study, amino acids (AAs) have been observed to be a prominent source of 
coformers. The AAs showed co-crystals formation with carboxylic acids, non-
steroidal anti-inflammatory drug (NSAID) and citric acid which overcome the 
hygroscopicity problems and improved the physical stability issues during 
storage. This study has also identified a new formulation which is helpful for 
improvement in the stability of effervescent tablets at various relative humidity 
(RH) conditions which will reduce the manufacturing cost associated with the 
production of effervescent tablets.   
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Chapter 1 Introduction 
The journey of a drug molecule passes through various stages from discovery 
to development and finally reaches the formulation. The preformulation studies 
are required for the development of formulations. These studies involve the 
thoughtful assessment of physicochemical, pharmacokinetic and 
pharmacodynamic properties of the selected drug molecule. It is helpful to meet 
the expected requirements for the drug design, development and delivery. 
In the preformulation studies, the drug-plasma protein binding (drug-PPB) study 
also becomes the vital part. It is a necessity nowadays along with the studies of 
solubility, lipophilicity and ionic behaviour of the desired drug molecule before 
its formulation (Vuignier et al. 2010a). Additionally, the selection of the 
crystalline material of considerable stability and solubility is one of the crucial 
parts of the solid-state preformulation studies of an active pharmaceutical 
ingredient (API) (Jones et al. 2006). 
Drug-PPB has an impact on the pharmacokinetic and pharmacodynamic activity 
of the drug molecule. This impact includes the disposition of drugs, their 
transportation and availability at the liver metabolism and excretion as well as 
the final drug concentration at the site of action. Because, once drug entered 
and distributed around the circulatory system, it binds to plasma proteins in 
varying degrees. In general, such binding is reversible and an equilibrium exists 
between bound and free molecular forms of the drug. In most cases, only the 
free drug molecules can cross membrane barriers, be distributed to tissues and 
then exert therapeutic effects (Lindup and Orme 1981; Vuignier et al. 2010a). 
Thus, it is necessary to study the drug-PPB before formulation. Ghafourian et 
al. have explained that this molecular binding is happening due to the 
hydrophobic and electrostatic interactions such as van der Waals and hydrogen 
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bonding (Ghafourian and Amin 2013). It was observed by Vuignier et al. that, 
the drug-PPB was studied in many ways, like Equilibrium Dialysis (ED), Ultra-
Filtration (UF) and Ultra-Centrifugation (UC) methods (Vuignier et al. 2010a). 
However, those previous methods were time-consuming, non-robust and 
showed inconsistency in results when repeated. Recently, Ghafourian et al.in 
2013, have shown a ‘quantitative structure-activity relationship’ based approach 
for drug-PPB in their studies (Ghafourian and Amin 2013). They observed PPB 
could be modelled using simple regression trees or multiple linear regressions 
with reasonable model accuracies. Thus, it could be helpful to identify the 
governing molecular factors for a high PPB. Valko et al. reported that there is 
involvement of ionic behaviour of molecules in drug-PPB. They used the fast 
gradient HPLC technique in their drug-PPB study (Valko et al. 2003). The 
current study also focuses on investigating such molecular interactions, and it is 
based on an approach of ‘structural properties governing drug-PPB’ using 
HPLC method and quantification of the ionic effects by using multiple linear 
regression (MLR) by Minitab 16 software and LFER method application. 
Similarly, there is another area where such molecular interactions are involved 
and explored widely, is the area of supramolecular complexes. The best 
example is co-crystals. “Co-crystals are the crystalline materials made up of two 
or more different molecules. Specifically, drug molecules and the co-crystal 
former molecule known as coformer are held together in one single lattice, 
either by hydrogen bonds, halogen bonds or π-π interactions”. Since last few 
decades, the term “co-crystals” was under debate. Recently, in August 2016 
United States Food and Drug Administration (US-FDA) department accepted 
the co-crystal term as described above (FDA 2016). 
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The co-crystallisation technique has recently demonstrated increased interest 
and plays an important role in the field of solid-state drug dosage formulations. 
The co-crystallisation improves the physicochemical properties of the active 
pharmaceutical ingredient (API) (Jones et al. 2006). These properties include 
stability, solubility, hygroscopicity and compressibility which could improve 
through the co-crystallisation process. It suggests that the co-crystallisation 
process can be used to reduce the hygroscopicity of the reacting molecules. 
Therefore, the reacting molecules improve in-process stability and storage 
stability to tolerate the change of different relative humidity (RH) conditions. 
The physical stability of the drug or its formulation depend on their 
hygroscopicity. If they are hygroscopic, they could interact with surrounded 
moisture and may dissociate. The structural integrity collapses and molecules 
stability is damaged. Therefore to avoid such contacts with moisture, these 
hygroscopic drug formulations are carried out in controlled environmental 
conditions. The final products are also packaged in an airtight, leakproof, 
moisture-proof packaging materials and are stored in a  moisture controlled 
area. It increases the cost of manufacturing as well as storage. 
However, through the process of cocrystallisation, such hygroscopic 
compounds may improve their physical stability and make them less or non-
hygroscopic. It will be helpful for reducing the cost of manufacturing, packaging 
and storage. 
1.1 Aims and Objectives 
The main aim of this research was to identify the molecular interactions involved 
in the pharmaceuticals preformulation and the supramolecular complexes 
limited to the co-crystals area of studies. To investigate such interactions role in 
drug-plasma protein binding studies as well as in the co-crystal formation. To do 
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an investigation of the role of structural properties in the molecular interactions 
between the drug and plasma protein. To understand how to use these 
interactions data for dosage optimisation in the formulation and to avoid the 
toxic effect. To understand the competitors in binding and choose alternative 
generally recognised as safe (GRAS) molecule to avoid moisture uptake in 
solid-state formulation through co-crystal technique. To improve the storage 
stability of the hygroscopic molecules by making them less/ non-hygroscopic 
through co-crystal method. 
 
Figure 1.1 Research structure of the current work 
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Specific aims and objectives of this research work were: 
1) To investigate drug-plasma protein interaction by using the high-
performance liquid chromatography technique.  
2) To identify structural properties which are important for drug-plasma 
protein binding using a broad range of structurally diverse compounds 
including drugs.  
3) To develop computational models for predicting drug-plasma protein 
binding interaction based on these properties. 
4) To develop the HPLC method for Drug- Human serum albumin/HSA and 
Drug-α-1-acid glycoprotein/AGP (plasma proteins) interaction studies 
and use of linear free energy relationship method for data analysis.  
5) To check amino acids as a coformers and synthesis of co-crystals. 
6) To improve the in-process and storage stability of hygroscopic 
compounds using the co-crystallisation method and its application. 
7) To understand the molecular interaction of drug-plasma protein binding 
and supramolecular complexes such as co-crystals. 
1.2 Thesis outline 
The thesis outline is represented in Figure 1.2 and after that described in detail. 
Figure 1.2 indicates the outline of the thesis. 
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Figure 1.2 Outline of Thesis 
Chapter 1 provides an introduction, aims and objectives and thesis outline. 
Chapter 2 provides background and is divided into two major sections; firstly, 
the concept of a drug-plasma protein binding is presented, including its 
importance in the preformulation studies, molecular interactions bases and 
methods of drug-PPB studies. The second section describes the molecular 
interactions involved in the supramolecular complex limited to the co-crystal 
formation. The physicochemical properties improvement through the co-crystal 
process was carried out with the use of amino acids as coformers. 
Chapter 3 describes details of the materials and methods adopted in the 
present research work and have been divided into two major sections; drug-
PPB study and amino acids co-crystals. 
Chapter 4 contains the results and discussion of the drug-plasma protein 
binding study. An important outcome of this study is first time quantification of 
the ionic behaviour of the drug and chemical compounds responsible for the 
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drug-PPB. Therefore, it will be helpful for the drug dosage optimisation in the 
formulations. 
Chapter 5 includes information of cocrystallisation, amino acids as coformer. It 
covers four sub-chapters as L-proline-carboxylic acids cocrystals, L-proline-
NSAID cocrystals, citric acid-amino acids cocrystals and application of 
cocrystals. 
Chapter 5.1 explains how the L-proline amino acid and carboxylic acid co-
crystals formed and how they are helping to reduce the hygroscopicity of the L-
proline. One new co-crystal form obtained through this research work along with 
the two already known co-crystals of L-proline and carboxylic acids. 
Chapter 5.2 showed the L-proline and non-steroidal anti-inflammatory drugs co-
crystals formation. As per the report of Tilborg et al., this was only the 
confirmation to find out their ability to form co-crystals with L-proline.  
Chapter 5.3 describes the co-crystal formation of amino acids with the 
pharmaceutically important compound - citric acid. Through this research work, 
five-cocrystals were obtained. One single crystal was obtained successfully 
amongst the five cocrystals of amino acids with citric acid. The obtained single 
crystal was 1:1 L-cysteine-citric acid cocrystal hydrate. It adopts one H2O 
molecule in their crystal lattice. 
Chapter 5.4 gives information about the application of the obtained co-crystal in 
effervescent tablet formulation. It had successfully shown the improvements in 
physical stability in various relative humidity conditions over 28 days of studies. 
Chapter 6 provides overall summary (global discussion) and conclusions of the 
work presented in this thesis followed by the scope of future work. 
Chapter 7 contains references to published work cited within the thesis. 
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Chapter 2 Background 
This chapter includes the literature survey for the drug-plasma protein binding 
studies and the co-crystals. It also gives in-detail information about the 
techniques and methodology used in these studies and current study focus. 
2.1 Drug-plasma protein binding study 
The drug-PPB is an important process that determines the activity and 
pharmacokinetics of many drugs in the body. After distributing with the 
circulatory system, the drug is bind to plasma proteins in varying degrees. In 
general, such binding is reversible, and equilibrium exists between bound and 
free molecular forms. In most cases, only the free drug molecules can cross 
membrane barriers, distribute to tissues and then exert therapeutic effects 
(Lindup and Orme 1981; Vuignier et al. 2010a). Figure 2.1 gives us a general 
idea regarding the drug distribution and the process of protein binding (Vuignier 
et al. 2010a). 
 
Figure 2.1 Drug distribution and binding with protein (Vuignier et al. 
2010a). 
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Drug-plasma protein binding acts as a reservoir for free drug concentration and 
prolongs the duration of drug action. Therefore drug-plasma protein binding is 
considered as an important property and needs to be characterised in the early 
stage of drug discovery (Wan and Holmen 2009). 
In plasma, two major proteins, Human Serum Albumin known as HSA and α1-
Acid Glycoprotein described as AGP are present in relatively high quantities. 
They can bind a variety of drugs with much affinity (Trainor 2007). 
2.1.1 Human serum albumin  
The 66–kDa, globular protein HSA is made up of 585 amino acids. It measures 
merely about 4.5% of the weight of human blood and exists as a major 
component of plasma protein. It is present at a relatively constant concentration 
of ~600µM in the plasma of healthy individuals. HSA tends to bind with 
endogenous ligands (e.g. metal ions and fatty acids) as well as drugs. Though 
there are multiple drugs–binding sites on HSA, Trainor observed that two are 
predominant amongst them and these have a slight inclination for binding to 
neutral and acidic drugs (Trainor 2007). Figure 2.2 shows three–dimensional 
structure of HSA (left side image) and locations of sites I and II (right side 
image), which were discovered by Sudlow, hence called Sudlow site I and II 
also (Sudlow et al. 1975; Wa et al. 2006). 
2.1.1.1 The binding sites of HSA 
The structural information about the low affinity as well as high-affinity binding 
sites is useful in the designing of new drug molecules. The understanding of 
structural information helps the researchers to decide whether to avoid the 
binding of the drug to HSA or modify the drug to achieve desired activity 
considering the extent of binding (Hein et al. 2010). Therefore, Yang et al. said 
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that the studies of drug binding sites on HSA are still essential since past (Yang 
et al. 2014). Sudlow et al. have done revolutionary studies in this field during 
1975–76, in which they used a fluorescent probe displacement method to 
discover binding sites (Sudlow et al. 1975; Sudlow et al. 1976). 
 
Figure 2.2 Three–dimensional structure of HSA (left) and the known 
locations of Sudlow site I and II (Sudlow et al. 1975; Reilly et al.). 
After careful observation, two unique binding sites on the HSA were discovered 
by Sudlow et al. in 1975. These are called as the site I (sometimes also 
described as warfarin binding site or henceforth as Sudlow site I) and site II 
(sometimes referred to the benzodiazepine binding site or Sudlow site II) as 
mentioned in Figure 2.2. 
2.1.2 Alpha (α) –1 – acid glycoprotein (AGP) 
The AGP is heavily glycosylated; an acidic, 38–kDa to 48–kDa protein. It 
includes a single amino acid chain of 204 residues. Its concentration in plasma 
varies from 0.55 to 1.4mg/ml, corresponding to ~2–31µM. AGP is a protein 
which synthesises in the liver in an acute phase, and thus, it can elevate in 
certain disease states as high as up to 3mg/ml in concentration, i.e. about 60µM 
(Kremer et al. 1988). AGP shows a preference for binding to basic drugs. There 
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are multiple drugs–binding sites described in AGP, but one site is to be most 
important which particularly binds to basic drugs (Kaliszan et al. 1995).  Figure 
2.3 shows crystal structure of AGP. 
 
Figure 2.3 The refined crystal structure of human AGP at 1.8 Å resolutions 
shown as a ribbon cartoon in stereo view (Schonfeld et al. 2008). 
It was observed that immunoglobulins and lipoproteins also might be involved in 
binding, but they have a lesser effect (Singh and Mehta 2006; Trainor 2007; 
Howard et al. 2010; Vuignier et al. 2010b).  
2.1.3 Techniques in plasma proteins binding (PPB) studies 
Numbers of techniques have been established for the quantitative determination 
of drug–PPB interactions in vitro. In these, Equilibrium Dialysis, Ultra–Filtration, 
and Ultra–Centrifugation have been used most commonly and conventionally 
(Vuignier et al. 2010a), along with Capillary electrophoresis (CE), Surface–
Plasmon Resonance (SPR)-based assays (Sprunger et al.), and Liquid 
Chromatography/LC. 
2.1.3.1 Equilibrium dialysis 
Equilibrium dialysis (ED) is based on the difference between the size and 
weight of the drug molecules. A standard ED experiment involves two partitions 
which are divided by a semi-permeable membrane. This membrane performs 
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as a molecular strainer, to permit only those molecules less than a specific 
molecular size and weight to permeate through it. Preferably the selected 
membrane is flawlessly permeable to the drugs, due to its low molecular size 
and weight and resistant to the drug-protein complex, as well as the protein due 
to their higher molecular size or weight.  
In ED, the protein is retained one side of the semi-permeable membrane and on 
the other side is present the drug molecule which is to be tested. Afterwards, 
within a precisely defined time span, equilibrium exists, and the unbound drug 
percentage is available, for the measurement from the second section. This 
method was in use for many years for the drug–PPB interaction studies. 
Additionally, this has executed in solutions of drug molecule and protein, which 
helps to establish a right equilibrium, throughout the full experiment. As a result, 
ED is recognised as the reference method (Vuignier et al. 2010a).  
The drawbacks of ED include: 
a) It takes a long time to establish equilibrium (around 12–48 hours). 
b) It necessitates a preliminary set of studies, such as the measurement of 
the necessary time required to establish the equilibrium.  
c) The volume shift linked with the form of osmotic pressure exerted by 
proteins. 
d) Another possible problematic situation associated with ED is unstable 
volume which happens because of the semipermeable membrane and 
the presence of proteins. This changed volume can range from +10 to 
+30%.  
e) The Donnan effect, which is the general attachment of proteins or drugs 
to the walls of the cell and the dialysis membrane, is another problem in 
ED. 
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f) The reduced aqueous solubility of the drug molecules is also the major 
problem and restraining factor for the use of equilibrium dialysis 
technique (Vuignier et al. 2010a). 
2.1.3.2 Ultrafiltration 
The ultrafiltration (UF) technique was recognised as a speedy substitute to ED. 
Its analysis speed had increased by pressure to increase the potency of the 
mixture of drug-protein solution to pass through the membrane. UF helps to 
reduce the process and analysis time by obtaining results more quickly. This will 
allow to pass the unbounded protein through membrane in less time than the 
ED. However, as in ED, the Donnan effect including protein escape (due to 
applied pressure, small size protein could be pass through the membrane) 
creates problems for the use of UF also (Vuignier et al. 2010a). 
2.1.3.3 Ultracentrifugation 
Ultracentrifugation (UC) is another technique related to ED and UF but more 
advanced. In this procedure, a mixture of drug and protein solutions is placed 
into a centrifugation chamber. Then centrifugation is carried out until the entire 
protein as well as the drug-protein complex is deposited at the bottom of the 
tube. As compared with the protein, the drug sedimentation coefficient is 
smaller; hence, the free drug molecule left over in the supernatant which can 
easily be calculated from it. UC becomes advanced in nullifying the 
complications related to the effects of the membrane, i.e. membrane absorption 
and as well as the Donnan effect.  
However, the equipment costs are higher than that of ED and UF. Additionally, 
with different types of drugs, comparative studies exposed that, there is 
measurable difference arose amongst the results obtained by ED and UC. 
Because the unbound drug quantity assessment can be exaggerated with 
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physical phenomena, such as sedimentation, back dispersion, and viscidness 
(Sebille et al. 1990; Vuignier et al. 2010a).  
Furthermore, these methods are shows some limitations such as very low 
throughput and poor reproducibility (Oravcova et al. 1996). Therefore, in 
comparison to these conventional methods, the HPLC method that employs 
stationary phases immobilised with plasma proteins observed an interesting 
approach because of the speed, simplicity and specificity of analysis and 
automation capability (Valko et al. 2003; Vuignier et al. 2013). 
In the liquid chromatography techniques, it is characteristically promising to 
carry out carefully controlled measurements and to help in achieving 
reproducibility in data generation. The development in the discovery of new 
methods and evaluating or modernise the established methodologies by 
inspired endeavours is the result of the increased number of compounds 
expected to be checked for PPB data (Trainor 2007). 
2.1.3.4 Chromatographic techniques 
2.1.3.4.1 Liquid chromatography or LC 
Liquid chromatographic techniques have been used to evaluate drug–PPB 
interactions. LC is a technique which used for a mixture to separate into its 
parts. A chromatography technique was firstly discovered by a Russian botanist 
Mikhail Tswett in the late 1890s for his work on chlorophyll by using a column of 
calcium carbonate (Scott 1995). However, it has been modified in various ways 
by different researchers over a period as per their requirement. LC is further 
divided into size–exclusion chromatography in short SEC and affinity 
chromatography (AC).  
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2.1.3.4.2 Size–exclusion chromatography or SEC 
In the SEC technique, the molecules are separated based on their size or their 
hydrodynamic volume capacity. A combination of the drug and the protein pass 
out through the column which is made up of porous material. This material has 
a pore size such that, it will only permit the unbound free drugs molecules to 
enter it. However, the drug-protein complex will not be able to enter and hence 
elute first. Thus, it is also called gel permeation chromatography or gel filtration 
chromatography. Proteins and drugs are both used free in a solution in SEC. 
However, it was observed that, for drug-protein analysis, this SEC method not 
suitable due to poor column efficiency and low protein yield. Therefore, 
nowadays it is rarely used. Recent columns are more robust but, have a short 
lifetime. 
Along with the techniques mentioned above, there are other procedures which 
have also been applied to study drug-protein interaction. These techniques 
include X-ray crystallography, fluorescence spectroscopy, absorption 
spectroscopy, surface–plasmon resonance and Nuclear Magnetic Resonance 
(NMR) spectroscopy. However, the technique which has gained enormous 
popularity in this field is high–performance affinity chromatography (Sebille et al. 
1990; Singh and Mehta 2006; Kim and Wainer 2008; Hage et al. 2009; Vuignier 
et al. 2010a). 
2.1.3.4.3 High–performance affinity chromatography (HPAC) 
High–performance affinity chromatography (HPAC) based on the technique in 
which the protein has immobilised on support like silica inside the column. The 
injection of the interacting solute (in this case the drug) in a large–plug (i.e. 
frontal analysis-FA) or small–plug (i.e. zonal elution-ZE) is used to check the 
pattern of drug-protein interaction. High attraction drugs will interact with the 
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immobilised protein and delayed elution, as compared to the drug that has less 
or no affinity towards the protein (Vuignier et al. 2010a). This HPAC can use 
only a small amount of protein for many studies is the main advantage, which 
made this method valuable. Additionally, same preparation of protein can be 
used for multiple experiments which can reduce the variations from run-to-run. 
Furthermore, other notable impacts of HPAC are its simplicity of automation and 
capacity to study the behaviour of chiral drug’s enantiomers (Vuignier et al. 
2010a). The newly developed chiral HSA columns have a stationary phase 
which has based on immobilised HSA protein.  
It has been widely described as an instrument to evaluate drug–PPB 
connections when used in an isocratic chromatographic method (Singh and 
Mehta 2006). In this method, drugs with high affinities interact strongly with the 
immobilised protein and are eluted later than drugs with no or fewer affinities. 
The affinity is expressed by the retention factor k, which is calculated through 
Eq. 1 
                                 𝑘 =
(𝑡𝑅−𝑡0)
𝑡0
 ………………………………. Eq.1 
In this Eq.1, tR and t0 are the retention times of the solute and an unretained 
compound respectively. 
In this current study, the data obtained from the HPLC experiments have been 
analysed with the help of Abraham’s LFER method of partitioning solutes 
determination. The interaction between these drugs and immobilised plasma 
proteins (HSA and AGP) was measured using the HPLC method. In order to 
establish quantitative structure-drug-plasma protein binding relationships and to 
unravel the structural parameters governing the interaction mechanisms, which 
are very important in drug design, a LFER model was used (Abraham and 
Acree 2010a; Abraham and Acree 2010c; Abraham 2011).  
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2.1.4 Linear free energy relationship (LFER) 
The partitioning of solutes ruled by structural determinants in chromatography 
systems and could be explained by the analytical method developed by 
Abraham et al. This method is known as, "Linear Free Energy Relationship 
(LFER)" (Abraham and Martins 2004; Zhang et al. 2011). It was used in this 
study to analyse the data obtained from HPLC experiments. This LFER will be 
helpful for comparison between diverse separating systems including in vivo 
and in-vitro ones. Also, it can serve to distinguish the partitioning of solutes 
governed by structural determinants in these systems (Abraham et al. 2004; 
Abraham and Zhao 2005; Sprunger et al. 2007). They developed an equation 
for it. See Eq.2 below: 
𝑆𝑃 = 𝑐 + 𝑒𝐸 + 𝑠𝑆 + 𝑎𝐴 + 𝑏𝐵 + 𝑣𝑉………………………………Eq.2 
Where E, S, A, B, and V represents solute descriptors. E means the excess 
molar refraction in (cm3 mol−1)/10, S stands for solute dipolarity / polarisability, A 
and B represent overall solute–hydrogen bond acidity and hydrogen bond 
basicity respectively, and V is representing the McGowan characteristic volume 
of the solute in (cm3 mol−1)/100. SP stands for a set of solute properties in each 
system, for example, SP may be the skin permeability log Kp, or maybe the 
retention factor log k as in our HSA–HPLC and AGP- HPLC study, for some 
solutes. 
The detailed information about the descriptors is as below. 
2.1.4.1 Solute property (SP) 
Solute Property is the property related to some free energy, such as distribution 
constant, retention factor, specific retention volume, relative adjusted retention 
time or retention index value (Poole 2003). 
18 
 
In this study, SP stands for the retention factor, i.e. log k. This log k value of a 
solute is linearly related to its partition coefficient between the two phases. For 
example, water - octanol phase. 
2.1.4.2 Excess molar refraction (E) 
Excess molar refraction is also closely related to the solute size used in the 
same correlation equation. E calculated from the refractive index of the solute at 
20°C.Excess molar refraction is straight forward for liquids as well as for solids. 
Refractive index values are easily estimated using available software for 
molecular property estimations. Also, E like the molar refraction is almost an 
additive quantity and values for solids. It can estimate through the addition of 
fragments with known E values (Poole 2003). 
Calculation of Excess molar refraction can be done from the refractive index of 
the solute, at 20°C for the sodium D- line, η, as per following equation Eq 3. 
𝐸 = 10𝑉 [
𝜂2−1
𝜂2+2
] − 2.832 𝑉 + 0.526……………………………Eq.3. 
In this Eq.3, ‘V’ means McGowan’s characteristic volume. 
The units used for V are cm3.mol-1/100 as per Eq.3, and therefore, E is writing in 
cm3.mol-1/10. 
For example, calculation of excess molar refraction ‘E’, for toluene, has carried 
out by using equation mentioned above as Eq.3. The refractive index (η) for 
toluene at 20°C (sodium D – line) = 1.496 and ‘V ‘for toluene is 0.857 in 
cm3.mol-1/100. 
E = 10 x 0.857 [(1.496)2- 1) / (1.496)2+2)] – 2.832 x 0.857 + 0.526 = 0.601 in 
cm3.mol-1/10. 
2.1.4.3 Dipolarity/polarisability (S) 
‘S’ is the descriptor for the dipolarity/polarisability of solute. It would be useful to 
have descriptors, related to the propensity of a solute to engage in dipole-dipole 
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and induced dipole-dipole interactions (Poole). In the event it was impossible to 
separate out descriptors for the two types of interactions but, Abraham et al. 
constructed a solute descriptor for dipolarity/polarisability S, combining the two 
interactions. The dipolarity/polarisability descriptor was initially determined 
through gas chromatographic measurements on polar stationary phases but it is 
now more commonly determined in combination with the hydrogen-bonding 
solute descriptors from liquid-liquid distribution constants and chromatographic 
measurements by using Abraham’s descriptor and LFER method (Poole 2003). 
2.1.4.4 Hydrogen bond acidity (A) and hydrogen bond basicity (B) 
During the development of solvation parameter model, Abraham et al. 
commenced the process by defining descriptors for solute hydrogen bond 
acidity (α2
H) or 𝐴 as well as solute hydrogen bond basicity (β2
H
) or 𝐵 (Poole 
2003). 
The solute structure has influences on the distribution process due to a 
consequence of hydrogen bonding of the solute to any surrounding solvent 
molecules, not just to one. Therefore the scales of “summation” or “overall” 
hydrogen bonding is needed, that refers to the tendency of interaction with a 
large excess of solvent molecules by a solute molecule (Poole). These 
hydrogen bond descriptors denoted as ∑α2
H alternatively, ∑𝐴 and ∑β
2
H
 
alternatively, ∑𝐵 to distinguish them from the 1:1 descriptors. New values of the 
effective hydrogen bonding solute descriptors now determined in conjunction 
with other solute descriptors using liquid-liquid distribution and chromatographic 
measurements. There is a small complexity that few solutes (sulfoxides, 
anilines, pyridines) show variable hydrogen bond basicity in distribution systems 
where the organic phase absorbs an appreciable amount of water. A new solute 
descriptor ∑β2
0 alternatively, 𝐵0 was defined for these solutes and should be 
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used in octanol-water distribution systems, for example, reversed-phase and 
micellar electrokinetic chromatography. For the same solutes ∑β2
H
 alternatively, 
∑𝐵 should be used for all other applications and always for gas 
chromatography. Except for the solutes types indicated above, the two 
hydrogen bond basicity scales are identical. It should also note that the scales 
of hydrogen bond acidity and basicity are non-related to the expression of pKa 
based proton transfer acidity and basicity (Poole 2003). 
2.1.4.5 McGowan’s characteristic volume (V) 
The McGowan’s characteristic volume, ‘V’ is in units of cm3.mol-1/100, It can 
calculate for any molecule whose structure is known by simple summation 
rules. Each atom has a defined characteristic volume, and the molecular 
volume is the sum of all atomic volumes less than 6.56 cm3.mol-1 for each bond, 
no matter whether single, double or triple (Poole 2003). 
This can be calculated as follows: - 
Calculation of McGowan’s characteristic volume (V), for toluene 
Atomic volumes: (atomic volumes = atomic weight/density of that element) 
 C=16.35, H=8.71, N=14.39, O=12.43, F=10.48, Si=26.83, P=24.87, S=22.91, 
Cl=20.95, B=18.23, Br=26.21, I=34.53 (Poole). 
Subtract 6.56 for each bond of any type. 
𝑉 = [𝑆𝑢𝑚 𝑜𝑓 𝑎𝑙𝑙 𝑎𝑡𝑜𝑚𝑖𝑐 𝑣𝑜𝑙𝑢𝑚𝑒𝑠 − 6.56(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑜𝑛𝑑𝑠)]…………Eq.4. 
Toluene = 7 carbon atoms + 8 hydrogen atoms – 15 bonds = 114.45+69.68-
98.40=85.73 in cm3.mol-1. After scaling V = 0.857 in cm3.mol-1/100.  
Eq.2 had tried efficiently in wide-ranging systems, which includes a various 
number of partitions from water to organic solvent (Abraham 2003; Abraham 
and Acree 2005; Abraham and Zhao 2005). Also various artificial membrane 
system models (Gil-Agusti et al. 2006; Sprunger et al. 2007; Wang et al. 2009) 
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and biological processes (Zhao et al. 2001; Zhao et al. 2003; Abraham and 
Martins 2004).In Eq.2, (c, e, s, a, b and v) or coefficients are obtained by 
multiple linear regression (MLR) analysis and used to characterise the given 
system.  
However, Eq.2 was set up only for neutral solutes (Zhao et al. 2001; Abraham 
2003; Zhao et al. 2003; Abraham and Martins 2004; Abraham and Acree 2005; 
Abraham and Zhao 2005; Gil-Agusti et al. 2006; Sprunger et al. 2007). 
Therefore, in the sense of use in ionic species extended by Abraham and Acree 
(Abraham and Acree 2010b; Abraham and Acree 2010a; Abraham and Acree 
2010c; Abraham and Acree 2010d) and developed Eq.5. This equation 5 
includes the same five descriptors of equation 2, but also an addition to a new 
descriptor for cations, J+ as well as for anions, J–. 
𝑆𝑃 = 𝑐 + 𝑒𝐸 + 𝑠𝑆 + 𝑎𝐴 + 𝑏𝐵 + 𝑣𝑉 + 𝑗+𝐽+ + 𝑗−𝐽−……………………Eq.5. 
In this, J+ = 0 for anions and J–=0 for cations, whereas both J+ and J– = 0 for 
neutral compounds. In another word, Eq.5 reverts Eq.2, when Eq.5 is only 
assembled for neutral species (Zhang et al. 2011). Sometimes, in certain 
particular systems, in the case of some solutes revised hydrogen bond basicity, 
B0, has to be used in its place of B (Abraham 1993). The examples of these 
solutes are aniline, toluidine, pyridine, alkyl pyridines and sulfoxides, excluding 
sulfones, and the systems which are of ever two-phase systems where water is 
in contact with an organic phase which itself contains a considerable amount of 
water. Examples of such systems include water–wet octanol and water–wet 
ether (Abraham et al. 2013). 
The obtained results of this study of drug-PPB have been explained in chapter 4 
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2.2 Molecular interactions in supramolecular complexes of co-
crystals 
The molecular interactions have been explored widely in the field of 
supramolecular complexes. The best example is that of co-crystals. 
The co-crystals were synthesised and explored for their ability to improve the 
physicochemical properties of the drug molecules (Jones et al. 2006). During 
improvement of physicochemical properties, various molecular interactions 
happened in between the drug or APIs molecules and the coformer molecules. 
2.2.1 General background of co-crystals 
The solid-state properties of drugs including crystal polymorphism, solvate or 
hydrate formation, salt formation, particle size and manufacturing ability may 
have an impact on two important properties. These properties are solubility and 
stability. These two properties play an essential role in the successful drug 
development.These improved properties make the drug suitable for oral 
administration (Buxton 2017). 
The orally administered drugs have covered three-quarters of the total drug 
market  (Bergström 2005). In general, oral ingestion is the most convenient and 
accessible route of drug delivery. The oral route is conventional because of its 
ease of administration, high patient obedience, affordable, minimum sterility 
restraints and elasticity in the strategy of the dosage form (Savjani et al. 2012).  
Still, the unpredictability about the absorption, disposition, metabolism, 
excretion and toxicity (ADMET) (Van De Waterbeemd and Gifford 2003) 
properties remains the main issues for the cessation of clinical testing of the 
many desired drug candidate molecules (Kennedy 1997; Borchardt et al. 2005).   
The drug is required to be in solution to be absorbed as well as permeated with 
ease through the intestinal membrane. The aqueous solubility (Savjani et al. 
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2012) and intestinal permeability (Artursson and Karlsson 1991) are the two 
most important factors influencing drug absorption (Bergström 2005). Studies 
on drug absorption from the gastrointestinal tract are therefore of reflective 
importance in the discovery and development of new drugs (Stenberg et al. 
2001; Van De Waterbeemd and Gifford 2003). 
Based on the solubility and permeability properties of the drugs, they are 
classified into four categories and known as Biopharmaceutics Classification 
System (BCS) See Table 2.1 
Table 2.1 Biopharmaceutics Classification System (BCS) (Amidon et al. 
1995). 
BCS Class Solubility Permeability 
I 
High 
(85-90% in 15-30 minutes) 
High 
(85-90% in 15-30 minutes) 
II 
Low 
 (at least 85% up to extended 
time) 
High  
(85% in 15 minutes) 
III 
High 
(85% in 15-30 minutes) 
Low  
(extended period of time) 
IV 
Low  
(variable) 
Low  
(variable) 
 
This Biopharmaceutics Classification System (BCS) developed by Amidon and 
co-workers in 1995 to reduce the need for in vivo bioequivalency studies and 
also adopted by the United States Food and Drugs Administration 
(USFDA)(FDA) department. The BCS is a scientific framework for classifying a 
drug substance based on its aqueous solubility and intestinal permeability 
(Amidon et al. 1995). “A highly soluble drug is defined as a drug where the 
highest marketed dose (highest dose strength) is soluble in 250 ml of aqueous 
media in over the entire gastrointestinal pH range (1.2–7.4), a conservative 
definition (Shah and Amidon 2014)”. The Scientists are still focusing on 
improving the solubility properties of BCS class II drugs in order to bring them 
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into the main development process. In this field, co-crystals have shown some 
promising results. One must consider the impact of the solid-state properties of 
drugs on solubility, hygroscopicity, stability and manufacturability (Shevchenko 
et al. 2012). 
It was observed that most marketed pharmaceuticals contain molecular crystals 
due to their physical stability. The molecular arrangement in a crystal governs 
its physical properties and, in some instances, its chemical properties. 
Therefore, they dramatically influence the processing as well as solid-state 
drugs formulations. They also act as essential drug properties such as stability 
and rate of dissolution. In-depth knowledge about the relationship between 
physical structures and the physicochemical properties of pharmaceutical solids 
is essential for selecting the most suitable form of API for the development of a 
drug product (Datta and Grant 2004).  
During drug development, it was observed that the modifications in the active 
pharmaceutical ingredients are limited up to the polymorphs, salts and hydrates 
or solvates. According to literature almost half of the drugs have been delivered 
in the form of salts (Wermuth et al. 2002). 
Salt formation involves one acid or basic molecule and requires an API with at 
least one ionisable centre (Yadav et al. 2015). Thus, neutral APIs are not 
suitable for salt formation. Moreover, most of the salt forms of the API are 
hygroscopic and have shown a tendency to absorb atmospheric moisture and 
exhibit stability problems. In contrast, co-crystals can be formed with ionisable 
or neutral APIs and have shown better stability than salts forms (Aitipamula et 
al. 2012a).  
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2.2.2 Co-crystals 
Over the last few decades a new term, “Co-crystals” has emerged as a new 
type of modification technique to tailor the physicochemical properties of the 
crystalline API (Jones et al. 2006; Thakuria et al. 2013). It was defined and 
accepted by the FDA in August 2016. The definition is mentioned already in 
Chapter 1 under section ‘1.0 Introduction, in paragraph 4’. Figure 2.4 represents 
the general scheme of the co-crystals formation.  
 
Figure 2.4 Representation of co-crystallisation  
Pharmaceutical co-crystals have opened vast opportunities for the engineering 
of solid state dosage forms beyond the conventional solid-state forms of an API, 
such as salts and polymorphs. As US-FDA says, co-crystals can be tailored to 
enhance the drug product bioavailability and stability to enhance processability 
of APIs during drug product manufacture. Co-crystals capabilities lead to 
another advantage of co-crystal as they generate a diverse array of solid state 
forms for APIs that lack ionisable functional group, which is a prerequisite for 
salt formation (FDA 2016).The co-crystal technology opened the fascinating 
formulation strategy of creating crystal forms with acceptable stability and 
improved physicochemical properties. Co-crystals offer new opportunities for 
intellectual properties (Trask and Day 2007) or may be extending the life of 
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current patented or patentable formulations resulting in an increasing number of 
research groups attracted towards co-crystal synthesis and their applications 
into the pharmaceutical formulations. It is well known that co-crystals have 
stability and advantages in synthesis over the hydrate, solvate (Vishweshwar et 
al. 2006) and salt (Schultheiss and Newman 2009). 
2.2.3 Coformer  
In the process of co-crystallisation, coformer  might be a stabilising excipient or 
a second active drug molecule (Jones et al. 2006). These are the inert 
molecules which will adhere to the drug molecule by hydrogen bonding, 
halogen bond or π-π interactions and not by a covalent bond. These molecules 
are recognised as safe (Bolla and Nangia) and not interact with drug molecule. 
For example, few carboxylic acids like adipic acid, glutaric acid (McNamara et 
al. 2006; Losev et al. 2011; Zakharov et al. 2012; Zakharov et al. 2013). Also, 
fumaric acid, succinic acid (Jones et al.), malic acid (Shete et al.), malonic acid 
(Aitipamula et al. 2010), and citric acid. Some of the compounds like saccharin 
(Shan and Zaworotko) and caffeine (Ghosh et al. 1991; Trask et al. 2005a; 
Trask et al. 2005b; Guo et al. 2009; Aher et al. 2010; Aitipamula et al. 2012b; 
Pagire et al. 2013a; Apshingekar et al. 2016b) are used as co-crystals  
coformer. The nicotinamide (Bhogala et al. 2005; Sheikh et al. 2009; Kelly et al. 
2012; Soares and Carneiro 2013; Patil et al. 2014; Soares and Carneiro 2014) 
is also used as co-crystals coformer. However, there are some limitations to the 
use of these chemicals repeatedly in high concentration. It can adversely affect 
human beings as high amount become toxic to health. Every drug and excipient 
has certain recommended daily dosage allowance (RDA) decided by the food 
and drug administration department of USA (US-FDA) (FDA 2000) and world 
health organisation (WHO) to avoid their lethal effects. 
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2.2.4 Amino acids as coformers 
In the current study, amino acids were considered as a CCF. In fact, amino 
acids are more favourable coformers as they are neutral molecules, safe and 
natural to human beings. They are safer as compared to the other chemical 
compounds already in use as a CCF. Some of the amino acids possess the 
ability to be in zwitterionic state at physiological condition around pH 7.0-7.4 
(Tilborg et al. 2014). This zwitterionic forms bearing capacity of amino acids is 
more promising for the bonding as well as tailoring the physicochemical 
properties of the drug molecule. These amino acids are an excellent source of 
hydrogen bond donor and hydrogen bond acceptor which can be helpful in 
bonding and synthons formation. It has binary pKa values as well. Therefore, 
there are more possibilities of hydrogen bonding and cocrystal formation. 
Please see the Table 2.2.Thus, the co-crystals of amino acids were prepared by 
using the liquid assisted grinding method. 
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Table 2.2 Amino acids - names, structures, physicochemical properties and reported co-crystals 
Sr. 
No. 
Name of 
Amino 
Acid 
3 
letter 
code
s 
Single 
letter 
code 
Structure 
Co-former/ Reported 
cocrystals 
pKa 
Isoelectric 
point (pI) 
Potential 
H-bonds 
Hygroscopi-
city 
Acidic/
Basic 
Solubility 
(g/100g 
water) 
Molecular 
weight 
(Da) 
Melting 
point 
°C 
non-
polar, 
aliphatic 
residues 
pK1 
(α-
COOH) 
pK2 
(α- 
+NH3) 
Hydropathy 
index / 
Hydropathy 
1 Glycine Gly G 
 
  
 
Glutaric Acid 
Tartaric Acid 
Phthalic Acid 
Urea 
2.33 9.6 6.06 0 
-0.4/ 
Hydrophobic 
Neutral 25.23 75.06 233 
2 Alanine Ala A 
 
 
 
L-ala-val-ala.H2O 
L-ala- S-mandelic acid 
L-ala-L-ala nitrate 
L-ala-R-mandelic acid 
hemihydrate 
2.35 9.59 6.01 0 
1.8/ 
Hydrophobic 
Neutral 16.63 89.09 314-316  
3 Valine Val V 
 
L-val/D-2-
aminobutanoic acid 
L val/ fumaric acid 
D-val/L-leu 
L-val/D-norvaline 
L val/ D met 
DL val/ succinic Acid 
D-val/L-Isoleucine 
L-val/D-norleucine 
2.35 9.62 6 0 
4.2 / 
Hydrophobic 
Neutral 5.87 117.14 315 
4 Leucine Leu L 
 
No 2.33 9.74 6.01 0 
3.8 / 
Hydrophobic 
Neutral 2.19 131.17 293 
The ‘sc’ in ‘pKa’ values stands for the ‘side-chain’ group (Tilborg et al. 2014). 
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Table No. 2.2 Amino acids - names, structures, physicochemical properties and reported co-crystals (Continue...) 
Sr. 
No. 
Name of 
Amino 
Acid 
3 
letter 
code
s 
Single 
letter 
code 
Structure 
Co-former/ Reported 
cocrystals 
pKa Isoelec
-tric 
point 
(pI)  
Potential 
H-bonds 
Hygroscopi-
city 
Acidic/
Basic 
Solubility 
(g/100g 
water) 
Molecular 
weight 
(Da) 
Melting 
point 
°C 
non-polar, 
aliphatic 
residues 
pK1 (α-
COOH) 
pK2 
(α- 
+NH3) 
Hydropathy 
index / 
Hydropathy 
5  Isoleucine  Ile I  
 
 
 
No 2.66 9.7 6.05 0 
4.5/ 
Hydrophobic 
Neutral 3.17 131.17 
286-
288 
6 L-proline Pro P 
 
L-pro/MnCl2.H20 
L-pro/LiCl 
L-pro 
methanolate/thiourea 
L-pro monohydrate/ 4 
aminobenzoic acid 
DL-pro/Hemisuccinic 
acid 
L-pro/L-pro perchlorate 
L-pro/L-pro nitrate 
1.8 10.63 6.3 0 
1.6/ 
Hydrophobic 
Neutral 130.07 115.13 228 
  
aromatic 
residues 
                          
7 
Phenylalani
ne 
Phe F 
 
No 2.2 9.31 5.49 0 
2.8/ 
Hydrophobic 
Neutral 2.8 165.19 
270-
275 
8 Tyrosine Tyr Y 
 
No 2.24 
 9.21, 
10.46 
SC 
5.64 3 
-1.39/ 
Hydrophobic 
Neutral 0.054 181.18 290 
 
The ‘sc’ in ‘pKa’ values stands for the ‘side-chain’ group (Tilborg et al. 2014). 
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Table No. 2.2 Amino acids - names, structures, physicochemical properties and reported co-crystals (Continue...) 
Sr. 
No. 
Name of 
Amino 
Acid 
3 
letter 
codes 
Single 
letter 
code 
Structure 
Co-former/ 
Reported 
cocrystals 
pKa 
Isoele
- 
ctric 
point 
(pI)  
Potential 
H-bonds 
Hygroscop-
icity 
Acidic/
Basic 
Solubility 
(g/100g 
water) 
Molecular 
weight 
(Da) 
Melting 
point °C 
pK1 (α-
COOH) 
pK2 
 (α- 
+NH3) 
Hydropathy 
index / 
Hydropathy 
  
aromatic 
residues 
                          
9 
Tryptopha
n 
Trp W 
 
No 2.46 9.41 5.89 1 
-0.9/ 
Hydrophobic 
Neutral 1.32 204.22 280-285 
  
polar, 
non-
charged 
residues 
                          
10 Serine Ser S 
 
L- ser/ pyridine- 
2,4 dicarboxylic 
acid 
2.31 9.73 5.68 3 
-0.8/ 
Hydrophillic 
Neutral 36.57 105.09 222 
11 Threonine Thr T 
 
 
 
L-thr/ L-ala-thr 2.32 9.03 5.6 3 
-0.7/ 
Hydrophillic 
Neutral 9.79 119.11 256 
12 Cysteine Cys C 
 
L-cys/S-mandelic 
acid 
L-cys/R-mandelic 
acid 
1.92 
 
8.18SC,  
 
10.70 
5.05 0 
2.5/ 
Moderate 
Neutral 2.56 121.15 220 
 
The ‘sc’ in ‘pKa’ values stands for the ‘side-chain’ group (Tilborg et al. 2014). 
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Table No. 2.2 Amino acids - names, structures, physicochemical properties and reported co-crystals (Continue...) 
Sr. 
No. 
Name of 
Amino 
Acid 
3 
letter 
codes 
Single 
letter 
code 
Structure 
Co-former/ 
Reported 
cocrystals 
pKa Isoel-
ectric 
point 
(pI)  
Potential 
H-bonds 
Hygrosco-
picity 
Acidic/
Basic 
Solubility 
(g/100g 
water) 
Molecular 
weight 
(Da) 
Melting 
point °C 
pK1 (α-
COOH) 
pK2 (α- 
+NH3) 
Hydropathy 
index / 
Hydropathy 
  
polar, 
non-
charged 
residues 
                          
13 
Methionin
e 
Met M 
 
No 2.13 9.28 5.74 0 
1.9/ 
Moderate 
Neutral 5.59 149.21 284 
14 
Asparagin
e 
Asn N 
 
 
 
L-asn/L tartaric 
acid 
2.16 8.84 5.41 5 
-3.5/ 
Hydrophillic 
Neutral 2.51 132.11 235 
15 Glutamine Gln Q 
 
 
 
No 
2.18, 
 
4.18SC   
9.64 5.65 5 
-3.5/ 
Hydrophillic 
Neutral 4.25 146.14 185 
  
positively 
charged 
residues 
 
  
 
          
 
  
 
    
16 Lysine Lys K 
 
No 2.15 
 9.16,  
 
10.67 
SC 
9.6 3 
-3.9/ 
Hydrophillic 
Basic 24.66 146.18 215 
 
The ‘sc’ in ‘pKa’ values stands for the ‘side-chain’ group (Tilborg et al. 2014). 
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Table No. 2.2 Amino acids - names, structures, physicochemical properties and reported co-crystals (Continue...) 
Sr. 
No. 
Name of 
Amino 
Acid 
3 
letter 
code 
Single 
letter 
code 
Structure 
Co-
former/ 
Reported 
cocrystals 
pKa 
Isoelect
ric 
point 
(pI) 
Potential 
H-bonds 
Hygroscopi
city 
Acidic/B
asic 
Solubility 
(g/100g 
water) 
Molecular 
weight 
(Da) 
Melting 
point 
°C 
pKa1 
(α-
COOH
) 
pKa2 
(α- 
+NH3) 
Hydropathy 
index / 
Hydropathy 
 
positively 
charged 
residues 
             
17 Arginine Arg R 
 
 
 
No 2.04 
9.04, 
 
12.48 
SC 
10.76 7 
- 4.5/ 
Hydrophillic 
Basic 19.59 174.2 223 
18 Histidine His H 
 
No 2.02 
6.22SC, 
 
9.42 
7.6 3 
- 4.5/ 
Moderate 
Basic 4.36 155.15 285 
 
negatively 
charged 
residues 
             
19 Aspartate Asp D 
 
No 
1.94, 
 
3.71 
SC 
9.63 2.85 4 
- 3.5/ 
Hydrophillic 
Acidic 0.51 133.1 270 
20 Glutamate Glu F 
 
 
 
No 2.17 9.01 3.15 4 
- 3.5/ 
Hydrophillic 
Acidic 0.88 147.12 205 
 
The ‘sc’ in ‘pKa’ values stands for the ‘side-chain’ group (Tilborg et al. 2014). 
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The synthesised co-crystal of amino acid was checked for the manufacture of 
effervescent tablets. The improved physical stability property was reported in 
the current study. It helps to prove the importance of understanding the 
physicochemical properties like hygroscopicity and stability of the molecule 
involved in solid-state formulations; and their impact on the development of 
solid-state dosage forms. The involvement of molecular interactions during this 
process was understood.  The study has found that new crystalline solid 
material obtained through co-crystallisation techniques can be used for tailor-
made physicochemical improvement in APIs for solid-state dosage 
formulations.  
2.2.5 Preparation of co-crystals 
Many laboratory levels and scalable type of technologies have been reported 
and in use for the preparation of co-crystals.These technologies include solution 
crystallisation technique (Vishweshwar et al. 2006) neat grinding and liquid-
assisted grinding (Trask et al. 2004); sonochemical (Friščić et al. 2006; Aher et 
al. 2010) and twin screw hot melt extrusion (Paradkar et al. 2003; Dhumal et al. 
2010). External energy input has been involved in all the methods mentioned 
above to stimulate the intermolecular interactions between API and the co-
crystals coformer. Energy input may be in the form of the shear as in the case 
of grinding or combination of shear and temperature in extrusion or sonic 
energy as observed in the ultrasound-assisted method (Pagire et al. 2013a).  
Recently, a new technique based on the green process approach was utilised 
for the co-crystal synthesis. Researchers from the University of Bradford have 
investigated Twin Screw Hot Melt extrusion for the solvent-free continuous 
production of co-crystals by Paradkar et al.2010 (Dhumal et al. 2010). An 
invention by Soares and Corneiro provides in-line Raman spectroscopy as a 
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process analytical technology (PAT) in the slurry-based co-crystallisation 
process. It will support the understanding of the co-crystallisation reaction and 
monitor it. This very helpful PAT avoids the unnecessary treatment of the 
reaction medium, reduces failure chances and generation of impurities with 
continuous process monitoring. It will result in an opportunity to adjust process 
parameters accordingly as well as supporting the green synthesis of co-crystals 
(Soares and Carneiro 2013).  
Recently Mehta et al. from the University of Bradford invented spray drying. 
Apshingekar et al. developed ultrasound assisted technologies for co-
crystallisation (Apshingekar et al. 2016a). Spherical crystallisation studies for 
the preparation of pharmaceutical co-crystals had been developed by Pagire et 
al. (Pagire et al. 2013b).  
2.2.6 Current study and green process 
Here, in this current study, the basic simple mechanochemical and green 
process technique has been used for co-crystallisation study with amino acids. 
This technique is known as liquid-assisted grinding or sometimes known as a 
solvent assisted grinding (LAG or SAG). It has been used as dry or neat 
grinding or with a suitable solvent (organic or inorganic), but here in this work 
water was used to develop a green process technology. However, it failed in 
some of the trials. 
Though there are so many techniques available and have been studied by 
many researchers and many to come in developing; LAG/SAG stands as a low 
cost and easy for developing at the laboratory level. The LAG procedure gives a 
more significant yield for the screening at the research laboratory level.  
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2.3 Summary 
The molecular interactions study is important to understand the drug-PPB 
interaction as well as the co-crystal formation. The knowledge of the bonding 
(hydrogen / π-π / electrostatic forces) will help and guide for understanding the 
activity of drug-PPB. Through the obtained results one can measure the free 
drug availability for the therapeutic effect as well as the toxicity. It will lead to 
optimisation of drug dosage in the formulation. Similarly, the study of molecular 
level interaction, electrostatic forces and hydrogen bonding mechanism will 
reveal the APIs and coformer molecule interaction for the cocrystal formation. It 
will guide for new coformer selections and provides alternative competitors 
information for the bonding with the APIs. The current study will lead to the 
development of physically stable solid state effervescent formulation. 
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Chapter 3 Materials and methods 
This chapter includes the information about the materials used for the drug-PPB 
study and amino acids co-crystals study. It also describes the methods used for 
the experiments and characterisation study. 
3.1 Materials 
All test compounds obtained from the Sigma–Aldrich Chemie Gmbh Munich, 
Germany. All solvents including methanol, ethanol, acetonitrile, and propanol 
were obtained from Fisher Scientific, UK and Sigma–Aldrich, U.K. All the 
solvents and chemicals were used without further purification. 
Deionised as well as filtered water achieved through an ELGA Maxima LS 
ultrapure water purification system. The chemicals, drugs used in this study are 
listed in Table 3.1 with their lot numbers. 
Table 3.1 List of chemicals, drugs with lot numbers 
Sr No. Name of Chemical/Drug Source Lot No. 
1 Amino acids kit DLAA Sigma Aldrich, USA 34H9015 
2 Amino acids LAA 10KT Sigma Aldrich, USA SLBK8201V 
3 L-Arginine Sigma Aldrich, USA CDBB2685V 
4 L-Cystine Sigma Aldrich Slovakia BCBS1903V 
5 Sodium Bicarbonate Sigma Aldrich, USA SLBP7821V 
6 L-Cysteine Alfa Aesar, UK 10192131 
7 L-Methionine Alfa Aesar, UK 10186273 
8 L-Cystine Alfa Aesar, UK 10191196 
9 L-Serine Alfa Aesar, UK 10135680 
10 Succinic acid Sigma Aldrich, Austria O5OM0082 
11 Citric acid Sigma Aldrich, USA SLBD0318V 
12 Citric acid Sigma Aldrich, USA SLBR3765V 
13 Fumaric acid Sigma Aldrich, Austria BCBK1778V 
14 L-proline  Sigma Aldrich, USA SLBL4766V 
15 Adipic acid Acros Organics, USA A016837701 
16 
Polyvinylpyrrolidone 
(PVP K30) 
(In this study K-17) 
ISP Technologies Inc. 
NJ, USA 
TX81102 
17 Mannitol Sigma Aldrich, UK BCBM0366V 
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Specifications of all solvents used in this research work are listed in Table 3.2. 
Table 3.2 Specification of solvents 
Sr.No. Name Supplier Grade 
1 Ethanol Fisher Chemicals, UK,  
Sigma-Aldrich/Merck, UK 
HPLC grade 
2 Methanol Fisher Chemicals, UK HPLC grade 
3 Acetonitrile Fisher Chemicals, UK HPLC grade 
4 Ethyl acetate Fisher Chemicals, UK HPLC grade 
5 Isopropyl 
alcohol 
Fisher Chemicals, UK,  
Sigma-Aldrich/Merck, UK 
HPLC grade 
 
All instruments/equipment utilised in this study are listed in Table 3.3  
Table 3.3 Specification of instruments 
Sr.No. Instrument Manufacturer Model 
1 DSC TA Instruments, UK. Q2000 
2 TGA TA Instruments, UK. Q5000 
3 PXRD Bruker, Billerica, USA. D8 powder 
diffractometer 
4 Raman Renishaw, UK. RX210 RIAS, 785nm. 
5 FT-IR PerkinElmer Frontier 
6 Tablet Pressing 
Machine 
Karnavati, India. Rimek mini tablet press 
7 DVS Surface Measurement 
Systems, UK. 
DVS Intrinsic  
8 SCXRD Bruker, Billerica, USA. Bruker APEX II X8 
9 HPLC Waters, Herts, UK Waters Alliance 
2695,996 PDA 
10 HPLC Shimadzu, Milton Keynes, 
UK 
LC-20AD, SPD-M20A 
PDA 
11 Chiral HSA 
column 
VWR, UK. 100 × 4.0 mm, 5um 
12 Chiral AGP 
column 
VWR, UK. 100 × 4.0 mm, 5um 
13 SEM INCAx-sight,Oxford 
instruments,UK 
FEI Quanta 400 
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All software used in this research work are listed in Table 3.4. 
Table 3.4 List of software and their purpose of use in this study 
Sr.No. Software  Purpose 
1 TA universal analysis Thermal analysis 
2 PowDLL converter PXRD pattern analysis 
3 GRAM  Vibrational spectral analysis 
4 Spectragryph ver.1.2.7 Spectroscopy analysis 
5 DVS Intrinsic DVS analysis 
6 Bruker APEX software9 SCXRD data analysis 
7 SHELXS10 SCXRD data analysis 
8 SHELXL10 SCXRD data analysis 
9 EmpowerPro HPLC data analysis for HSA study 
10 LabSolutionsLite HPLC data analysis for AGP study 
11 XT microscope V 2.3 SEM control 
 
3.2 Methods 
3.2.1 Drug-PPB studies 
In HSA and AGP studies the mobile phase A was 20mM, potassium phosphate 
buffer solution, pH 7.0, and the mobile phase B was isopropyl alcohol (IPA). 
The flow rate of mobile phase was kept constant as 0.8ml/min (0.9ml/min in 
AGP) throughout the analysis. The temperature of the column also kept 
constant throughout the analysis at around 20°C, (25°C in AGP experiments), 
i.e. room temperature. The injection volume was 10µl. In our experiments, we 
used the isocratic method, in which the mobile phase composition was kept 
constant at 15% B: 85% A throughout one complete set of test compounds.  
The compounds were detected using the maximum absorption wavelength, 
λmax of the ultraviolet–visible spectroscopy (UV–VIS) detector. Each set of test 
compounds was repeated twice (n=2) (three times n=3 in AGP) to get the 
relative data of retention time by using the Empower Pro software (by using the 
LabSolutionsLite software in AGP studies) which connected to the HPLC 
system. 
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3.2.1.1 Validation of our HPLC method 
Here in these experiments the aim was to find out primarily the retention times 
of drug samples but not the concentrations. Thus, normal procedures of HPLC 
to obtain standard calibration curve was not implicated here. However, the 
columns integrity was checked from time to time to ensure the obtained results, 
which are of equal standards. To check column integrity or stability of HSA 
stationary phase was controlled by injecting 4 compounds namely as, 17α-
hydroxyprogesterone, salicylic acid, warfarin and penbutolol (n=5; s.d.≤ 0.03) 
throughout the study, whereas the compounds used for stability control of AGP 
column were 17α-hydroxyprogesterone, mefenamic acid, warfarin and 
penbutolol (n=5; s.d.≤ 0.03).  
Any analytical method is based on the purpose to deliver some qualitative 
and/or quantitative results with an acceptable uncertainty level. By theory, 
“validation” means “measuring uncertainty”. In fact, method validation is 
performed by evaluating a series of method-performance characteristics, such 
as precision, trueness, selectivity/specificity, linearity, operating range, 
recovery, limit of detection (LOD), limit of quantification (LOQ), sensitivity, 
ruggedness/robustness, and applicability (Taverniers et al. 2004; Şengül 2016). 
The LOD and LOQ are two important parameters in quantitative analysis. The 
definition of LOD is defined by the United States Pharmacopeia as “a parameter 
of limit tests”. It is the lowest concentration of the analyte that can be detected, 
but necessarily not quantitated, under the stated experimental conditions”. In 
contrast, LOQ is defined as a parameter of quantitative assays for low levels of 
compounds in sample matrices. The LOQ is the lowest concentration in a 
sample that may be measured with an acceptable level of accuracy and 
precision under the stated experimental conditions (Şengül 2016). A variety of  
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approaches are used to calculate detection limits, which are the most important 
parameters of validation. These approaches are the visual evaluation, signal-to-
noise, standard deviation of the blank, and calibration curve methods. In this 
current study we used the visual evaluation in the form of  difference in retention 
time at different concentration. Therefore, as a result we confirm and use the 
concentration of our compounds as 100mM to 0.1mM and use in 10-20 µl of 
injection volume. In few cases we used 0.01mM concentration of the 
compounds. 
𝐿𝑂𝐷 = 3 × 𝑆𝐷 + 𝐵𝑎𝑣𝑒…Eq. for LOD 
𝐿𝑂𝑄 = 10 × 𝑆𝐷 + 𝐵𝑎𝑣𝑒…Eq. for LOQ. 
SD: standard deviation of measurements 𝐵𝑎𝑣𝑒: average concentration of spike 
samples. 
In our studies we checked the standard deviation of obtained retention time 
from 3 subsequent injections. The obtained data processed for retention factor 
(k) as per the equation (1). The Abraham’s linear free energy relationship 
(LFER) method was used in this study as per the equations 2 and 5, as 
explained in Chapter 2. 
3.2.2 Amino acid cocrystals 
Amino acid cocrystals were prepared and by liquid assisted grinding (LAG) 
technique. The mixture in 1:1 stoichiometric ratio of the amino acid with 
carboxylic acid/ NSAID molecule/ citric acid was taken into a clean mortar and 
pestle and grind for 20-25 minutes. This grinding process is catalysed with the 
addition of 4-6 drops of distilled water or ethanol through 5 ml sterile syringe. 
This process is known as liquid assisted / solvent assisted grinding (LAG/SAG). 
In the presence of water sometimes LAG gives sticky material, while in the 
presence of ethanol it gives free flow powder material. As this experiment was 
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aimed at the hygroscopicity reduction, all sticky materials were discarded. The 
obtained free flow powder materials through the LAG process were 
characterised for cocrystals development using powder crystal X-ray 
diffractometry, DSC, TGA, Raman, FTIR and dynamic vapour sorption 
measurements techniques. 
3.2.2.1 L-proline - carboxylic acid cocrystals 
The L-proline was taken as a 1:1 stoichiometric ratio with each of the nine 
carboxylic acids to screen for the cocrystal development. The used carboxylic 
acids are namely as oxalic acid,malonic acid, succinic acid, glutaric acid, adipic 
acid, malic acid, fumaric acid, ascorbic acid and citric acid. The free-flowing 
powder materials obtained from the LAG process were subjected to the further 
characterisation studies using DVS, PXRD, DSC, TGA, Raman and FT-IR 
techniques for the cocrystal formation and to understand the molecular 
interaction in between these reacting molecules. 
3.2.2.2 L-proline - non-steroidal anti-inflammatory drugs (NSAIDs) co-
crystals 
The cocrystals of L-proline  and NSAIDs was carried out in a 1:1 stoichiometric 
ratio. These NSAIDs were ibuprofen, flurbiprofen, ketoprofen and aspirin. The 
obtained free flow powder material was characterised by DVS, PXRD, DSC, 
TGA, Raman and FT-IR techniques for the cocrystal formation and to 
understand the molecular interaction in between these reacting molecules. 
3.2.2.3 Citric acid-amino acid cocrystals 
All amino acids (18 amino acids) were screened for the cocrystal formation with 
citric acid in the 1:1 stoichiometric ratio by using the LAG method. The obtained 
free flow powder material was characterised by DVS, PXRD, DSC, TGA, 
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Raman and FT-IR techniques for the cocrystal formation and to understand the 
molecular interaction in between these reacting molecules. 
3.2.2.4 Single crystal preparation  
An attempt was made to obtain a well grown single crystal of the cocrystals 
obtained using solvent evaporation method. All cocrystal formed were taken in 
the 1:1 stoichiometric ratio and transfer into the clean conical flasks. Then these 
mixtures warmed at 60°C until the clear saturated solutions observed in the 
presence of different solvent systems like methanol, ethanol, acetonitrile, ethyl 
acetate. All flasks were kept covered with perforated aluminium foil for 
evaporation without disturbing. After few days (2 days to 3 weeks) crystalline 
entity was separated and dried. A well grown single crystal was then subjected 
to the single crystal x-ray diffractometer analysis. 
3.2.3 Characterisation methods for amino acids cocrystals 
3.2.3.1 Powder X-ray diffraction (PXRD) 
PXRD patterns of all samples were recorded at room temperature on a Bruker 
D8 diffractometer (Billerica, USA) equipped with a Cu Kα radiation source tube, 
1.540 Å X-ray wavelengths and the emission filament voltage and ampere were 
40 kV and 40 mA respectively. A scanning range of 3° to 30° 2θ° angle was 
used with a step size of 0.01°at the rate of 1 sec. time count. The scatter slit 
and receiving slit was 0.2° and 1° respectively. 
3.2.3.2 Differential scanning calorimetry (DSC) 
DSC was performed using a Differential Scanning Calorimeter Q2000 from TA 
Instruments, Crawley, UK. This machine equipped with the RSC90 cooling unit 
to analyse and comprehend heat flow in the starting crystalline components as 
well as the resulting crystalline products. Indium metal was used for the 
calibration of instrument. Approximately 1 to 2 mg of the sample was weighed in 
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a crimped standard aluminium pan. The top of the pan was pierced with sharp 
needle to create a tiny hole before crimping. This will allow evaporation of the 
excessive moisture during experiment. DSC runs were carried out at a heating 
rate of 10°C/min from 0°C to 300°C under nitrogen atmosphere. DSC data were 
analysed using TA Universal analysis software version 4.5A. 
3.2.3.3 Thermogravimetric analysis (TGA) 
TGA was performed using Thermo Gravimetric Analyser Q5000 from TA 
Instruments, Crawley, UK, equipped with a water bath. Each cleaned platinum 
pan was tared to store the weight of the pan as an offset before loading the 
samples. About 2-3 mg of the sample was loaded in the standard platinum pan 
and heated as a ramp run from 25°C to 350°C some cases up to 400°C at a 
heating rate of 10°C /min under nitrogen atmosphere. TGA data were analysed 
using TA Universal analysis software version 4.5A. 
3.2.3.4 Raman spectroscopy 
Raman spectra were recorded of all amino acids and chemical compounds and 
their respected co-crystals by using Raman microscope analyser made by 
Renishaw (UK), equipped with a diode laser which emits light of wavelength 
785nm. Maximum output of the diode laser was 50mV at source point and 
approximately 20mV at the sample. A 50X objective was used to emit a light 
beam of diameter 2 µm for 10 secs at the sample. Few particles of each sample 
were spread over the clean metal coated background glass slide and processed 
under the 785 nm laser beam. Three acquisitions of each sample were taken at 
4 cm-1 spectral resolution and scan were collected at wavenumber 100-3500 
cm-1 and sometimes 100-2000 cm-1. A charged coupled device detector was 
used to collect the data. 
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3.2.3.5 Fourier transform infra-red (FT-IR) spectroscopy 
FT-IR spectra were recorded of each compound and their respected co-crystals 
using Perkin-Elmer’s make the FT-IR machine. A small amount of powder of a 
sample was kept on the diamond crystal at the centre of the platform in such a 
way that it should cover the area of diamond crystal with the help of rotating the 
vertical shaft. Powdered material was pressed against the diamond crystal to a 
predetermined pressure, which was confirmed by generation of signal sound. 
Once the sample was placed correctly, measurements were recorded. Each 
sample was analysed at four times acquisition rate and from 600 to 4000 
wavelengths (cm-1) range. The assembly involves an electronically stabilised 
source and detector for accurate results with high repeatability. 
3.2.3.6 Dynamic vapour sorption (DVS) study 
Approximately 40-50 mg sample was carefully transferred to the previously 
tared DVS pan. Sample sizes were used to give the optimum balance between 
sensitivity and equilibration time. Sample pan was transferred to the humidity 
chamber of DVS intrinsic machine. Samples were subjected to an increment 
program of relative humidity. Relative humidity was maintained using a mixture 
of dry nitrogen gas and water. The experiment was carried out from 0% RH to 
90% RH relative humidity by 10% RH increase in each step and at 25°C 
temperature programme condition. The step change was done using dm/dt 
principle, i.e. a change in RH step was achieved when the difference between 
two time points was less than 0.001%.  
3.2.3.7 Single crystal X-ray diffraction (SCXRD) 
The single crystal structure was determined using intensity data collected on a 
Bruker APEX II X8 diffractometer using Cu K radiation at 170 K. The data was 
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collected and processed using the Bruker APEX software9 and the structures 
were solved using SHELXS10 and refined with SHELXL10. 
3.2.3.8 Scanning electron microscopy (SEM) 
Scanning electron microscope (INCAx-sight,Oxford instrument, UK) was used 
to characterise surface and visual morphology of cocrystal. Self-adhesive 
carbon mounts were used to mount samples on aluminium pin stubs (Agar 
Scientific, Stansted, UK). SEM images were taken using a FEI Quanta 400 
microscope under high vacuum and high voltage of 20KV at working distance 
as 10mm at various magnification levels 40x to 250x. All samples were gold 
plated prior to the analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
Chapter 4 Drug- plasma protein interaction studies 
The drug plasma protein studies are discussed and explained in chapter 1 and 
2. The part of this study has been published in the journal of pharmaceutical 
and biomedical analysis, Volume 149, 5 February 2018, Pages 16-21. The link 
to this publication is  https://doi.org/10.1016/j.jpba.2017.10.022 (Kamble et al. 
2018). 
 In 2003, Valko et al. have used a fast gradient HPLC method to study a variety 
of compounds on an immobilised HSA column (Valko et al. 2003).  Valko et al. 
showed that the ionic compounds are responsible for the drug-plasma protein 
binding, but they could not quantify them exactly. However, this current study 
focuses specifically on quantifying the percentage of ionic behaviour 
responsible for drug-plasma protein binding. As well as an understanding of the 
molecular interactions involved in this drug-PPB. The following part of this 
chapter is similar to the published article entitled as, “Structural properties 
governing drug-plasma protein binding determined by high-performance liquid 
chromatography method” (This publication is attached to this thesis in the 
Appendix).  
4.1 Results and Discussion 
In this study, a set of 65 compounds with a broad structural diversity (in terms of 
E, S, A, B, V, J+ and J-) were selected. The solutes consist of neutrals, acidic 
and basic compounds which are present as neutral or ionic (cationic or anionic) 
at the experimental condition of pH 7, which is as close as possible to the 
physiologic pH and compatible with the stability of the stationary phase (pH no 
higher than 7.0). Their retention factor log k was determined using immobilised 
HSA and AGP HPLC columns at the isocratic mobile phase condition. 15% (v/v) 
of IPA was used as the organic modifier to allow the elution of most of the 
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solutes in a reasonable time. The two columns were stable during the study 
period. The stability of HSA stationary phase was controlled by injecting 4 
compounds (17α-hydroxyprogesterone, salicylic acid, warfarin and penbutolol) 
throughout the study, whereas the compounds for stability control of AGP 
column were 17α-hydroxyprogesterone, mefenamic acid, warfarin and 
penbutolol. Some of the chromatograms obtained from HSA and AGP studies 
are shown below in Figure 4.1 and 4.2 respectively. 
 
Figure 4.1 HPLC chromatogram from HSA-HPLC studies  
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Figure 4.2 HPLC chromatogram from AGP-HPLC studies 
The log k values and other physicochemical parameters including dissociation 
constant pKa, n-octanol/water partition coefficient (log Poct), n-octanol/water 
distribution coefficient at pH 7 (log D7.0), as well as the values of the solute 
descriptors are shown in Table 4.1. 
AGP HPLC Experiments 
 
1-Chloro 2-Nitrobenzene 
 
4-Chlorobenzoic acid 
 
Acebutolol 
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Table 4.1 Physicochemical parameters of the investigated compounds 
 
 Solutes pKaa Charge 
state 
log kHSAb  log kAGPb 
 
log Pocta log 
D7.0c 
E S A B V J+ J- 
 Neutrals              
1 Acetaminophen 9.50 neutral -0.35 -0.73 0.51 0.51 1.120 1.63 1.01 0.91 1.1724 0.0000 0.0000 
2 Acetophenone N neutral 0.05 -0.30 1.58 1.58 0.818 1.01 0.00 0.48 1.0139 0.0000 0.0000 
3 Acridine 5.58 neutral 1.22 0.90 3.40 3.38 2.356 1.32 0.00 0.58 1.4133 0.0000 0.0000 
4 Aniline 4.60 neutral -0.21 -0.45 0.90 0.90 0.955 0.96 0.26 0.41 0.8162 0.0000 0.0000 
5 2-Chloroaniline 2.64 neutral 0.31 0.05 1.91 1.91 1.033 0.92 0.25 0.31 0.9386 0.0000 0.0000 
6 N-Ethylaniline 5.12 neutral 0.15 -0.05 2.16 2.15 0.945 0.85 0.17 0.43 1.0980 0.0000 0.0000 
7 Nitrobenzene N neutral 0.33 -0.13 1.85 1.85 0.871 1.11 0.00 0.28 0.8906 0.0000 0.0000 
8 1-Chloro-2-nitrobenzene N neutral 0.75 0.24 2.52 2.52 1.020 1.24 0.00 0.24 1.0130 0.0000 0.0000 
9 1-Fluoro-2,4-dinitrobenzene N neutral 0.26 -0.29 1.47 1.47 1.006 1.69 0.00 0.45 1.0825 0.0000 0.0000 
10 Benzyl alcohol N neutral -0.23 -0.42 1.10 1.10 0.803 0.87 0.39 0.56 0.9160 0.0000 0.0000 
11 4-Chlorobenzylalcohol N neutral 0.28 -0.09 1.96 1.96 0.911 0.96 0.40 0.50 1.0384 0.0000 0.0000 
12 2-Aminobiphenyl 3.84 neutral 0.79 0.72 2.84 2.84 1.600 1.48 0.26 0.41 1.4240 0.0000 0.0000 
13 Carbamazepine N neutral 0.23 0.71 2.19 2.19 2.154 1.90 0.50 1.15 1.8106 0.0000 0.0000 
14 Corticosterone N neutral 0.31 0.18 1.94 1.94 1.860 3.43 0.40 1.63 2.7389 0.0000 0.0000 
15 m-Cresol 10.10 neutral 0.23 -0.11 1.96 1.96 0.822 0.88 0.57 0.34 0.9160 0.0000 0.0000 
16 p-Cresol 10.26 neutral 0.24 -0.15 1.94 1.94 0.820 0.87 0.57 0.31 0.9160 0.0000 0.0000 
17 Estradiol N neutral 1.26 0.74 3.03 3.03 1.800 1.77 0.86 1.10 2.1988 0.0000 0.0000 
18 Estriol N neutral 0.68 -0.03 2.54 2.54 1.970 1.74 1.06 1.63 2.2575 0.0000 0.0000 
19 Hydrocortisone N neutral -0.02 -0.15 1.61 1.61 2.030 3.49 0.71 1.90 2.7976 0.0000 0.0000 
20 Hydrocortisone- 21-acetate N neutral 0.24 0.18 2.19 2.19 1.890 2.88 0.46 2.16 3.0951 0.0000 0.0000 
21 2- Naphthol 9.57 neutral 0.94 0.47 2.70 2.70 1.520 1.08 0.61 0.40 1.1441 0.0000 0.0000 
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22 3-Chlorophenol 9.11 neutral 0.71 0.26 2.50 2.50 0.909 1.06 0.69 0.15 0.8975 0.0000 0.0000 
23 4-Bromophenol 9.31 neutral 0.82 0.30 2.59 2.59 1.080 1.17 0.67 0.20 0.9501 0.0000 0.0000 
24 4-Chlorophenol 9.40 neutral 0.65 0.17 2.39 2.39 0.915 1.08 0.67 0.20 0.8975 0.0000 0.0000 
25 4-Chloro-3,5-dimethyl phenol 9.70 neutral 1.22 0.82 3.27 3.27 0.980 0.94 0.61 0.26 1.1793 0.0000 0.0000 
26 4-Chloro-2-methylphenol 9.60 neutral 0.92 0.50 2.78 2.78 0.890 0.91 0.63 0.22 1.0384 0.0000 0.0000 
27 3-Nitrophenol 8.40 neutral 0.48 -0.09 2.00 1.98 1.050 1.57 0.79 0.23 0.9493 0.0000 0.0000 
28 Phenylacetonitrile N neutral 0.10 -0.52 1.56 1.56 0.751 1.03 0.00 0.50 1.0120 0.0000 0.0000 
29 Phenytoin 8.33 neutral 0.41 0.25 2.47 2.45 1.713 2.23 0.86 1.00 1.8693 0.0000 0.0000 
30 Prednisolone N neutral 0.02 -0.12 1.62 1.62 2.210 3.10 0.71 1.92 2.7546 0.0000 0.0000 
31 17α-Hydroxyprogesterone N neutral 0.78 0.71 3.17 3.17 1.640 3.35 0.25 1.31 2.6802 0.0000 0.0000 
32 21-Hydroxyprogesterone N neutral 0.81 0.60 3.10 3.10 1.740 3.50 0.14 1.31 2.6802 0.0000 0.0000 
33 Salicylamide 8.37 neutral 0.02 -0.26 1.28 1.26 1.160 1.58 0.61 0.51 1.0315 0.0000 0.0000 
34 Testosterone N neutral 0.78 0.66 3.32 3.32 1.540 2.56 0.32 1.17 2.3827 0.0000 0.0000 
 Acidic compounds              
35 Aspirin 3.48 Anion 0.86  1.13 -2.39 1.000 4.15 0.00 3.28 1.2664 0.0000 2.2560 
36 4-Bromobenzoic acid 3.97 Anion 1.33  2.86 -0.17 1.150 3.25 0.00 2.60 1.0852 0.0000 2.1480 
37 3-Chlorobenzoic acid 3.82 Anion 1.04  2.71 -0.47 0.990 3.13 0.00 2.57 1.0326 0.0000 2.0340 
38 4-Chlorobenzoic acid 3.98 Anion 1.07  2.65 -0.37 0.990 3.37 0.00 2.60 1.0326 0.0000 2.1790 
39 Flurbiprofen 3.91 Anion  0.14 3.81 0.72 1.590 4.56 0.07 3.36 1.8174 0.0000 2.5383 
40 Ibuprofen 4.43 Anion  0.04 3.87 1.30 0.880 3.50 0.08 3.31 1.7556 0.0000 2.4188 
41 Mefenamic acid 4.33 Anion  0.63 5.12 2.45 1.800 4.71 0.09 3.14 1.8996 0.0000 2.6427 
42 3-Phenylpropanoic acid 4.25 Anion 1.08  1.89 -0.86 0.900 3.43 0.03 3.02 1.1920 0.0000 2.1879 
43 4-Phenylbutanoic acid 4.72 Anion 1.50  2.42 0.14 0.910 3.59 0.04 3.01 1.3829 0.0000 2.2184 
44 8-Phenyloctanoic acid 5.03 Anion  0.67 4.09 2.12 0.940 3.87 0.07 3.26 1.8965 0.0000 2.4256 
45 Salicylic acid 2.97 Anion 0.93  2.26 -1.77 1.050 3.51 0.14 2.18 0.9689 0.0000 1.6351 
46 Warfarin 4.98 Anion 1.57 0.35 2.70 0.68 2.130 5.62 0.00 4.40 2.2862 0.0000 2.7628 
 Basic compounds              
47 Acebutolol 9.52 Cation -0.02 0.14 2.02 -0.50 1.450 6.69 3.62 0.00 2.7771 2.2965 0.0000 
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48 Alprenolol 9.59 Cation 0.31 0.71 3.10 0.51 1.100 4.46 1.78 0.00 2.1802 2.2574 0.0000 
49 Atenolol 9.60 Cation -0.19 0.06 0.16 -2.44 1.300 6.27 2.91 0.00 2.1978 2.4800 0.0000 
50 Bupivacaine 8.10 Cation 0.36 0.64 3.41 2.28 1.170 4.67 2.92 0.00 2.5354 1.5920 0.0000 
51 Imipramine 9.40 Cation 0.83 1.18 4.80 2.40 1.000 3.66 2.02 0.00 2.4230 1.6110 0.0000 
52 Lidocaine 8.01 Cation 0.06 0.26 2.44 1.39 0.960 4.18 2.12 0.00 2.0804 1.7490 0.0000 
53 Mepivacaine 7.70 Cation -0.05 0.23 1.95 1.17 1.170 4.69 2.98 0.00 2.1127 1.5607 0.0000 
54 Metoprolol 9.63 Cation -0.02 0.12 1.95 -0.68 1.020 5.35 2.16 0.00 2.2819 2.3476 0.0000 
55 Oxprenolol 9.57 Cation 0.08 0.50 2.51 -0.06 1.160 5.09 2.35 0.00 2.2389 2.2029 0.0000 
56 Penbutolol 9.92 Cation 0.81 1.35 4.62 1.70 0.775 4.66 1.98 0.00 2.6195 1.9630 0.0000 
57 Pindolol 9.54 Cation 0.21 0.43 1.75 -0.79 1.550 4.60 2.36 0.00 2.0305 2.2661 0.0000 
58 Procaine 9.03 Cation 0.01 0.25 2.14 0.11 0.999 4.58 1.86 0.00 1.9982 2.1487 0.0000 
59 Promazine 9.36 Cation 1.01 1.34 4.55 2.19 1.900 3.78 1.76 0.00 2.3047 2.5263 0.0000 
60 Propafenone 9.62 Cation 0.65 1.09 3.64 1.02 1.680 5.69 3.08 0.00 2.8467 2.3780 0.0000 
61 Propranolol 9.47 Cation 0.54 0.98 3.48 1.01 1.690 4.31 2.07 0.00 2.1695 2.4319 0.0000 
62 Quinidine 8.56 Cation 0.47 0.77 3.44 1.87 2.320 5.81 1.23 0.00 2.5727 4.1570 0.0000 
63 Quinine 9.05 Cation 0.50 0.89 3.44 1.39 2.319 5.81 1.23 0.00 2.5727 4.1565 0.0000 
64 Sotalol 9.43 Cation -0.12 0.11 0.24 -2.19 1.320 6.18 2.38 0.00 2.1225 2.8119 0.0000 
65 Verapamil 8.92 Cation 0.57 0.77 3.79 1.86 1.660 7.70 4.33 0.00 3.8076 2.4040 0.0000 
 
a Taken from (Zhang et al. 2012) and bioloom Software (Biobyte Corporation, Claremont, U.S.A.). 
b Calculated from Eq. (NCBI); n=3, s.d.≤ 0.03. 
c Calculated according to 𝑙𝑜𝑔𝐷 = 𝑙𝑜𝑔𝑃𝑜𝑐𝑡 − log (1 + 10
𝑝𝐾𝑎−𝑝𝐻) for bases and 𝑙𝑜𝑔𝐷 = 𝑙𝑜𝑔𝑃𝑜𝑐𝑡 − log (1 + 10
𝑝𝐻−𝑝𝐾𝑎) for acids. 
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From Table 4.1, one can understand that, there are large log k values of the 
acidic compounds on the immobilised HSA HPLC column (log k HSA). At the 
experimental condition of pH 7, the acidic compounds (35-46 in Table 1) are 
negatively charged. This indicates the strong interaction of anionic species with 
HSA stationary phase. Four acidic compounds with high lipophilicity 
(flurbiprofen, ibuprofen, mefenamic acid and 8-phenyloctanoic acid) could not 
be eluted from the HSA column (within 4 hours), implying the contribution of 
lipophilicity of the solute to the binding in addition to their negative charges. In 
this case, we eluted the injected samples by mobile phase with a higher ratio of 
IPA before next injection. On the contrary, the acidic compounds showed much 
weaker retention on the AGP HPLC column. All the acidic compounds with log 
Poct values lower than 3 do not retain in AGP column. The four highly lipophilic 
acids (flurbiprofen, ibuprofen, mefenamic acid and 8-phenyloctanoic acid) 
showed a low degree of retention, indicating that the negative charges of the 
solutes do not favour the interaction with AGP, while lipophilicity plays a role.  
Fig 4.3 shows the correlations between the values of log D7.0 and log k on the 
immobilised HSA (log k HSA) 4.3(1a) and AGP (log k AGP) 4.3(1b) stationary 
phases from this study. From Fig 4.3 (1a), it can be further verified that anions 
interact much stronger with HSA stationary phase than 7 cations and neutral 
compounds. Fig 4.3 (1b) shows that the cations have a higher affinity to AGP 
stationary phase than anions in general. The neutral compounds bind least to 
both proteins. Within each set of the solutes, the larger the lipophilicity 
(expressed by log D7.0), the higher the affinity with the proteins. It is indicating 
that both electrostatic forces and lipophilicity control the drug binding to 
immobilised proteins. This is in good agreement with drug binding data from 
soluble human plasma proteins in previous studies (Urien et al. 2001).  
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Figure 4.3 Correlations between log D7.0 and log kHSA (1a) as well as log 
kAGP (1b). Markers: ●, neutral molecules; ■, anions; ○, cations (Kamble et 
al. 2018). 
To reveal the structural properties that govern the drug interaction with the 
immobilised HSA and AGP in HPLC system, the multilinear regression (MLR) of 
log k against the solute descriptors yielded the LFER model shown in Eq. 6 and 
Eq. 7. 
𝑙𝑜𝑔𝑘𝐻𝑆𝐴 =  −0.271(±0.298) + 0.470(±0.276) 𝐸 − 0.331(±0.190) 𝑆
− 0.177(±0.197) 𝐴 − 1.233(±0.393) 𝐵 + 1.086(±0.350) 𝑉
− 0.231(±0.229) 𝐽+ + 2.024(±0.460)𝐽−       
𝑁 = 61, 𝑅2 = 0.812, 𝑆𝐷 = 0.215, 𝐹 = 33, 𝑃𝑟𝑒𝑠𝑠 = 3.204, 𝑄2 = 0.756 … … … 𝐸𝑞. 6 
log 𝑘𝐴𝐺𝑃 = − 0.756(±0.315) + 0.428(±0.275)𝐸 − 0.354(±0.196)𝑆
− 0.156(±0.206) 𝐴 − 1.253(±0.397) 𝐵 + 1.278 (±0.361) 𝑉
− 0.051(±0.230) 𝐽+ + 1.562(±0.426) 𝐽−                                         
    𝑁 = 58, 𝑅2 = 0.796, 𝑆𝐷 = 0.228, 𝐹 = 28, 𝑃𝑟𝑒𝑠𝑠 = 4.143, 𝑄2 = 6.74 … … … 𝐸𝑞. 7 
In these equations, 95% confidence limits are given in parentheses; N is the 
number of compounds; R2 is the squared correlation coefficient; SD is the 
standard deviation, and F is the Fisher’s test. Press and Q2 are the leave-one-
out statistics. The values of Q2 are good enough to indicate that Eq. 6 and Eq. 
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7 are soundly based. The coefficients of Eq. 6 and Eq. 7 showed that for the 
electrically neutral compounds, McGowan’s characteristic molecular volume (V), 
dipolarity/polarizability (S) and hydrogen bond basicity (B) are the three 
significant molecular descriptors of solutes determining the interaction with 
immobilised plasma proteins. Whereas excess molar refraction (E) is less 
important, and hydrogen bond acidity (A) is not of statistical significance in both 
systems. For acids and bases in this study, compared logarithm of the retention 
factors of neutral species and the corresponding anions or cations on the two 
stationary phases as shown in Table 4.2.  
For immobilised HSA stationary phase, we use Eq. 6 to calculate log kHSA for 
the 8 neutral, acidic compounds and 19 basic compounds using descriptors for 
the neutral species. These can then be compared to experimental values of log 
kHSA of the corresponding anions 8 and cations, measured in this study. Over 
the 8 acidic compounds, the average difference log kHSA (anions) – log kHSA 
(neutral acids) = 0.80 (±0.03) log units. So that on average the retention factor 
on immobilised HSA column for the anions is 6.3 times that for the neutral, 
acidic compounds, further quantitatively verifying the contribution of the 
electrostatic interactions between the anions and the immobilised HSA. It also 
means that for the electrically neutral acids, hydrogen bond acidity (A) is not 
important for binding with the HSA phase. 
In the case of 19 basic compounds, the average difference log kHSA (cations) - 
log kHSA (neutral base) = - 0.14 (±0.01) log units, meaning that retention factor 
on HSA HPLC column for the protonated base cation is 0.71 times that for the 
neutral bases. This indicates that positive charge of the solute does not greatly 
favour the interaction with HSA stationary phase.  
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Thus, for the first time, this study able to show the effect of negative or positive 
charge on binding to HSA quantitatively. Valko et al. (Valko et al. 2003) have 
used a fast gradient HPLC method to study a variety of compounds on an 
immobilised HSA column. By comparison of log kHSA with calculated values of 
log P (octanol) at pH 7.4 (log D), they concluded that acid anions were strongly 
bound. However, they could not quantify any increased binding due to the 
negative charge 
Table 4.2 The observed log k values of ionic species and predicted log k 
values of the neutral species of acids and bases in this study by Eq 6 and 
Eq 7. 
Species E S A B V J+ J- 
logkHSA
a 
logkAGP
b 
Acids          
Aspirin, anion        0.86  
Aspirin 0.781 1.69 0.71 0.67 1.2879 0.0000 0.0000 -0.02  
4-Bromobenzoic acid, anion        1.33  
4-Bromobenzoic acid 1.000 1.01 0.63 0.26 1.1067 0.0000 0.0000 0.63  
3-Chlorobenzoic acid, anion        1.04  
3-Chlorobenzoic acid 0.840 0.95 0.63 0.32 1.0541 0.0000 0.0000 0.45  
4-Chlorobenzoic acid, anion        1.07  
4-Chlorobenzoic acid 0.840 1.02 0.63 0.27 1.0541 0.0000 0.0000 0.49  
Flurbiprofen, anion         0.14 
Flurbiprofen 1.440 1.45 0.62 0.76 1.8389 0.0000 0.0000  0.65 
Ibuprofen, anion         0.04 
Ibuprofen 0.730 0.70 0.57 0.79 1.7771 0.0000 0.0000  0.50 
Mefenamic acid, anion         0.63 
Mefenamic acid 1.650 1.35 0.65 0.54 1.9211 0.0000 0.0000  1.15 
3-Phenylpropanoic  acid, anion        1.08  
3-Phenylpropanoic acid 0.750 1.18 0.60 0.60 1.2135 0.0000 0.0000 0.16  
4-Phenylbutanoic acid, anion        1.50  
4-Phenylbutanoic acid 0.760 1.29 0.61 0.57 1.3544 0.0000 0.0000 0.32  
8-Phenyloctanoic acid, anion         0.67 
8-Phenyloctanoic acid 0.790 1.28 0.59 0.63 1.9180 0.0000 0.0000  0.70 
Salicylic acid, anion        0.93  
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Salicylic acid 0.900 0.85 0.73 0.37 0.9904 0.0000 0.0000 0.36  
Warfarin, anion        1.57 0.35 
Warfarin 1.980 1.88 0.29 1.57 2.3077 0.0000 0.0000 0.56 0.36 
Bases          
Acebutolol, cation        -0.02 0.14 
Acebutolol 1.600 2.42 0.90 2.10 2.7556 0.0000 0.0000 -0.08 -0.18 
Alprenolol, cation        0.31 0.71 
Alprenolol 1.250 1.09 0.15 1.44 2.1587 0.0000 0.0000 0.50 0.32 
Atenolol, cation        -0.19 0.06 
Atenolol 1.450 1.90 0.62 2.03 2.1763 0.0000 0.0000 -0.47 -0.67 
Bupivacaine, cation        0.36 0.64 
Bupivacaine 1.320 2.10 0.34 1.33 2.5139 0.0000 0.0000 0.68 0.56 
Imipramine, cation        0.89 1.08 
Imipramine 1.150 1.45 0.00 1.04 2.4015 0.0000 0.0000 1.12 0.99 
Lidocaine, cation        0.06 0.26 
Lidocaine 1.110 1.51 0.07 1.24 2.0589 0.0000 0.0000 0.45 0.25 
Mepivacaine, cation        -0.05 0.23 
Mepivacaine 1.320 2.14 0.34 1.33 2.0912 0.0000 0.0000 0.21 0.00 
Metoprolol, cation        -0.02 0.12 
Metoprolol 1.170 1.33 0.17 1.76 2.2604 0.0000 0.0000 0.09 -0.07 
Oxprenolol, cation        0.08 0.50 
Oxprenolol 1.230 1.45 0.15 1.62 2.2174 0.0000 0.0000 0.21 0.04 
Penbutolol, cation        0.81 1.35 
Penbutolol 0.925 1.15 0.08 1.51 2.5980 0.0000 0.0000 0.73 0.65 
Pindolol, cation        0.21 0.43 
Pindolol 1.700 1.59 0.30 1.40 2.0090 0.0000 0.0000 0.40 0.18 
Procaine, cation        0.01 0.25 
Procaine 1.149 1.34 0.26 1.44 1.9767 0.0000 0.0000 0.15 -0.06 
Promazine, cation        1.01 1.34 
Promazine 2.050 1.49 0.00 1.08 2.2832 0.0000 0.0000 1.35 1.16 
Propafenone, cation        0.65 1.09 
Propafenone 1.730 2.09 0.29 1.74 2.8252 0.0000 0.0000 0.72 0.63 
Propranolol, cation        0.54 0.98 
Propranolol 1.840 1.43 0.44 1.31 2.1480 0.0000 0.0000 0.76 0.56 
Quinidine, cation        0.47 0.77 
Quinidine 2.469 1.23 0.37 1.97 2.5512 0.0000 0.0000 0.76 0.60 
Quinine, cation        0.50 0.89 
Quinine 2.469 1.23 0.37 1.97 2.5512 0.0000 0.0000 0.76 0.60 
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Sotalol, cation        -0.12 0.11 
Sotalol 1.470 1.55 0.68 2.06 2.1010 0.0000 0.0000 -0.47 -0.68 
Verapamil, cation        0.57 0.77 
Verapamil 1.807 3.17 0.00 2.37 3.7861 0.0000 0.0000 0.72 0.76 
a Observed logkHSA values for ionic species and predicted logkHSA values for neutral species by Eq6 
b Observed logkAGP values for ionic species and predicted logkAGP values for neutral species by Eq7 
 
In the same way, here Eq 7 was used to calculate log kAGP for the neutral 
species of the acids and bases used in this study. After that, compared to 
experimental values of log kAGP of the corresponding ionic species of neutral, 
acidic compounds and basic compounds obtained from this work on 
immobilised AGP stationary phase (shown in Table 2.2). For the 5 acidic 
compounds, the average difference log kAGP (neutral acids) – log kAGP 
(anions) = 0.31 (±0.05) log units, so that on average the retention factor on 
HPLC AGP stationary phase for the neutral, acidic compounds is twice that for 
the anions. This further quantitatively confirms that anions do not favour 
interaction with the AGP stationary phase. For the 19 basic compounds, the 
average difference log kAGP (cation) – log kAGP (neutral base) = 0.32 (±0.02), 
meaning that the retention factor on HPLC AGP stationary phase for the 
protonated base cations is about 2.1 times that for neutral bases. This indicates 
the importance of the positive charge in the drug binding with immobilised AGP 
phase. 
Thus, through these experiments, the aims and objectives from 1 to 4 have 
been achieved successfully.  
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Chapter 5 Amino acid cocrystals 
5.0 Introduction 
Cocrystallisation approach has been used to tailor the physicochemical 
properties of the drug molecules. Though there is a major focus on 
improvement in dissolution rate of the drug molecule, cocrystallisation has been 
successfully used to improve compressional properties (Chattoraj and Sun; 
Chow et al. 2012), photostability (Vangala et al. 2011) and controlling hydrate 
formation (Trask et al. 2005b). Recently, Pagire and Paradkar et al. used 
cocrystallisation to control hygroscopicity of carboxylic acids (Paradkar and 
Pagire 2017).  
In all these applications selections of coformer is an important aspect; 
especially considering the regulatory requirements like the selection of generally 
recognised as safe (GRAS) molecule. An ideal coformer should have strong 
synthons to form hydrogen or halogen bond which will maintain stability during 
processing and storage. Recently, Alsirawan et al. demonstrated destabilisation 
of cocrystals due to the presence of a structurally related molecule in the 
formulation (Alsirawan et al. 2016). Another important aspect in pharmaceutical 
cocrystals is the safety of using a coformer in the stoichiometric proportion 
equal to the dose of the drug. Hence, recently there is growing trend towards 
the use of nutritional supplement molecules as coformers. However, for 
nutritional supplement molecules also there is a limit due to ‘recommended daily 
dosage allowance’ (RDA). Another advantage of nutritional supplement 
molecules is they are relatively low cost, but this category of molecules suffers 
from limitations such as instability in the presence of oxygen and moisture.  
The amino acid is a major class of nutritional supplement molecules which have 
high RDAs, low cost and most importantly high chemical diversity in terms of 
59 
 
hydrogen bond donor and acceptor groups and pKa values as shown in     
Table 2.2. Amino acids have amino and carboxylic groups which are donor and 
acceptor groups (Tan et al. 2006; Liu et al. 2016). They have a tendency to form 
hydrogen bonds with hydroxyl, carboxyl, pyridyl, amide and phenolic groups 
(Saha et al. 2005; Aakeroy et al. 2013; Liu et al. 2016). Recently, there are few 
reports of amino acid cocrystals. Cocrystallisation with a fumaric acid has 
achieved resolution of enantiomers of DL-arginine with fumaric acid (Iwama et 
al. 2014), ezetimibe–L-proline cocrystals have shown five times faster 
dissolution compared to pure ezetimibe (Shimpi et al. 2014). Liu et al. reported 
1:2 stoichiometric cocrystal of myricetin with L-proline, which showed 7.7 fold 
increases in dissolution and three-fold increases in bioavailability of myricetin 
compared to crystalline myricetin (Liu et al. 2016). 
Considering, chemical diversity and relatively unexplored molecular cocrystals 
of amino acids stimulated to investigate applications of cocrystal approach to 
amino acids. There are many opportunities, but we selected a molecular 
complex of an amino acid with the carboxylic acid group containing coformer for 
our research.  The major reason for selection of a carboxylic acid group is its 
tendency of forming a hydrogen bond. It is also found very commonly in most of 
the drugs and excipients which might be as abundant as amino or amide group. 
The carboxylic acid group is also associated with performance issues such as 
hygroscopicity, hydrate formation and acidity of drugs.   
The amino acids were screened for their sorption behaviour using DVS and the 
data are summarised in Table 5.1. 
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Table 5.1 DVS of amino acids 
Sr.No. Name of compound 
dm/dt in % (at 25 °C and 90% 
RH) 
1 L-serine 0.01 
2 L-threonine 0.02 
3 L-asparagine 0.02 
4 L-valine 0.03 
5 L-glycine 0.05 
6 L-aspartate 0.10 
7 L-phenylalanine 0.11 
8 L-arginine 0.12 
9 L-histidine 0.13 
10 L-alanine 0.14 
11 L-methionine 0.16 
12 L-isoleucine 0.23 
13 L-lysine 0.31 
14 L-tryptophan 0.33 
15 L-glutamate 0.38 
16 L-cysteine 0.43 
17 L-leucine 0.98 
18 L-proline 148.70 
 
The DVS data shows that most of the amino acids do not absorb significant 
moisture even at very high levels of %RH at 25 °C. However, L-proline was 
observed to absorb about 148.70 % moisture and dissolves in the absorbed 
moisture forming a solution. This state is known as deliquescence. However, L-
Serine absorbs 0.1% moisture only at 90% RH. Though there is no clear 
mechanistic understanding about high hygroscopic nature of L-proline, it is 
attributed to the presence of polar groups which favour moisture absorption 
(Lloyd and Phillips 1933).  
In the literature, some amino acid co-crystals pairs are reported (Tilborg et al. 
2014). These include L-glycine – glutaric acid, L-glycine-phthalic acid, L-glycine 
– tartaric acid, L-glycine–urea, L-serine–ascorbic acid and L-asparagine – 
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tartaric acid. These all reported pairs use amino acids which are non-
hygroscopic amino acids.  
Jayasankar et al. investigated the role of moisture in cocrystal formation by 
grinding technique, where deliquescent materials such as fructose, sucrose 
were added as excipients with the cocrystal pair and demonstrated that the 
absorbed moisture helps in the synthesis of cocrystals by grinding if 
temperature and humidity are maintained above deliquescent relative humidity 
(DRH) (Jayasankar et al. 2007). DRH is the function of the chemistry of the 
material as well as temperature. The substances like sugars and organic and 
inorganic salts exhibit deliquescence (Parsons et al. 2004; Salameh et al. 2006; 
Salameh and Taylor 2006b; Salameh and Taylor 2006a). On the similar basis, 
we hypothesise that L-proline; a deliquescent amino acid will help the formation 
of cocrystal in the neat grinding process (Please see Figure 5.1). In this current 
experiment ‘B’ is L-proline or citric acid and ‘A’ is API or another coformer. 
 
Figure 5.1 Mechanism of cocrystal formation in the presence of 
deliquescent material updated from Jayasankar et al. work. 
The DVS isotherm (n=3; s.d. ≤ 0.03)(Figure 5.2) of L-proline shows that L-
proline starts absorbing moisture at about 30% RH and continuous to maintain it 
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at about 15% till 70% RH above which moisture absorption took place at the 
rapid rate. This DVS profile makes L-proline an ideal deliquescent coformer 
material to explore cocrystal synthesis by neat grinding. Therefore, we 
investigated cocrystal synthesis of L-proline cocrystals with nine carboxylic 
acids. 
 
Figure 5.2 DVS of L-proline 
5.1 Screening of L-proline-carboxylic acid cocrystallisation 
In the current study, total nine carboxylic acids were screened for the co-
crystals formation with L-proline. The carboxylic acids include oxalic acid, 
malonic acid, succinic acid, glutaric acid, adipic acid, malic acid, fumaric acid, 
ascorbic acid and citric acid. Surprisingly, the neat grinding method for 
carboxylic acid and L-proline failed to generate cocrystals. This failure can be 
attributed to the critical amount of moisture required to cause cocrystallisation 
may not have reached due to the atmospheric humidity condition. In other 
words, the atmospheric humidity in the day of experiments might be less than 
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deliquescent relative humidity (DRH). It is relatively challenging to accept 
reason as at least 15% of moisture is absorbed in 30% RH. To address this 
issue of DRH few drops of water were added during grinding. These moistures 
assisted experiments also failed to generate any cocrystal formation instead 
resulted in a sticky mass (refer Table 5.2).  
The separation of cocrystal phase is dependent on the phase solubility 
behaviour of the cocrystal forming agents and the cocrystal. If the cocrystal has 
a high solubility or the cocrystal itself is hygroscopic or deliquescent then 
successful separation of the cocrystal phase will be challenging. Jayasankar et 
al., when proposed the hypothesis about the role of moisture in cocrystal 
formation by grinding they have used carbamazepine, theophylline, caffeine and 
sulfadimidine with nicotinamide, saccharine and carboxylic acids as coformers 
and sucrose and fructose as deliquescent agents.  
It was observed that DRH of sugars decreases significantly in the presence of 
coformers. The success of these experiments with sugar as deliquescence may 
be due to relatively less solubility of the cocrystal phase in the slurry state. 
Similar successes have been shown in slurry experiments of caffeine with 
carboxylic acids by Pagire et al., Apshingekar et al., in microwave (Pagire et al. 
2013a) and ultrasound slurry cocrystallisation (Apshingekar et al. 2016b) 
respectively. Apshingekar et al. have shown detained phase diagram during 
slurry experiments which indicates generation of cocrystal phase in low 
moisture region. Another reason for the failure of neat grinding process is a 
depression in DRH of L-proline leading to the formation of dilute slurry 
dissolving the cocrystal phase. The solubility of coformer does not affect 
significantly because we have selected some carboxylic acids with high 
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solubility as well as relatively less soluble NSAIDs molecules like ibuprofen, 
ketoprofen, flurbiprofen and aspirin. 
The next trials were conducted with ethanol as a solvent for liquid assisted 
grinding. So, including NSAIDs there were total 13 pairs used to carry out LAG 
of L-proline with carboxylic acid and NSAID. Out of 13 cocrystal experimental 
pairs, six pairs resulted in sticky mass even with ethanol and only seven pairs 
provided free-flowing powder (for details refer Table 5.2).  
Table 5.2 Screening of non-hygroscopic cocrystal with the LAG method. 
Co-crystal 
pair 
Stoichiometry Reported 
/ New 
Solvent Results   
L-proline-
fumaric acid 
1:1 Reported 
H2O 
EtOH 
Sticky 
Free flow 
L-proline- 
adipic acid 
1:1 Reported 
H2O 
EtOH 
Sticky 
Free flow 
L-proline-
succinic acid 
1:1 New 
H2O 
EtOH 
Sticky 
Free flow 
L-proline-
citric acid 
1:1 New 
H2O 
EtOH 
Sticky 
Sticky 
L-proline-
glutaric acid 
1:1 New 
H2O 
EtOH 
Sticky 
Sticky 
L-proline-
ascorbic acid 
1:1 New 
H2O 
EtOH 
Sticky 
Sticky 
L-proline- 
malic acid 
1:1 New 
H2O 
EtOH 
Sticky 
Sticky 
L-proline- 
malonic acid 
1:1 New 
H2O 
EtOH 
Sticky 
Sticky 
L-proline- 
oxalic acid 
1:1 New 
H2O 
EtOH 
Sticky 
Sticky 
L-proline- 
aspirin 
1:1 New 
H2O 
EtOH 
Sticky 
Free flow 
L-proline-
ibuprofen 
1:1 New 
H2O 
EtOH 
Sticky 
Free flow 
L-proline-
flurbiprofen 
1:1 New 
H2O 
EtOH 
Sticky 
Free flow 
L-proline-
ketoprofen 
1:1 New 
H2O 
EtOH 
Sticky 
Free flow 
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The powder mass obtained was further characterised using PXRD for the 
presence of any new peak (refer Table 5.3). The phases patterns obtained in 
screening experiments were characterised using PXRD. The new crystalline 
phase formation confirmed by comparison of the PXRD pattern of generated 
crystalline phase with that of the starting materials. The newly generated 
crystalline phase PXRD pattern matched completely with the starting material 
suggests no new crystalline phase formation occurred. However, the additional 
new peaks formation with subsequent disappearance of starting material 
indicates that there is new crystalline phase developed. The results of the 
screening study are summarised in Table 5.3. 
Table 5.3 Summary of screening experiment using PXRD 
Co-crystal pair 
Stoichio
metry 
Reported 
/New 
Solvent 
PXRD 
observation 
Result 
L-proline-
fumaric acid 
1:1 Reported 
H2O 
EtOH 
No new peaks  
New peaks  
No 
Yes 
L-proline- 
adipic acid 
1:1 New 
H2O 
EtOH 
No new peaks  
New peaks  
No 
Yes 
L-proline-
succinic acid 
1:1 New 
H2O 
EtOH 
No new peaks  
New peaks  
No 
Yes 
L-proline-citric 
acid 
1:1 New 
H2O 
EtOH 
No new peaks 
No new peaks 
No 
No  
L-proline-
glutaric acid 
1:1 New 
H2O 
EtOH 
No new peaks 
No new peaks 
No 
No  
L-proline- 
aspirin 
1:1 New 
H2O 
EtOH 
No new peaks  
New peaks  
No 
Yes 
L-proline-
ibuprofen 
1:1 New 
H2O 
EtOH 
No new peaks  
New peaks  
No 
Yes 
L-proline-
flurbiprofen 
1:1 New 
H2O 
EtOH 
No new peaks  
New peaks  
No 
Yes 
L-proline-
ketoprofen 
1:1 New 
H2O 
EtOH 
No new peaks  
New peaks  
No 
Yes 
 
Thus, only free flow powder formed compounds were subjected to further 
characterisation study with PXRD, DSC, TGA analysis. Based on the above 
PXRD results L-proline did not generate any new crystal phases using citric 
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acid and glutaric acid as cocrystal former. Thus, no further analysis of this pair 
was performed. 
5.1.1 Cocrystal characterisation 
5.1.1.1 L-proline- fumaric acid  
1 PXRD 
 All processed and starting materials were analysed using PXRD analyser to 
investigate the crystal phase (n=3). In the Figure below (Figure 5.3) it is 
observed that new characteristic crystal peaks at 8.88, 13.12 and 19.92 2θ° are 
generated in the L-proline-fumaric acid sample.  The PXRD pattern of L-proline-
fumaric acid is entirely different from individual starting materials as the 
characteristic peaks of starting materials are absent in the final sample. The 
PXRD pattern of L-proline-fumaric acid correctly coincides with the previously 
reported PXRD pattern by Tilborg et al. 2013 (Tilborg et al. 2013). 
 
Figure 5.3 PXRD patterns of L-proline-fumaric acid cocrystal and their 
original material 
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2 Thermal analysis 
2.1 DSC analysis 
Below Figure (5.4) describes the DSC thermograms of starting materials, their 
physical mixtures and processed samples of L-proline and fumaric acid (n=3). 
Based on the presence of the melting endotherm it is observed that single 
distinct melting endotherm at 159.2°C followed by degradation was observed for 
the processed samples of L-proline-fumaric acid cocrystal. This melting 
endotherm is different from the melting event of L-proline (221°C) (Ash and Ash 
2006; Hautala et al. 2016) and fumaric acid (287°C) (Figure 5.5) (Batisai et al. 
2014) respectively. Melting endotherm of the L-proline-fumaric acid physical 
mixture in 1:1 stoichiometric ratio displays endotherm (162.2°C) event which is 
correlate or gives an idea of cocrystal formation while compared to cocrystal 
sample. Based on the previous studies by Tilborg et al. in 2013, the melting 
endotherm of L-proline-fumaric acid rightly matches with the cocrystal phase 
(Tilborg et al. 2013). The endothermic event occurred at 217.8°C in L-proline is 
similar to the event observed by Shimpi et al.in their studies (Shimpi et al. 
2014). 
 
Figure 5.4 DSC thermograms of L-proline pure, L-proline-fumaric acid 
cocrystal and physical mixture (1:1) 
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Figure 5.5 DSC thermogram of fumaric acid. 
2.2 TGA analysis 
TGA analysis was performed to check the onset of melting point and 
degradation patterns of starting materials, processed materials and their 
physical mixtures (n=3). Based on the data it is observed that the onset of 
melting for L-proline–fumaric acid cocrystal at 113.6°C is lower and different 
from that of onset melting points of both L-proline and fumaric acid or their 
physical mixture. The presence of single degradation event for cocrystal sample 
proves that single phase is generated. 
The difference in onset melting and single degradation event of the LAG 
material suggests that there is new crystalline phase has occurred. The results 
of PXRD and DSC corroborate well with each other. See Figure 5.6. 
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Figure 5.6 TGA of L-proline pure, fumaric acid pure, their physical mixture 
(1:1) material and L-proline-fumaric acid cocrystal. 
3 DVS analysis 
DVS analysis was performed to investigate the water uptake profile for L-
proline-fumaric acid cocrystal compared to their starting material and physical 
mixture (n=3; s.d.≤ 0.03). Based upon the DVS profile the moisture absorption 
capability of L-proline in cocrystal phase with fumaric acid is drastically reduced 
compared to L-proline raw material and L-proline-fumaric acid physical mixture. 
Based on the tabular data in Table no 5.4 it is observed that L-proline-fumaric 
acid cocrystal did not absorb any moisture until 40% RH at 25°C which was 
further followed by negligible rise by 0.15% moisture uptake until 80%RH after 
which at 90% RH 81.17% moisture uptake occurred. In comparison with 
moisture absorption profile of L-proline raw 89.6%, moisture absorption took 
place at 80% RH followed by forming deliquescent material.  
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Thus, based on DVS data, upon cocrystallisation of L-proline with fumaric acid 
the water absorption capacity of L-proline is highly reduced or its stable in the 
presence of high moisture conditions. Figure 5.7 represents the DVS absorption 
profile of raw L-proline, a physical mixture of L-proline- fumaric acid and their 
cocrystal. The change in the water absorption of L-proline in its cocrystal state 
can be attributed to the hydrogen bond interactions with a carboxylic acid. This 
indicates that the cocrystallisation helps to reduce the hygroscopicity of L-
proline.   
Table 5.4 DVS of L-proline, fumaric acid with their physical mix and 
cocrystal 
RH (%) 
L-proline-
fumaric acid 
cocrystal 
(dm/dt) 
fumaric acid 
(dm/dt) 
L-proline-
fumaric acid 
physical 
mix 
(dm/dt) 
L-proline 
pure  
(dm/dt) 
0.0 0.00 0.00000 0.00 0.0 
10.0 0.01 0.00248 0.00 0.0 
20.0 0.02 0.00397 0.00 0.1 
30.0 0.03 0.00459 0.01 0.2 
40.0 0.00 0.00360 0.01 15.5 
50.0 0.00 0.00385 0.01 15.7 
60.0 0.03 0.00385 7.10 15.7 
70.0 0.07 0.00497 27.89 16.0 
80.0 0.15 0.00670 35.79 89.6 
90.0 81.17 0.01217 66.49 148.7 
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Figure 5.7 DVS of L-proline, fumaric acid and their physical mixture (1:1) 
and cocrystal. 
4 Summary 
Based on the PXRD and thermal data generation of L-proline-fumaric acid 
cocrystal was confirmed. Additionally, the stability of the cocrystal was 
described by generating comparative moisture absorption profile between L-
proline-fumaric acid cocrystal and individual starting materials.  
5.1.1.2 L-proline- adipic acid  
1 PXRD 
Below Figure no 5.8 represents the PXRD pattern of L-proline, adipic acid 
starting materials and L-proline-adipic acid cocrystal (n=3). The PXRD pattern 
reveals the absence of characteristic peaks of L-proline (12.5 2θ°) and adipic 
acid (15 2θ°) in L-proline-adipic acid cocrystal. Instead, a new characteristic 
peak at 10.88 2θ° angle is observed. This change in the PXRD pattern and 
generation of new peaks reveals the formation of new crystal phase. 
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Figure 5.8 PXRD results of L-proline-adipic acid cocrystal 
2 Thermal analysis 
Thermal analysis was performed to investigate the melting endotherm and 
phase purity of cocrystal generated for the same. 
2.1 DSC data 
Below Figure 5.9 represents the DSC thermogram for starting materials of L-
proline, adipic acid, physical mixture and processed cocrystal sample of L-
proline-adipic acid (n=3). Based on the literature review the melting endotherm 
event for L-proline and adipic acid is observed at 121°C (Ash and Ash 2006) 
and 151-154°C (Batisai et al. 2014) respectively. On analysing processed L-
proline-adipic acid sample single distinct endotherm was observed at 120.56°C, 
this endotherm is different when compared to raw material melting endotherms. 
Thus, it can be concluded that new phase is generated which can be correlated 
to cocrystal formation. The melting endotherm event observed at 116°C could 
be a hydrate or solvate formation or may be a solid to solid transition but need 
5 10 15 20 25 30
0
1000
2000
 Angle 2 ()
 Proline-Adipic acid cc pXRD
 
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 Proline -Adipic acid CC
 Adipic Acid Pure
 Proline pure10.68
73 
 
to confirm. The absence of an endothermic event in between 80-110°C reveals 
that there is no bound or unbound solvent molecule. The physical mix of both 
showed endotherm at 123.28°C.  
 
Figure 5.9 DSC of L-proline, adipic acid and their cocrystal and physical 
mixture (1:1). 
2.2 TGA data 
TGA analysis was performed for starting materials, their physical mixtures and 
processed samples (n=3).  Based on TGA thermogram the onset of melting 
event for L-proline-adipic acid cocrystal is different compared to individual 
components (refer Figure 5.10). L-proline-adipic acid onset melting started at 
105.82°C compared to melting event of L-proline at 144.67°C and adipic acid at 
120.11°C. The single degradation event suggests that the obtained material is 
single phase. 
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Figure 5.10 L-proline - adipic acid co-crystal TGA with L-proline, adipic 
acid and their physical mixture (1:1). 
3 DVS data 
The moisture absorption profile of L-proline, adipic acid, physical mixtures and 
cocrystal was evaluated using DVS analyser (n=3; s.d.≤ 0.03). Based on the 
data (refer Table 5.5) it is revealed that cocrystal of L-proline and adipic acid 
water absorption capacity is negligible until 80%RH compared to L-proline as 
starting material (89.6%). As adipic acid is non-hygroscopic, it did not absorb 
any moisture. Below is the Table 5.5 percent moisture uptake of raw, physical 
mixture and processed samples of L-proline and adipic is reported against 
percent RH and after that represented pictographically in Figure 5.11.   
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Table 5.5 DVS of L-proline, adipic acid and their physical mix and 
cocrystal. 
RH (%) 
L-proline-
Adipic acid 
cocrystal 
(dm/dt) 
Adipic acid 
(dm/dt) 
L-proline-
Adipic acid 
physical mix 
(dm/dt) 
L-proline 
pure  
(dm/dt) 
0.0 0.00 -0.00009 0.00 0.0 
10.0 0.01 0.00214 0.00 0.0 
20.0 0.01 0.00250 0.00 0.1 
30.0 0.01 0.00161 0.00 0.2 
40.0 0.02 0.00402 0.01 15.5 
50.0 0.02 0.00500 0.01 15.7 
60.0 0.03 0.00705 5.50 15.7 
70.0 0.04 0.00937 20.85 16.0 
80.0 0.12 0.01178 19.71 89.6 
90.0 70.66 0.01795 48.88 148.7 
 
 
Figure 5.11 DVS of L-proline, adipic acid and their cocrystal and physical 
mixture (1:1). 
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4 Summary 
These studies suggest that there is the formation of cocrystal between L-
proline-adipic acid and it confirms with the PXRD crystalline phase pattern and 
DSC results. Additionally, it is supported by TGA studies. This study also 
supports the L-proline-fumaric acid study, that the cocrystallisation can improve 
the hygroscopicity of the molecules like L-proline. In the current study total, 
52.48% reduction in the hygroscopicity of L-proline was observed after 
cocrystallisation with adipic acid. 
5.1.1.3 L-proline-succinic acid  
1 PXRD 
L-proline- succinic acid in 1:1 stoichiometric ratio was processed using liquid 
assisted grinding (n=3). The PXRD analysis was performed to check generation 
of new crystal peaks. Below Figure 5.12 describes the PXRD data for raw and 
processed samples of L-proline and succinic acid. PXRD patterns displayed 
that L-proline and succinic acid retains their characteristic peaks at 15, 17.88 
2θ° angle and 26.5 2θ° angle respectively. In LAG sample of L-proline-succinic 
acid new characteristic peaks are observed at 9 and 13.8 2θ° angle which are 
not present in starting materials of L-proline and succinic acid. This change in 
the PXRD pattern and generation of new peaks reveals the formation of new 
crystal phase. 
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Figure 5.12 PXRD results of L-proline-succinic acid cocrystal 
 
2 Thermal analysis 
2.1 DSC data 
The DSC analysis of the L-proline, succinic acid raw materials, their physical 
mix and LAG processed sample was carried out 3 times (Figure 5.13). DSC 
thermogram of L-proline-succinic acid reveals a distinct characteristic 
endothermic peak at 115.55°C, which is different from the melting events of 
individual starting materials. This correlates with the melting peak observed in 
the physical mix DSC analysis of the L-proline and succinic acid. As per the 
PubChem records, the melting point of L-proline is 121°C (Ash and Ash 2006), 
and a melting point of succinic acid is 185-190°C (Soewandhi). Based on the 
DSC data new crystal phase of L-proline-succinic acid is generated, similar 
results were also observed in the PXRD analysis 
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Figure 5.13 DSC of L-proline, succinic acid and their cocrystal and 
physical mixture (1:1). 
 
2.2 TGA data 
In the thermogravimetric analysis (Figure 5.14) of the L-proline-succinic acid 
cocrystal (n=3), it was observed that the onset melting pattern of the material is 
different from that of the starting material. The cocrystal material onset melting 
start point observed at 97.10°C temperature. However, the L-proline showed 
onset melt at 144.67°C temperature. The succinic acid showed onset melt at 
111.39°C. The difference in the onset melting pattern and single phase 
degradation pattern indicates the new crystalline phase formation and absence 
of impurities.  
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Figure 5.14 TGA of L-proline, succinic acid and their cocrystal. 
3 DVS data 
Absorption profile of L-proline, succinic acid raw materials, physical mixture and 
cocrystal was generated using DVS analyser (n=3; s.d.≤ 0.03). Below Table 5.6 
reveals that L-proline-succinic acid cocrystal displayed very negligible moisture 
absorption until 80%RH followed by an increase in the moisture absorption 
profile. Negligible moisture absorption was observed in case of succinic acid as 
it is non-hygroscopic. L-proline, as it is hygroscopic, 15.70% absorption was 
observed at 80% RH followed by 148.70% absorption at 90%RH turning it into 
deliquescent. 
This states that the hygroscopic property of L-proline is minimised by preparing 
cocrystal of L-proline and succinic acid. Below Figure 5.15 represents the 
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graphical representation of absorption profile of individual starting material, 
physical mixture and end cocrystal product. 
Table 5.6 DVS of L-proline-succinic acid and their cocrystal and physical 
mixture (1:1). 
RH (%) 
Succinic acid 
(dm/dt) 
L-proline- 
Succinic acid 
physical mix 
(dm/dt) 
L-proline- 
Succinic 
acid CC 
(dm/dt) 
L-proline pure 
(dm/dt) 
0.0 0.0001 0.00 0.00 0.0 
10.0 -0.0001 0.00 0.01 0.0 
20.0 0.0011 0.00 0.00 0.1 
30.0 0.0018 0.01 0.00 0.2 
40.0 0.0014 0.01 0.00 15.5 
50.0 0.0026 0.02 0.01 15.7 
60.0 0.0045 4.76 0.03 15.7 
70.0 0.0083 16.52 1.83 16.0 
80.0 0.1002 24.87 44.12 89.6 
90.0 0.5149 42.96 80.78 148.7 
 
 
Figure 5.15 DVS of L-proline, succinic acid and their cocrystal and 
physical mixture (1:1). 
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4 Raman spectroscopy data 
Raman spectroscopic analysis was performed to elucidate further the formation 
of bonding between L-proline and succinic acid cocrystal produce using liquid 
assisted grinding (n=3). 
Raman spectroscopy analysis of L-proline-succinic acid co-crystal reveals that 
there was no salt formation occurred. It means that there may be the formation 
of a co-crystal. If there had been a salt formation, then the primary amine salts 
absorption of -NH3+ would have been in the region of 3350cm-1 and 3100cm-1 of 
Raman shift. However, in this case, no such bands were observed. The Amines 
with >NH2+ and C=NH+ would have been absorbed in between 2700-2250cm-1 
Raman shift (Larkin 2017). However, no such bands/peaks were observed. It 
means that the obtained material is co-crystal of L-proline and succinic acid 
(1:1). It has been supported by the PXRD and DSC data of the same.  See the 
Figure 5.16. 
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Figure 5.16 Raman spectrograph of L-proline-succinic acid cocrystal with 
starting material. 
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5 Summary 
The cocrystal process of L-proline with carboxylic acids was carried out for all 
the powdered samples out of which L-proline failed to generate cocrystals with 
citric and tartaric acid and successfully generated cocrystal with fumaric, adipic 
and succinic acid. Cocrystallisation of L-proline and fumaric acid was already 
explored by Tilborg et al. in 2013. New crystalline phase was observed in all the 
L-proline-carboxylic acid cocrystal pairs which were further supported by 
thermal data. The hygroscopic property of L-proline had decreased 
considerably in all the cocrystal pairs compared to L-proline as starting material. 
 
5.2 L-proline and non-steroidal anti-inflammatory drugs (NSAIDs) 
cocrystallisation 
Based on the hydrogen bonding capability of L-proline, we have further 
explored the cocrystal formation between L-proline and different active 
pharmaceutical ingredients. Recently, Shimpi and group have reported the 
cocrystallisation of L-proline molecule with certain imidazole and ezetimibe 
categorised active components (Shimpi et al. 2014). Tilborg and group have 
recently published the cocrystallisation of L-proline with different profen groups 
of NSAID (Tilborg et al. 2014). Thus, based on the previous studies we have 
selected different API molecule which belong to NSAID group such as 
ibuprofen, flurbiprofen, ketoprofen and aspirin. Both L-proline and NSAID were 
selected in 1:1 molar stoichiometric ratio and further cocrystals screening were 
done using liquid assisted grinding technique.  
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5.2.1 Characterisation studies of L-proline- NSAIDs co-crystals 
1 PXRD 
Different characterisation studies using PXRD and thermal analysis were 
performed to reveal the formation of cocrystals with amino acids. 
1.1 L-proline - aspirin  
The LAG processed sample of L-proline-aspirin and L-proline, aspirin original 
samples were analysed using PXRD analyser to investigate the crystal phase 
(n=3). In the following Figure 5.17, it is observed that new characteristic 
crystalline phase peaks at 5.4 2θ° and 11.2 2θ° are observed in L-proline-
aspirin 1:1 ratio LAG sample. The PXRD pattern of the L-proline-aspirin sample 
is completely different from individual starting material as the characteristic 
peaks of L-proline at 15 2θ° and aspirin at 15.5 2θ° are absent in the PXRD 
pattern of L-proline-aspirin processed sample. This change in the PXRD pattern 
and generation of new peaks reveals the formation of new crystal phase. 
 
Figure 5.17 PXRD of L-proline- aspirin LAG (1:1) sample with starting 
material 
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1.2 L-proline-flurbiprofen  
The Figure no. 5.18 represents the PXRD pattern of L-proline, flurbiprofen 
starting material and L-proline-flurbiprofen 1:1 LAG sample (n=3). The PXRD 
pattern reveals the formation of new characteristic peaks at 8.2,14.8 and 18.64 
2θ°values. However, the strong characteristic peaks of L-proline from 15,18 and 
19 2θ° and of aspirin from 7.5, 11.5, 21 and 23 2θ° values are absent in the 
newly formed crystalline phase. It indicates that there is new crystal phase 
formed. 
 
Figure 5.18 PXRD of L-proline-flurbiprofen LAG (1:1) sample with starting 
material 
1.3 L-proline – ketoprofen PXRD results 
The LAG processed sample of L-proline-ketoprofen and starting material 
samples were analysed using PXRD analyser to investigate the crystal phase 
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(n=3). In the following Figure 5.19, it is observed that new characteristic 
crystalline phase peaks at 8.12, 24.76 2θ° angle and 25.88 2θ° angle are 
observed in L-proline-ketoprofen 1:1 ratio LAG sample. The PXRD pattern of 
the L-proline-ketoprofen sample is completely different from individual starting 
material as the characteristic peaks of starting materials are absent in the newly 
developed crystalline phase sample. This change in the PXRD pattern and 
generation of new peaks reveals the formation of new crystal phase. 
 
 
Figure 5.19 PXRD of L-proline-ketoprofen 1:1 LAG  sample with starting 
material 
1.4 L-proline – Ibuprofen PXRD results 
The PXRD analysis of the L-proline-ibuprofen 1:1 LAG sample along with 
starting material was performed using Bruker D8 PXRD analyser to investigate 
the crystal phase (n=3). (Figure 5.20) Through this PXRD analysis, it was 
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observed that there are two characteristic peaks were generated at 4.12 and 
5.12 2θ° values in the L-proline-ibuprofen LAG sample. These two peaks are 
absent in the original starting material. Original L-proline peak at 15 2θ° and that 
of ibuprofen at 6.092θ° values are absent in the newly formed crystal phase. 
This change in the PXRD pattern and newly generated peaks indicate the 
formation of new crystal phase. While working on these NSAIDs and amino 
acids co-crystal, similar kind of work was published by Othman (Othman et al. 
2016). The PXRD pattern of L-proline-ibuprofen 1:1 LAG sample is correctly 
coinciding with the reported PXRD pattern by Othman. 
 
Figure 5.20  PXRD of L-proline- ibuprofen 1:1 LAG sample with starting 
material 
2 DSC 
Table 5.7 describes the DSC thermograms of starting materials and processed 
samples of L-proline and NSAIDs (n=3). Based on the presence of the melting 
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endotherms of L-proline and NSAIDs used in 1:1 LAG sample it is observed that 
single distinct melting endotherm followed by degradation was observed for the 
processed samples of L-proline-NSAIDs (Figure 5.21). This melting endotherm 
is different from the melting event of L-proline (221°C) (Ash and Ash 2006; 
Hautala et al. 2016). The melting point of ibuprofen is at 74.45°C and 
ketoprofen is at 92.85°C (Xudong and Capomacchia 2010).The flurbiprofen has 
shown the melting point at 116°C (Varma and Pandi 2005) and aspirin melting 
point is at 135°C (Huang et al. 2005). Based on the previous studies the melting 
endotherm of L-proline-ibuprofen (Othman et al. 2016) rightly matches with the 
cocrystal phase.  
Table 5.7 Melting points of L-proline and NSAIDs with their 1:1 LAG 
samples. 
Sr.No. Name of Compound/Drug Melting point (°C) 
1 L-proline pure 221 
2 Aspirin 135 
3 Flurbiprofen 116 
4 Ketoprofen 92.9 
5 Ibuprofen 74.5 
6 L-pro-asp (1:1) LAG sample 86.4 
7 L-pro-flurb (1:1) LAG sample 150.7 
8 L-pro-keto (1:1) LAG sample 63.1 
9 L-pro-ibu (1:1) LAG sample 111.5 
L-pro=L-proline, asp=aspirin, flurb=flurbiprofen, keto=ketoprofen and 
ibu=ibuprofen. 
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Figure 5.21 DSC thermogram of L-proline-NSAIDs and their 1:1 LAG 
samples. 
 
3 Summary 
Amino acid L-proline was screened for cocrystallisation development with the 
NSAIDs molecules. Total four drugs were screened under this experimental 
study. 
The DSC and PXRD characterisation study results were promising for the 
consideration as a new cocrystal formation. After careful observation of the 
difference in the melting points of cocrystals with their original starting materials 
one can assume that the cocrystals are changing their physicochemical 
properties. Such as, aspirin melting point is 135°C and its cocrystal showed 
melting point around 86.43°C, mean it could be more soluble form of aspirin. 
Similarly, ketoprofen has melting point as 92.85°C and its cocrystal with L-
proline has melting point around 63.13°C, means it may be more soluble than 
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the original ketoprofen. However, in the case of ibuprofen and flurbiprofen, it is 
reverse. These both cocrystals showed more melting points than their pure 
forms. During this study, the similar work was published by Othman et al. 
(Othman et al. 2016). This work was could not go further. However, it could be 
possible to explore in future. 
5.3 Citric acid – amino acids cocrystallisation 
Based on the application of amino acid in the formation of molecular bonding 
with organic molecules we have selected citric acid as model component and 
explored the possibility of cocrystallisation with different amino acid molecules. 
Citric acid is widely used an organic molecule in pharmaceutical and food 
industry. The use of citric acid is limited due to its hygroscopic nature which on 
exposure to higher moisture conditions, readily absorbs moisture and loses its 
structural integrity.  
Initially, to understand the moisture absorption profile of citric acid we have 
performed DVS analysis for citric acid only (n=3). Below Figure 5.22 reveals the 
DVS isotherm of citric acid, it demonstrates that it is stable until 70% RH 
followed by drastic absorption of moisture and forming deliquescence. 
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Figure 5.22 DVS of citric acid 
In all the experiments of citric acid and amino acids, they were accurately 
weighed in 1:1 stoichiometric ratio and ethanol was used as the solvent system 
for liquid assisted grinding (n=3;s.d.≤ 0.03). Table 5.8 reveals the experimental 
data.
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  Table 5.8 Screening of amino acids co-crystals with citric acid. 
Sr. 
No. 
Molecules selected Molar 
ratio 
Solvent 
Liquid 
Obtained 
material phase 
PXRD DSC DVS Raman FT-IR 
1 L-Alanine: citric acid 1:1 H2O/EtOH 
sticky 
sticky x x X x x 
2 L-proline: citric acid 1:1 H2O/EtOH sticky x x X x x 
3 L-Valine: citric acid 1:1 H2O/EtOH sticky x x X x x 
4 L-Leucine: citric acid 1:1 H2O/EtOH Dry, free flow ✓  ✓  ✓  ✓  ✓  
5 L-Isoleucine: citric acid 1:1 H2O/EtOH 
Sticky Et 
Dry, free flow ✓  ✓  ✓  ✓  ✓  
6 L-Phenylalanine: citric acid 1:1 H2O/EtOH sticky x x X x x 
7 L-Serine: citric acid 1:1 H2O/EtOH Dry, free flow ✓  ✓  ✓  ✓  ✓  
8 L-Threonine: citric acid 1:1 H2O/EtOH sticky x x X x x 
9 L-Asparagine: citric acid 1:1 H2O/EtOH sticky x x X x x 
10 L-Aspartate: citric acid 1:1 H2O/EtOH sticky x x X x x 
11 L-Arginine: citric acid 1:1 H2O/EtOH sticky x x X x x 
12 L-Histidine: citric acid 1:1 H2O/EtOH sticky x x X x x 
13 L-Methionine: citric acid 1:1 H2O/EtOH Dry, free flow ✓  ✓  ✓  ✓  ✓  
14 L-lysine: citric acid 1:1 H2O/EtOH  sticky x x X x x 
15 L-Tryptophan: citric acid 1:1 H2O/EtOH  sticky x x X x x 
16 L-Glutamate: citric acid 1:1 H2O/EtOH  sticky x x X x x 
17 L-Cysteine: citric acid 1:1 H2O/EtOH  Dry, free flow ✓  ✓  ✓  ✓  ✓  
 
✓ =    selected for characterisation        x = not selected 
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Based on the above experimental data, citric acid has failed to generate any 
cocrystal phase with 12 of the amino acids; this may be due to the molecular 
structure of the amino acids or binding affinity of citric acid with amino acids. 
Only five amino acids successfully generated cocrystals with citric acid. 
They are namely citric acid - L-leucine, citric acid - L-isoleucine, citric acid - L-
serine, citric acid - L-methionine, and citric acid - L-cysteine. These five samples 
were further examined for characterisation.  
5.3.1 Citric acid - L- leucine study 
1 PXRD data:  
Based on the PXRD data it was observed that new peaks at 6.68, 18.68 and 
19.64 2θ° were observed for citric acid-L-leucine processed samples (n=3). 
Citric acid and L-leucine amino acid pattern displayed characteristic peaks at 15 
and 6.1 2θ° respectively. These characteristic peaks of individual components 
were absent in citric acid-L-leucine processed samples. Instead, generation of 
new peaks were detected. Thus, PXRD pattern indicates the formation of a new 
crystalline complex which is different from starting material. Below Figure 5.23 
represents the PXRD pattern for citric acid, L-leucine starting materials and their 
processed samples. 
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Figure 5.23 PXRD of citric acid, L-leucine starting material and their LAG 
processed material 
2 DSC data 
Based on the literature review and experimental data, the citric acid melting 
point is 153°C (Barbooti and Al-Sammerrai 1986; NCBI 2018a) and the leucine 
melting point is 293°C (NCBI 2017b). (See-Figure 5.24). In the DSC 
thermograms of citric acid-leucine LAG material (n=3), it was observed that 
there is single endothermal melting point showed at 126.20°C, which is different 
from the original starting material melting points. Which might be suggest that 
this product will be highly soluble than the starting material. It correlates with its 
DVS studies, where it absorbs more moisture and become deliquescent. It 
indicates that there may be a cocrystal formation occurred between leucine and 
citric acid. As there was no endothermic event observed in the region between 
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80 to 110°C no bound or unbound residual solvent is present in the final 
sample. 
 
Figure 5.24 DSC thermogram of citric acid - L-leucine physical mixture 
(1:1), starting material and LAG complex of citric acid- L-leucine. 
3 Spectroscopic data 
Spectroscopic analysis was performed to further investigate the formation of 
hydrogen bonding between the two components.  
3.1 Raman spectroscopy 
In the below Raman spectra (Figure 5.25) analysis it was observed that there is 
no similarity in the peaks of the newly formed material by LAG of leucine and 
citric acid when compared with the individual starting material (n=3). It indicates 
that there may be the co-crystals formed between L- leucine and citric acid 
molecules.  
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Figure 5.25 Raman spectra of L- leucine - citric acid co-crystals. 
In Raman spectrum analysis, CH2-CH torsion was not observed in the co-
crystal at 209.2 cm-1. A Raman shift occurred at 679 to 670 cm-1 for C=O 
stretching, for NH3 rock from 1085 to 1081.5 cm-1, CH2 wag from 1217 to 
1237.8 cm-1. Then, O-CO bending of COOH occurred from 1345.2 to 1342.2 
cm-1, NH3 symmetric bend from 1511 to 1506 and asymmetric bending from 
1558 to 1554.1 cm-1 occurred.  
Table 5.9 shows the Raman spectrum bands of L-leucine- citric acid and their 
co-crystal. 
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Table 5.9 Raman spectra band and associated functional groups in L-
leucine, citric acid and their co-crystal 
Transition energies (cm-1) 
with mode descriptions of 
L-leucine 
citric acid L-leucine -citric acid cc 
Raman spectra 
observed 
Raman  A functional 
group 
associated. 
Raman A functional 
group 
associated. 
Raman 
209.2 CH2-CH torsion 212     
258.8   258m 
broad 
    
296.2 CH2-CH-CO2 
bend 
      
    301m     
331.2         
    345m   348.6 
367.2 S-H out-of-plane 
bend 
    362.1 
  N-CH-CO2 bend 417m     
452 CH2-CH-SH 
bend 
    457.8 
513   499w     
531.3 CH2-CH-N bend 539sh   533.8 
  NH3 torsion 550m     
    593m sC-CH3 599.2 
  CH-CO2 stretch 636w     
679.2   682m C=O 
stretching 
670.1 
  C-S stretch       
        725.8 
777.6 CH2 rock 780s   783.5 
  CH2 Scissors       
841.5       846.3 
  CO2 wag       
    877w     
921.1   900m C-C bends 
and OH out-of-
plane bending 
  
  N-CH stretch 939s C-C symmetric 
stretch 
943.1 
959.2         
97 
 
996 CH2-CH stretch       
        1029.4 
1034.6 S-H in-plane 
bend 
1050m C-O stretch 1054.4 
1,085 NH3 rock 1082m  C-O stretch 1081.5 
1126 NH3 rock 1141m   1128.6 
1178   1165w   1187.8 
  CH2 twist 1205m C-C stretching 1213.8 
1,231 CH2 wag 1217m   1237.8 
1260, 
1274 
C-H bend       
1294, 
1326 
C-H bend       
1309.1         
1345.2 CO2 symmetric 
stretch 
1346w O-CO bending 
of COOH 
1342.2 
1410 CH2 Scissors 1387s CH2 scissors 1407.1 
    1430m 
broad 
C-OH def.   
1465   1466 m 
broad 
CH2 scissors 1454.2 
1511 NH3 symmetric 
bend 
    1506.1 
1558 NH3 asymmetric 
bend 
    1554.1 
  NH3 asymmetric 
bend 
      
1627   1630 m 
broad 
  1625.1 
1678 CO2 asymmetric 
bend 
    1689, 1719 
 
Symbols used are r: rocking, ν: stretching, δ: deformation, t: twisting, ω: 
wagging, γ: deformation out of the plane, τ: torsion, as: antisymmetric, s: 
symmetric, skel.: skeleton, sh: shoulder, w: weak peak intensities 
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3.2 FT-IR spectroscopy 
FT-IR spectroscopic analysis was performed on raw and processed samples 
(n=3) (refer Figure 5.26). 
 
900 1000 1100 1200 1300 1400 1500 1600 1700 1800
50
100
150
200
250
300
%
 T
ra
n
sm
it
ta
n
ce
Wavenumber cm
-1
 Citric acid
 L-leucine
 L-leucine-citric acid cocrystal
157615101406
 
Figure 5.26 FT-IR spectra of citric acid, L-leucine and their co-crystal.        
The obtained results with peak bands with their associated functional groups 
are represented in Table 5.10. 
Table 5.10 FT-IR spectra peak band and associated group of L-leucine, 
citric acid and their co-crystal 
L-leucine cm-1  
associated 
group 
citric acid 
associated 
group 
L-leucine - citric acid 
cc IR 
 
CH-CO2 
stretch 
639.6 
 
648.8 
668 C-S stretch 686.2m 
C=O 
stretching  
768.2 CH2 rock 770.5 
 
744.6 
 
CH2 
Scissors 
818.4s 
 
818.5 
847     
865.8 CO2 wag 
  
882 
  
881.2w 
 
885.5 
943 
N-CH 
stretch 
900m 
C-C bends 
and OH 
                  910 
99 
 
out-of-
plane 
bending 
1003 
CH2-CH 
stretch 
934.3s 
C-C 
symmetric 
stretch 
981.8 
 
S-H in-
plane bend 
1.053.82 
 
1049 
1032 NH3 rock 1050m 
C-O 
stretch  
1085 NH3 rock 1082m 
C-O 
stretch  
1134 
 
1138m 
 
1138 
1,185 CH2 twist 1171w 
  
1239 CH2 wag 1216.72m 
C-C 
stretching 
1215 
 
C-H bend 1217m 
 
1272 
1295 C-H bend 1293.86 
 
1308 
1362 
CO2 
symmetric 
stretch 
1358.80 
 
1356 
 
CH2 
Scissors 
1389.78w 
O-CO 
bending of 
COOH 
1416 
  
1387s 
CH2 
scissors  
1405 
 
1426m 
broad 
C-OH def. 1461 
 
NH3 
symmetric 
bend 
1466 m 
broad 
CH2 
scissors  
1511    1517 
1575 
NH3 
asymmetric 
bend 
  
1574 
 
NH3 
asymmetric 
bend 
  
1616 
 
CO2 
asymmetric 
bend 
1630 m 
broad   
 
 
1695 vs 
C=O 
stretching 
1687 
 S-H stretch 1743s n(COOH)  
2124.9     
2617 N-H stretch 
  
 
2869 N-H stretch 
  
2869 
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The FT-IR analysis of L-leucine, citric acid and their co-crystals showed CH-
CO2 stretch at 648.8 cm-1. The CH2 rock was observed at 744.6 cm-1 and CH2 
scissors was observed at 818.5 cm-1 and CO2 wag was observed at 882 cm-1. 
The N-CH stretch and C-C bends and OH out-of-plane bending peak was 
observed at 910 cm-1. S-H in-plane bend was observed at 1049, CH2 wag and 
C-C stretching were observed at 1215 cm-1. CH2 scissors and O-CO bending of 
COOH was observed at 1416 cm-1. NH3 asymmetric bends were observed at 
1574 cm-1 and 1616 cm-1. These IR peaks suggest that there may be bonding 
between these two molecules and due to the co-crystal hydrate formation. 
Though there are chances of proton transfer in these reacting molecules as 
leucine has –NH group and –COOH functional groups and citric acid has –
COOH groups, but no such proton transfers occurred. Therefore, the obtained 
pair is a cocrystal and not salt.  
4 DVS data 
DVS analyser was used to investigate the moisture absorption capability of the 
synthesised cocrystal (n=3;s.d.≤ 0.03). Below Table 5.11 reveals that citric 
acid-leucine cocrystal displayed higher absorption profile than individual 
component. It indicates that the cocrystal formation of leucine-citric acid could 
  
2949w 
  
2957 
 
2956w 
 
2961 
 
 
2979w 
 
2972 
 C-H stretch 2993w 
  
 
CH2 
symmetric 
stretch 
  
3136 
 
CH2 
asymmetric 
stretch 
   
 N-H stretch 3283 
  
  3494 
 
3447 
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not improve citric acids hygroscopic nature rather it absorbs more moisture than 
the pure citric acid molecule. The obtained cocrystal material was mixed with 
sodium bicarbonate in the molar ratio of 1.5 times of sodium bicarbonate to the 
citric acid content in the cocrystal to understand the stability property of 
cocrystals during formulation of effervescent tablets. When this mixture 
subjected to the DVS, it was observed that it showed less moisture absorption 
than the pure citric acid molecule.  Figure 5.27 represents the DVS isotherm for 
raw and processed samples. 
Table 5.11 DVS of L-leucine, citric acid and their co-crystal. 
%RH citric acid 
L-leucine-
CA cc 
L-leucine pure 
L-leucine - CA cc 
+1.5x SBC 
0.0 0.00 0.00 0.0005 0.00 
10.0 0.00 0.06 0.0318 0.02 
20.0 0.00 0.12 0.0454 0.00 
30.0 0.00 0.18 0.0842 -0.01 
40.0 0.00 0.18 0.1110 0.03 
50.0 0.00 0.23 0.1493 0.03 
60.0 0.01 0.28 0.1967 0.01 
70.0 0.02 5.13 0.2865 0.78 
80.0 4.65 35.91 0.4439 4.54 
90.0 31.21 56.58 0.9806 12.85 
 
CA= Citric acid, cc= cocrystal, SBC= Sodium bicarbonate 
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Figure 5.27 DVS of L-leucine, citric acid and their co-crystal. 
 
5.3.2 Citric acid - L- isoleucine study 
1 PXRD data 
Based on the PXRD data (Figure 5.28) it is observed that citric acid and 
isoleucine starting materials retain their characteristic peaks at 15 and six 2θ°. 
When citric acid- isoleucine LAG sample was analysed through PXRD (n=3), 
new peaks were detected at 6.92, 8.88 and 13.24 2θ° which reveal that new 
crystal phase of citric acid-isoleucine is formed which can be attributed to 
cocrystal generation. The characteristics peaks of starting materials are absent 
in the processed samples.  
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Figure 5.28 PXRD  of citric acid, L- isoleucine and their LAG processed 
material. 
2 DSC data 
To further analyse the formation of the new crystal phase of citric acid and 
isoleucine thermal analysis was performed (n=3). Figure 5.29 represents the 
DSC thermogram of citric acid raw, isoleucine raw and citric acid-isoleucine 
LAG processed sample in 1:1 stoichiometric ratio. Based on the DSC data it is 
observed that single endotherm event at 126.84°C was obtained for citric acid-
isoleucine cocrystal complex. This melting point is completely different 
compared to melting endotherm of individual starting materials. The absence of 
any major endothermic event between 80-110°C reveals that no solvent 
interactions have occurred. 
Thus, based on PXRD and DSC data we can conclude that new crystal phase 
has been generated in citric acid-isoleucine processed samples which can be 
attributed to the weak hydrogen bonding between two components. To further 
L-Isoleucine 
Citric acid 
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investigate the type of interactions and bonding involved between the two 
components spectroscopic analysis was performed.  
 
Figure 5.29 DSC of citric acid, L- isoleucine and their LAG processed 
material. 
 
3. Spectroscopic analysis 
3.1 Raman spectroscopy 
On comparison of Raman spectra of raw and processed samples (n=3), it is 
observed that molecular interactions have occurred between the two 
components and new events at 310 cm-1, 1361 cm-1 and 1087 cm-1 have been 
detected. Below Figure 5.30 represents the Raman spectra of citric acid, 
isoleucine and LAG processed citric acid-isoleucine complex.  
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Figure 5.30 Raman spectrum of L-isoleucine- citric acid co-crystals. 
Based on Raman spectra isoleucine-citric acid, the CH2-CH-CO2 bend at 310 
cm-1 was observed with Raman shift from 296.2 cm-1. The NH3 torsion was 
observed at 564 cm-1.  The CH-CO2 stretch 635-650 cm-1, NH3 rock and C-O 
stretch was observed at 1087 with Raman shift from 1082 cm-1 and the CO2 
symmetric stretch and O-CO bonding of COOH was observed at 1361 cm-1 
Raman shift from 1346 cm-1. This indicates that there is hydrogen bonding 
occurred in between the isoleucine and citric acid molecule. Thus, these 
interactions may attribute to cocrystal formation. 
Table 5.12 for Raman spectra details of citric acid, isoleucine and their co-
crystal. 
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Table 5.12 Raman spectra band and associated functional groups in L-
isoleucine, citric acid and their co-crystal 
Transition energies 
(cm-1) with mode 
descriptions of L-
isoleucine 
citric acid 
L-isoleucine - citric acid cc 
Raman spectra observed 
Raman  A functional 
group 
associated. 
Raman A functional 
group 
associated. 
Raman 
        125.1 
137.1       176.4 
  CH2-CH 
torsion 
212     
    258m 
broad 
  268 
  CH2-CH-
CO2 bend 
    310 
    301m     
    345m     
  S-H out-of-
plane bend 
    356 
381.6         
  N-CH-CO2 
bend 
417m   414 
452 CH2-CH-SH 
bend 
      
485   499w   505 
533.1 CH2-CH-N 
bend 
539sh     
  NH3 torsion 550m   564 
    593m sC-CH3 598 
  CH-CO2 
stretch 
636w   650 
671.6   682m C=O 
stretching 
  
705.7 C-S stretch       
        748 
764.8 CH2 rock 780s   783.5 
820 CH2 
Scissors 
    822 
848         
  CO2 wag       
    877w     
917   900m C-C bends 
and OH out-
of-plane 
bending 
890 
  N-CH 
stretch 
939s C-C 
symmetric 
942.7 
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stretch 
987 CH2-CH 
stretch 
    986.9 
1028 S-H in-
plane bend 
1050m C-O stretch 1048 
1,087 NH3 rock 1082m  C-O stretch 1087 
1131 NH3 rock 1141m   1145 
1186   1165w   1191 
  CH2 twist 1205m C-C 
stretching 
  
1,231 CH2 wag 1217m     
1253 C-H bend       
1323 C-H bend       
1349 CO2 
symmetric 
stretch 
1346w O-CO 
bending of 
COOH 
1361 
1391 CH2 
Scissors 
1387s CH2 
scissors 
  
1444   1430m 
broad 
C-OH def. 1446 
    1466 m 
broad 
CH2 
scissors 
1470 
1509 NH3 
symmetric 
bend 
    1502 
1551, 
1576 
NH3 
asymmetric 
bend 
      
1617 NH3 
asymmetric 
bend 
      
    1630 m 
broad 
    
1678 CO2 
asymmetric 
bend 
    1,658 
 
Symbols used are r: rocking, ν: stretching, δ: deformation, t: twisting, ω: 
wagging, γ: deformation out of the plane, τ: torsion, as: antisymmetric, s: 
symmetric, skel.: skeleton, sh: shoulder, w: weak peak intensities. 
3.2 FT-IR spectra: 
Below Figure 5.31 represents the spectral overlay of citric acid starting material, 
isoleucine starting material and citric acid-isoleucine cocrystal (n=3). 
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Figure 5.31 FT-IR spectra of L-isoleucine, citric acid and their co-crystal. 
In FT-IR spectroscopy of L-isoleucine - citric acid cocrystal and starting 
materials, it was observed that there are some new peaks at different 
wavelength are detected. The bending of functional groups, wag and stretch 
pattern is observed, l. The C-S stretch and C=O stretching was observed at 
685.6 cm-1, CH2 rock was observed at 749 cm-1, CH2 scissors was observed at 
825 cm-1, CO2 wag was observed at 882 and N-CH stretch as well as C-C 
bends and OH out-of–plane bending was observed at 929.2cm-1. CH2-CH 
stretch, and C-C symmetric stretch was observed at 987.3 cm-1. The S-H in-
plane bend was observed at 1050 cm-1, NH3 rock and C-O stretch were 
observed at 1086 cm-1 and CO2 symmetric stretch was observed at 1351 cm-1. 
CH2 scissors and O-CO bending of COOH was observed at 1394 and NH3 
symmetric bending was observed at 1453 cm-1. In this pair also, a peak was 
detected at 3492 cm-1 confirming the presence of a water molecule. This may 
be because the citric acid has a strong affinity towards the water molecule. 
However, there was no any proton transfer observed. No peaks dedicated to –
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COO- and –NH+ were observed. It indicates that there is no salt formation 
occurred. Table 13 represents the FT-IR spectra. 
Table 5.13 L-isoleucine, citric acid and their co-crystal FT-IR peaks with 
associated groups.  
L-
isoleucine 
cm-1  
associated 
group 
citric acid 
associated 
group 
L-isoleucine - citric 
acid cc IR 
 
CH-CO2 
stretch 
639.6 
 
639.9 
674 C-S stretch 686.2m 
C=O 
stretching 
685.6 
709.9     
768.8 CH2 rock 770.5 
 
749.8 
800.9    799.4 
825.1 
CH2 
Scissors 
818.4s 
 
825.2 
872.4 CO2 wag 881.2w 
 
882 
920.9 
N-CH 
stretch 
900m 
C-C bends 
and OH out-of-
plane bending 
 929.2 
962.9 
CH2-CH 
stretch 
934.3s 
C-C symmetric 
stretch 
               987.3 
991.7 
    
1034 
S-H in-
plane bend 
1.053.82  1050 
 
NH3 rock 1050m C-O stretch 
 
1085 NH3 rock 1082m C-O stretch 1086 
1126 
 
1138m 
  
1,186 CH2 twist 1171w 
 
1180 
 
CH2 wag 1216.72m C-C stretching 
 
1249 C-H bend 1217m 
 
1252 
1328 C-H bend 1293.86 
 
1307 
1350 
CO2 
symmetric 
stretch 
1358.80 
 
1351 
1393 
CH2 
Scissors 
1389.78w 
O-CO bending 
of COOH 
1394 
  
1387s CH2 scissors 
 
  
1426m 
broad 
C-OH def. 
 
1463 
NH3 
symmetric 
bend 
1466 m 
broad 
CH2 scissors 1453 
1573 
NH3 
asymmetric 
bend 
  1579 
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4 DVS analysis 
Based on the DVS isotherm data for citric acid-isoleucine cocrystal (n=3; s.d.≤
0.03) it is observed that negative values or sample weight loss is observed 
which is attributed to the non-stable nature of the sample at 30%RH. Table 5.14 
and Figure 5.32 represent the numerical and graphical data for raw and 
processed samples of citric acid and isoleucine respectively. 
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Table 5.14 DVS study of L-isoleucine - citric acid cocrystal  
%RH citric acid isoleucine pure isoleucine-CA cc 
0.0 0.00 -0.01 0.00 
10.0 0.00 -0.01 0.01 
20.0 0.00 0.00 0.00 
30.0 0.00 0.01 -1.29 
40.0 0.00 0.02 -1.97 
50.0 0.00 0.03 -3.01 
60.0 0.01 0.05 -3.66 
70.0 0.02 0.08 -3.75 
80.0 4.65 0.12 2.40 
90.0 31.21 0.23 25.01 
CA= citric acid 
 
Figure 5.32 DVS isotherm of L-isoleucine, citric acid and their co-crystal. 
5.3.3 Citric acid – L- serine cocrystals 
1 PXRD data 
Based on the PXRD pattern (Figure 5.33), in citric acid-serine LAG sample 
(n=3), new crystal peaks were detected at 6.32, 13, 17.68, 21, 23 and 25.5 2θ° 
which does not coincide with any of the characteristic peaks of citric acid and 
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serine starting material. Thus, based on this new crystal phase has been 
generated which can be attributed to cocrystal phase. 
 
Figure 5.33 PXRD pattern of citric acid - L- serine  LAG material. 
 
2 DSC data 
Below Figure 5.34 represents the overlay of DSC thermogram of citric acid and 
serine amino acid starting material and LAG processed sample (n=3). 
According to the PubChem records the melting point of the citric acid is 153°C 
and the melting point of the serine is 228°C (NCBI 2017c). The experimental 
endotherm melting events for citric acid and serine amino acid is similar to 
previously reported values (Rehder et al. 2011). In the DSC thermogram of citric 
acid-serine LAG material, it was observed that there is a single broad 
endothermic peak at 116.15°C followed by degradation this can be attributed to 
new crystal phase generation or even presence of bound solvent along with 
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cocrystal phase.  This is different than the original starting materials melting 
points. 
 
Figure 5.34 DSC of L- serine-citric acid and their LAG material. 
3 Spectroscopic analysis 
3.1 Raman spectroscopy 
In the Raman analysis of the L-serine-citric acid LAG mixture (n=3), it was 
observed that Raman shifts occurred in some regions of the citric acid-L-serine 
complex which indicates that there is stretching, and new bond formation has 
happened. (See Figure 5.35) 
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Figure 5.35 Raman spectrum of L-serine- citric acid co-crystals. 
It was observed that, in the region 1090, -NH3 rock shifted slightly from 1082 to 
1090. The -O-CO bonding of COOH was found to be absent around 1345, 
1354, 1346 regions. The NH3- symmetric band from 1525 and -NH3 asymmetric 
band from 1610.1 were absent. The details of Raman spectrum observed in the 
experiment are shown below in Table 5.15. 
Table 5.15 Raman spectra band and associated functional groups in L-
serine, citric acid and their co-crystal. 
Transition energies 
 (cm-1) with mode 
descriptions of L-
serine 
citric acid L-serine - citric acid cc 
Raman spectra observed 
Raman  A functional 
group 
associated. 
Raman A 
functional 
group 
associated. 
Raman 
137.7       140.3 
209 CH2-CH 
torsion 
      
222.2   212     
258.8   258m 
broad 
  260.9 
296.2 CH2-CH-
CO2 bend 
    296.7 
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    301m     
    345m     
363.2 S-H out-of-
plane bend 
    362.1 
  N-CH-CO2 
bend 
417m     
441,450 CH2-CH-
SH bend 
      
513   499w   514.5 
536 CH2-CH-N 
bend 
539sh     
  NH3 torsion 550m     
608.8   593m sC-CH3 609.8 
639 CH-CO2 
stretch 
636w     
    682m C=O 
stretching 
  
693 C-S stretch       
773 CH2 rock 780s     
813.6 CH2 
Scissors 
    813.3 
852.1 CO2 wag     852.6 
    877w     
920.9   900m C-C bends 
and OH 
out-of-
plane 
bending 
  
968.1 N-CH 
stretch 
939s C-C 
symmetric 
stretch 
968.1 
1,007 CH2-CH 
stretch 
    1007.3 
1067 S-H in-
plane bend 
1050m C-O stretch   
1005, 
1011 
NH3 rock 1080m  C-O stretch 1090.1 
1134.5 NH3 rock 1141m   1132.1 
    1165w     
1,199 CH2 twist 1205m C-C 
stretching 
  
1,218 CH2 wag 1217m   1220.1 
1260, 
1274 
C-H bend       
1294, 
1326 
C-H bend     1324.9 
1345, 
1354 
CO2 
symmetric 
stretch 
1346w O-CO 
bending of 
COOH 
  
1398, 
1425 
CH2 
Scissors 
1387s CH2 
scissors 
1413.2 
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    1430m 
broad 
C-OH def.   
1461.1   1466 m 
broad 
CH2 
scissors 
1461.5 
1525 NH3 
symmetric 
bend 
      
1574, 
1581 
NH3 
asymmetric 
bend 
    1597.1 
1610.1 NH3 
asymmetric 
bend 
      
    1630 m 
broad 
  1627.1 
1644 CO2 
asymmetric 
bend 
      
 
Symbols used are r: rocking, ν: stretching, δ: deformation, t: twisting, ω: 
wagging, γ: deformation out of the plane, τ: torsion, as: antisymmetric, s: 
symmetric, skel.: skeleton, sh: shoulder, w: weak peak intensities. 
 
3.2 FT-IR spectra: 
The FT-IR spectroscopy was carried out on the citric acid, L-serine and the 
resulting co-crystal obtained through the LAG process (n=3).  The overlay of 
FTIR spectra and tabular data of raw and processed data is demonstrated in 
Figure 5.36 and Table 5.16 respectively.  
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Figure 5.36 FT-IR spectra of L-serine-citric acid cc with starting material 
 
Table 5.16 FT-IR spectra peak bands and associated functional groups of 
citric acid – L- serine cc and starting material. 
L-
serine 
cm-1  
associated 
group 
citric acid 
associated 
group 
L-serine-citric acid cc IR 
607.8    617.4 
 
CH-CO2 
stretch 
639.6 
 
640.1 
 
C-S stretch 686.2m 
C=O 
stretching 
696.7 
727.9     
 
CH2 rock 770.5 
 
780.4 
803.1     
 
CH2 
Scissors 
818.4s 
 
818.7 
852.2 CO2 wag 881.2w 
 
881.8 
917.7 
N-CH 
stretch 
900m 
C-C bends 
and OH 
out-of-
plane 
bending 
 902.5 
 
CH2-CH 
stretch 
934.3s 
C-C 
symmetric 
stretch 
 934.2 
1011.8 
S-H in-
plane bend 
1.053.82  1028.5 
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NH3 rock 1050m C-O stretch 1082 
1085 NH3 rock 1082m C-O stretch 1094 
1124 
 
1138m 
 
1139 
1,182 CH2 twist 1171w 
 
1172 
1219 CH2 wag 1216.72m 
C-C 
stretching 
1217 
1247 C-H bend 1217m 
  
1303 C-H bend 1293.86 
 
1311.6 
1341     
1360.9 
CO2 
symmetric 
stretch 
1358.80 
 
1352 
 
CH2 
Scissors 
1389.78w 
O-CO 
bending of 
COOH 
 1390 
  
1387s 
CH2 
scissors  
1410 
 
1426m 
broad 
C-OH def. 1429 
1468 
NH3 
symmetric 
bend 
1466 m 
broad 
CH2 
scissors  
1501 
   
1503 
1589 
NH3 
asymmetric 
bend 
  1570 
 
NH3 
asymmetric 
bend 
  
1592 
 
CO2 
asymmetric 
bend 
1630 m 
broad  
1632 
  
1695 vs 
C=O 
stretching 
1695 
 S-H stretch 1743s n(COOH) 1741 
2040 
   
2052 
2116    2114 
2163    2152 
2325     
2384    2387 
2597 N-H stretch   2560 
2731 N-H stretch 
  
2648 
    
2773 
2942  2949w  2943 
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The FT-IR spectra of L-serine-citric acid showed many similarities to the original 
citric acid material. However, after careful observation, it was revealed that 
there are differences between a few peaks intensities. C-S stretch and C=O 
stretch showed at 696.7 cm-1, which is slightly different from the 686 of Citric 
acid. N-CH stretch and C-C and OH out of plane bending were observed to be 
at 902.5 cm-1. There was a more significant difference between NH3 rock and C-
O stretch as compared to the original materials at 1094 cm-1. O-CO bending of 
COOH was observed at 1390 cm-1. Therefore, this data reveals that slight 
changes in the bend and stretch of the co-crystal molecule confirm it is a new 
form rather than the original material. 
 4 DVS data 
The DVS isotherms (Figure 5.37) of L-Serine, Citric acid and their co-crystal 
(n=3; s.d.≤ 0.03), showed some different results from the previous two pairs of 
co-crystals. Although L-serine itself showed the non - hygroscopic nature, its co-
crystal with citric acid becomes more hygroscopic. Again, this could be correlate 
with the DSC studies of these all. Where the cocrystal showed a lower melting 
point than that of their original materials. It absorbs 58.80% of moisture at 90 % 
  
2956w 
 
 
  
2979w 
 
 
 C-H stretch 2993w 
 
 
 
CH2 
symmetric 
stretch 
  
 
 
CH2 
asymmetric 
stretch 
  
 
 N-H stretch 3283 
 
3288 
 
 
3494 
 
3496 
3711     
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RH. At 30% RH it showed 0.48% moisture absorption, but after 50% RH, it 
starts to absorb more moisture. See Table 5.17. 
Table 5.17 DVS of L-serine, citric acid and their co-crystal. 
% RH citric acid serine-CA cc serine pure 
0.0 0.00 0.00 0.00 
10.0 0.00 0.00 0.00 
20.0 0.00 0.06 0.00 
30.0 0.00 0.48 0.00 
40.0 0.00 2.02 0.00 
50.0 0.00 4.27 0.00 
60.0 0.01 9.85 0.01 
70.0 0.02 20.71 0.01 
80.0 4.65 36.03 0.01 
90.0 31.21 58.80 0.01 
CA= citric acid. 
 
Figure 5.37 DVS of L-serine, citric acid and their co-crystal. 
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5.3.4 Citric acid–L-methionine study 
1 PXRD 
In the PXRD analysis of the citric acid-L-methionine LAG material (n=3), it was 
observed that new peaks were generated at 6.8, 19, 20.44 and 22.4 2θ° which 
significantly vary from characteristic peaks of individual starting materials. Thus, 
based on the PXRD pattern new crystal phase of citric acid-methionine is 
generated. See Figure 5.38. 
 
 
Figure 5.38 PXRD of citric acid–L-methionine LAG sample with starting 
material 
 
2 DSC data 
As per the PubChem database records, the melting point of citric acid is 153°C 
and the melting point of methionine is 283°C (Hautala et al. 2016). 
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The DSC analysis of citric acid-methionine LAG material (n=3), showed a single 
endothermal melting peak at 124.65°C which is different from the starting 
materials melting points. See Figure 5.39. 
 
 
Figure 5.39 DSC of citric acid, L-methionine and their LAG material 
 
3 Spectroscopic analysis 
3.1 Raman spectroscopy 
Based on the Raman spectral overlay of raw and LAG processed sample of 
methionine and citric acid (n=3), it was observed that new distinct peaks were 
generated which are different from starting materials (right the region of new 
peaks) are different from the starting materials. It indicates that there may be 
interactions occurring between L-methionine and citric acid molecules. See 
Figure 5.40. 
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In Raman analysis of the citric acid, L-methionine and their LAG mixture, it was 
observed that there are some stretch and wag and bends which are the 
indication of some kinds of bonding and attraction between atoms happened in 
the co-crystal molecule. Therefore, the Raman shift was observed at those 
points. This bonding or reaction by force was predicted around the -NH2 group 
of amino acid and -COOH group of citric acid.  
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Figure 5.40 Raman spectra of citric acid–L-methionine LAG processed 
sample with starting material. 
This citric acid–L-methionine co-crystal compound showed, NH3 torsion at 518 
cm-1, which showed a Raman shift from their original molecule from 552.4 of L-
methionine and 550 of Citric acid. C=O stretch was not observed. NH3 rock and 
C-O stretch were observed at 1076 cm-1 which showed a Raman shift from 
1082 of Citric acid and 1073 cm-1 of L-methionine. CO2 symmetric stretch and 
O-CO bending of COOH was observed at 1337 cm-1 and a Raman shift from  
1362 cm-1 of L- methionine and 1346 cm-1 of Citric acid were observed at the 
same point.  
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The Raman spectrometric analysis of citric acid and methionine co-crystals did 
not show the salt formation functional group (like CO2-, NH4+) peaks. Thus, it 
reveals that these are the co-crystals and not salts. Table 5.18 represents the 
Raman spectra observed in L-methionine and citric acid and their co-crystal. 
Table 5.18 Raman spectra band and associated functional groups in citric 
acid - L- methionine and their co-crystal 
Transition energies 
(cm-1) with mode 
descriptions of L-
methionine 
citric acid L-methionine-citric acid cc 
Raman spectra observed 
Raman  A 
Functional 
group 
associated. 
Raman A Functional 
group 
associated. 
Raman 
126.7   127   129.9 
137.1   182.8     
  CH2-CH 
torsion 
215.9     
257.1   258m 
broad 
    
  CH2-CH-
CO2 bend 
      
    301m     
345.7   345m     
  S-H out-of-
plane bend 
      
426.1 N-CH-CO2 
bend 
417m   417 
  CH2-CH-SH 
bend 
      
    499w   489 
  CH2-CH-N 
bend 
539sh     
552.4 NH3 torsion 550m   518 
    593m sC-CH3 599 
  CH-CO2 
stretch 
636w   655 
682.7   682m C=O 
stretching 
  
710 C-S stretch     694 
        731 
759 CH2 rock 780s     
  CH2 
Scissors 
    795 
125 
 
        818 
  CO2 wag       
872   877w   876 
    900m C-C bends 
and OH  
out-of-plane 
bending 
  
  N-CH 
stretch 
939s C-C 
symmetric 
stretch 
935 
1,005 CH2-CH 
stretch 
      
1035 S-H in-
plane bend 
1050m C-O stretch 1048 
1,073 NH3 rock 1082m  C-O stretch 1076 
  NH3 rock 1141m   1137 
1165   1165w     
  CH2 twist 1205m C-C 
stretching 
1183 
  CH2 wag 1217m     
1273 C-H bend       
1303 C-H bend       
1362 CO2 
symmetric 
stretch 
1346w O-CO 
bending of 
COOH 
1337 
1411 CH2 
Scissors 
1387s CH2 
scissors 
  
    1430m 
broad 
C-OH def. 1430 
    1466 m 
broad 
CH2 
scissors 
  
  NH3 
symmetric 
bend 
      
  NH3 
asymmetric 
bend 
      
  NH3 
asymmetric 
bend 
      
    1630 m 
broad 
    
  CO2 
asymmetric 
bend 
    1,688 
 
126 
 
Symbols used are r: rocking, ν: stretching, δ: deformation, t: twisting, ω: 
wagging, γ: deformation out of the plane, τ: torsion, as: antisymmetric, s: 
symmetric, skel.: skeleton, sh: shoulder, w: weak peak intensities 
 
3.2 FTIR spectra 
The vibrational spectroscopy FT-IR was carried out for L- methionine, citric acid 
and their co-crystal through the LAG mixture (n=3). The overlay of collected 
spectra is demonstrated in below Figure 5.41 and regions corresponding the 
spectral events are included in Table 5.19  
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Figure 5.41 FT-IR spectra of citric acid–L-methionine cc with starting 
material. 
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Table 5.19 FT-IR spectra band and associated group of L-methionine, 
citric acid and their co-crystal. 
L-
methionine 
cm-1  
Associated 
group 
Citric acid 
Associated 
group 
L-methionine-citric acid cc 
IR 
643.4 
CH-CO2 
stretch 
639.6 
 
645.4 
681 C-S stretch 686.2m 
C=O 
stretching 
692 
720     
750 CH2 rock 770.5 
 
755 
805     
 
CH2 
Scissors 
818.4s 
 
818.3 
874 CO2 wag 881.2w 
 
887 
917.7 
N-CH 
stretch 
900m 
C-C bends 
and OH 
out-of-
plane 
bending 
 887 
951 
CH2-CH 
stretch 
934.3s 
C-C 
symmetric 
stretch 
                    950 
980 
S-H in-
plane bend 
1.053.82  980 
 
NH3 rock 1050m 
C-O 
stretch 
1048 
1070 NH3 rock 1082m 
C-O 
stretch 
1085 
1119 
 
1138m 
 
1137 
1,150 CH2 twist 1171w 
  
1185    1191 
 
CH2 wag 1216.72m 
C-C 
stretching 
1219 
1243 C-H bend 1217m 
  
1275 C-H bend 1293.86 
 
1304 
1316     
1352 
CO2 
symmetric 
stretch 
1358.80 
 
 
 
CH2 
Scissors 
1389.78w 
O-CO 
bending of 
COOH 
 
  
1387s 
CH2 
scissors  
1406 
 
1426m 
broad 
C-OH def. 1427 
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Symbols used are r: rocking, ν: stretching, δ: deformation, t: twisting, ω: 
wagging, γ: deformation out of the plane, τ: torsion, as: antisymmetric, s: 
symmetric, skel.: skeleton, sh: shoulder, w: weak  
 
NH3 
symmetric 
bend 
1466 m 
broad 
CH2 
scissors  
1509 
    
1561 
NH3 
asymmetric 
bend 
  1524 
 
NH3 
asymmetric 
bend 
  
1581 
 
CO2 
asymmetric 
bend 
1630 m 
broad   
  
1695 vs 
C=O 
stretching 
1682 
 S-H stretch 1743s n(COOH) 1711 
    1980 
 
   
2030 
2108     
    2164 
    2215 
 N-H stretch    
2736 N-H stretch 
  
 
2915  2949w  2927 
  
2956w 
 
 
  
2979w 
 
 
 C-H stretch 2993w 
 
 
 
CH2 
symmetric 
stretch 
  
 
3144 
CH2 
asymmetric 
stretch 
  
3100 
 N-H stretch 3283 
 
3288 
 
 
3494 
 
3439 
129 
 
The FT-IR spectra of L-methionine–citric acid co-crystal showed CH-CO2 
stretch at 645 cm-1. The C-S stretch and C=O stretching was observed at 692 
cm-1. N-CH stretch and C-C bends and OH out–of–plane bending was observed 
at 887 cm-1. S-H in-plane bend was observed at 980 cm-1. NH3 rock and C-O 
stretch were observed at 1048,1085 cm-1. CH2 wag and C-C stretching were 
observed at 1219 cm-1. The stretch and bend observed in the co-crystals are 
slightly different as compared to the original materials indicating the formation of 
a new compound. The bend and stretch pattern supports the formation of H - O 
bonds but salt form functional groups were not observed. It indicates that there 
may be the co-crystals formed in between L-methionine and citric acid. 
4 DVS data 
Based on the DVS isotherm of L-methionine, citric acid and their co-crystal 
(n=3; s.d.≤ 0.03), that co-crystal process can improve the non-hygroscopicity of 
the Citric acid molecule. The co-crystal of citric acid and L-methionine only 
absorbed 0.46% moisture was absorbed in 90% RH.  
Therefore, to understand its absorption profile in the presence of sodium 
bicarbonate, in the ratio of 1.5:1 to the citric acid amount in the cocrystal was 
added to this mixture and subjected to different humidity conditions. Figure 5.42 
and Table 5.20 represents the DVS isotherm for SBC, based on the data 
generated it is observed that loss in weight is occurring which is due to the 
instability of citric acid-methionine cocrystal in the presence of SBC. 
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Table 5. 20 DVS of L - methionine, citric acid and their co-crystal 
%RH 
Citric acid Methionine 
pure 
Met-CA cc 
280716 
Met-CA cc + 1.5x 
NaHCO3 
0.0 0.00 0.00 0.001 0.001 
10.0 0.00 0.01 0.013 -0.246 
20.0 0.00 0.02 0.047 -0.337 
30.0 0.00 0.02 0.094 -0.443 
40.0 0.00 0.03 0.150 -0.575 
50.0 0.00 0.04 0.221 -0.730 
60.0 0.01 0.05 0.307 -0.866 
70.0 0.02 0.07 0.460 -0.765 
80.0 4.65 0.09 1.027 0.388 
90.0 31.21 0.16 1.817 8.340 
Met=L-methionine, CA=citric acid, cc=cocrystal, NaHCO3=Sodium 
bicarbonate. 
 
Figure 5.42 DVS of citric acid, L- methionine and their co-crystal. 
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5.3.5 Citric acid –L-cysteine study 
1 PXRD data 
Based on the overlay of PXRD patterns of citric acid, cysteine starting materials 
and LAG processed samples (n=3) (Figure 5.43) change in crystal phase is 
identified. In LAG processed sample new peaks at 7.96, 11.36 and 22.92 2θ° 
were detected which are absent in both the starting materials.  Thus, based on 
the PXRD data new crystal phase of citric acid-cysteine in 1:1 ratio is obtained. 
 
Figure 5.43 PXRD of citric acid, L- cysteine and their cocrystal  
 
2 DSC data 
To further investigate the presence of a residual solvent and phase impurity 
thermal analysis using DSC analyser was performed for all processed and raw 
samples (Figure 5.44). 
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In the DSC analysis of citric acid- cysteine 1:1 LAG mixture (n=3), a sharp 
single endothermal peak of melting point was observed around 72.77°C, which 
is different from the starting materials melting points. As per the previous 
record, the melting point of citric acid is 153°C (Rehder et al. 2011) and a 
melting point of L-cysteine is 240°C (NCBI 2017a). The observed results 
suggest that there is new crystalline phase formed, which could be a cocrystal 
of citric acid –L-cysteine in 1:1 stoichiometry. This result is supporting to the 
PXRD data.  
 
Figure 5.44 DSC results of citric acid - L - cysteine cocrystal 
 
3 Spectroscopic analysis 
3.1 Raman spectroscopy 
Based on the spectral overlay of citric acid, L- cysteine and cocrystal sample 
(n=3), it was observed that the cocrystal has no significant peaks similarity to 
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characteristic peaks of starting materials. This indicates that there may be the 
formation of a new molecule. See Figure 5.45. 
  
Figure 5.45 Raman spectrum of citric acid – L- cysteine co-crystals 
processed by Spectragryph version 1.2.7. 
The study of the structures of these two molecules indicates that both 
molecules can donate as well as to accept the H-bonds/hydrogen bonds. See 
Figure 5.46. 
  
                           
 Figure 5.46 L-cysteine (left), citric acid (right) . 
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From Raman, it was observed that there is a slight Raman shift in the region of -
NH2+ group. It was noticed that NH3 rock changed slightly from 1005, 1011, 
1080 to 1070. C-S stretch peak was absent from 692-693 region. CH2-CO2 
stretch was absent from 636-639 region. NH3 torsion was absent at 550 
regions. CH2-CH-N bend at 536 regions was also absent from the co-crystal 
molecule. It reveals that there may be stretching, and new bond formation 
occurs in between citric acid and L-cysteine molecules at -NH3+ region of L-
cysteine and COOH group of citric acid. Table 5.21 shows the Raman spectra 
results of citric acid, L-cysteine and their co-crystal. 
Table 5. 21 Raman spectra band and associated functional groups in citric 
acid, L-cysteine and their co-crystal. 
Transition energies (cm-1) 
with mode descriptions of 
L-cysteine 
citric acid 
L-cysteine-citric acid cc 
Raman spectra 
observed 
Raman  
A functional 
group 
associated. 
Raman 
A functional 
group 
associated. 
Raman 
167 
   
128.8 
209 
CH2-CH 
torsion   
175.3 
  
212 
  
  
258m 
broad   
298 
CH2-CH-CO2 
bend   
281.3 
  
301m 
  
  
345m 
 
349.9 
364 
S-H out-of-
plane bend   
389.7 
 
N-CH-CO2 
bend 
417m 
  
441,450 
CH2-CH-SH 
bend   
438.1 
  
499w 
 
498.4 
536 
CH2-CH-N 
bend 
539sh 
  
 
NH3 torsion 550m 
  
  
593m sC-CH3 600.1 
135 
 
639 
CH-CO2 
stretch 
636w 
  
  
682m 
C=O 
stretching 
677.4 
693 C-S stretch 
   
    
733.3 
773 CH2 rock 780s 
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Symbols used are r: rocking, ν: stretching, δ: deformation, t: twisting, ω: 
wagging, γ: deformation out of the plane, τ: torsion, as: antisymmetric, s: 
symmetric, skel.: skeleton, sh: shoulder, w: weak  
 
3.2 FTIR data 
The Fourier transform infrared spectra (FT-IR) analysis of citric acid, L-cysteine 
and their 1:1 cocrystal by LAG was processed (n=3) and it showed the pattern 
as in Figure 5.47 and the bands were recorded in the Table 5.22 as follows. 
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Figure 5.47 FT-IR spectra of citric acid, L- cysteine and their co-crystal. 
The change in the patterns of the wavenumber gives an idea of the new 
bonding formation or stretch and bend pattern of the molecules. Obtained peaks 
were compared with the original material peak patterns and changes noted. S-H 
in-plane bend was observed around wavenumber 1043 cm-1. The NH3 rock and 
C-O stretch were observed at 1128 cm-1 in the new co-crystal molecule. CH 
wag and C-C stretching were observed at 1201 cm-1. C-H bend was observed 
at 1248, 1296 cm-1. C-OH deformation peak was observed at 1427 cm-1. C=O 
stretching was observed at 1681 and n(COOH) S-H stretch peak was observed 
at 2564 cm-1. A water peak of OH stretch was observed at 3478 cm-1. It 
indicates that there may be a water molecule is present in this co-crystal, which 
suggests that there is co-crystal hydrate formation occurred. 
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Table 5. 22 FT-IR spectra band and an associated functional group of 
citric acid, L-cysteine and their co-crystal molecule. 
L-
cysteine 
cm-1  
associated 
group 
citric acid 
associated 
group 
L-cysteine-citric acid cc 
IR 
 
NH3 torsion 550m 
  
  
593m sC-CH3 
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Symbols used are r: rocking, ν: stretching, δ: deformation, t: twisting, ω: 
wagging, γ: deformation out of the plane, τ: torsion, as: antisymmetric, s: 
symmetric, skel.: skeleton, sh: shoulder, w: weak peak intensities 
4 DVS data 
After DVS study of L-cysteine, citric acid and their LAG processed samples 
(n=3; s.d.≤ 0.03), it was observed that it remains in powder form at 90 % RH 
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with only 12.07% of moisture absorption. After obtaining single crystal of the 
same pair through slow solvent evaporation method, it was observed that it has 
further improved its non-hygroscopic nature and absorb only 3.18 % of moisture 
at 90% RH. However, when tested with 1.5 times addition of sodium 
bicarbonate equivalent  to citric acid content, it reacted at 80% RH by -2.76 %, 
but still, only 5.74 % of moisture was absorbed in 90 % RH. It means that up to 
70% RH condition, there was no reaction in the mixture of co-crystallised citric 
acid and sodium bicarbonate. It will help in reducing the cost of maintenance 
regarding environmental conditions in the manufacturing of effervescent tablets. 
Please see table 5.23 and Figure 5.48. 
Table 5.23 DVS study of citric acid-L-cysteine and their co-crystal. 
%RH citric 
acid  
L-cysteine 
pure 
sigma 
CA-L-
cysteine  
CA-L-
cysteine 
single crystal 
CA-L-CYS SC 
+1.5x SBC  
0.0 0.00 0.00 0.00 0.001 0.000 
10.0 0.00 0.04 0.07 0.015 0.000 
20.0 0.00 0.07 0.26 0.062 0.003 
30.0 0.00 0.10 0.61 0.394 0.008 
40.0 0.00 0.13 0.87 0.586 0.013 
50.0 0.00 0.15 1.06 0.677 0.016 
60.0 0.01 0.18 1.31 0.740 0.015 
70.0 0.02 0.21 1.72 0.813 0.046 
80.0 4.65 0.27 2.43 0.886 -2.760 
90.0 31.21 0.43 12.07 3.184 5.740 
 
RH: relative humidity, CA: citric acid, L-CYS: L-cysteine, SC: single crystal, 
SBC: sodium bicarbonate. 
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Figure 5.48 DVS study of citric acid –L- cysteine and their co-crystal. 
 
5 Summary  
The DVS study of citric acid showed that citric acid compound has high affinity 
towards water. It was observed that citric acid could tolerate moisture up to 70% 
relative humidity condition but after 70% RH reacts and starts absorbing 
moisture and becomes deliquescent at 90%RH. Therefore, it was attempted 
through the co-crystallisation process in this current study, to reduce the 
hygroscopicity of citric acid in order to improve its storage capability by making 
it non-hygroscopic. The amino acids were found to be prominent to form 
cocrystal with citric acid. Total five amino acids amongst 17 were screened for 
successful cocrystal formation in 1:1 ratio with citric acid. Obtained LAG 
samples were characterised by PXRD, DSC, and spectroscopic analysis and 
finally checked for their moisture absorption by DVS. Through DVS study only 
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one cocrystal (L-cysteine-citric acid in 1:1 ratio) was observed to be less 
hygroscopic at various moisture conditions as compared to the citric acid.  
All obtained cocrystals were further examined for single crystal development 
study. 
5.3.6 Citric acid-amino acid solution crystallisations 
All five pairs of amino acid-citric acid co-crystals were selected in 1:1 
stoichiometric ratio and subjected to solution/solvent slow evaporation 
crystallisation process (n=2) to generate single crystals. The range of solvent 
systems like methanol, ethanol, water, a mixture of ethanol and water (1:1 v/v) 
as well as methanol and water (1:1 v/v) were used for this study. Molar 
equivalents of citric acid-amino acid was selected in 1:1 stoichiometry ratio and 
completely dissolved in the solvent system under external heating conditions of 
70°C temperature with continuous stirring. This solution was further filtered 
through Whatmann filter paper no.1 and left for solvent evaporation at room 
temperature until crystallisation occurs. In some cases, crystallisation occurs 
after 4-5 days such as citric acid – L-methionine, citric acid-L-leucine, citric acid 
-L-isoleucine; but in other cases (citric acid-L-serine and citric acid -L-cysteine) 
no crystallisation was observed even after 22 days. Instead they form a jelly like 
glassy transparent material. Then the sticky mass was agitated using a clean 
spatula, which led to nucleation at the bottom of the conical flask and eventually 
a complete crystalline phase was observed in the conical flask after 40 days 
with citric acid-L-cysteine (see Figure 5.49). 
Based on the solution evaporation experiments, citric acid failed to generate 
any crystals with L-leucine, L-isoleucine and L-methionine. In these experiments 
due to the solubility of amino acids in the solvent system, they crystallised out 
first as an impurity.  For amino acid L-serine and L-cysteine water was used as 
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the solvent system for generation of crystals with citric acid. The generated 
crystalline material (Figure 5.49) was used as a seed to generate good quality 
single crystals from a saturated solution (made up of only 1ml of deionised 
water and mixture of citric acid and L-cysteine in 1:1 stoichiometry) of citric acid-
L-cysteine amino acid. 
 
Figure 5.49 A crystalline material obtained from citric acid-L-cysteine 1:1 
mixture solution in water after complete evaporation of water. 
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Figure 5.50  A single crystal of citric acid-L-cysteine monohydrate 1:1 co-
crystal. 
The generated single crystals were dried properly and subjected to further 
different characterisation techniques to investigate the cocrystal phase. One of 
the best single crystal has been observed and imaged under compound 
microscope at 40x (See Figure 5.50). 
1.0 PXRD 
Below Figure 5.51 represents the PXRD pattern of citric acid, L-cysteine starting 
material and single crystal of citric acid-L-cysteine solution crystallised (n=3). It 
is observed that solution crystallised citric acid-L-cysteine crystal material 
displayed distinct characteristic peaks at 8.32, 14.76 and 24.56 2θ°angle. These 
peaks are absent in the PXRD pattern of starting materials. This generated 
PXRD pattern of the single crystal is similar to the pattern obtained in a LAG 
experiment in our previous experiments. 
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Figure 5.51 PXRD of a single crystal of citric acid-L-cysteine monohydrate 
(SC= single crystal). 
 
2.0 Thermal analysis 
2.1 DSC 
Below Figure 5.52 demonstrates the overlay of DSC thermogram of citric acid-
L-cysteine single crystal and starting material (n=3). The single crystal of citric 
acid-L-cysteine displayed a single distinct endothermic peak at 78.25°C which is 
quite different from the melting point of citric acid (157.17°C) and L-cysteine 
(225.84°C) respectively. 
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Figure 5.52 DSC of a single crystal of citric acid -L-cysteine monohydrate 
and their original material, physical mixture (1:1) ratio. 
 
2.2 TGA 
The thermogravimetric analysis of single crystal (n=2) (Figure 5.53) showed the 
difference in degradation and melting point pattern from the original starting 
material. The onset melting point of the obtained cocrystal is at 53.13°C. This 
was earlier compared to the starting material onset melting points. The onset 
melting point of citric acid and cysteine was at 128.50°C and 164.98°C 
respectively. 
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Figure 5.53 TGA of the single crystal of citric acid-L-cysteine monohydrate 
and starting material 
 
3.0 DVS data 
The DVS analysis (n=3; s.d.≤ 0.03), showed that the obtained single crystal 
absorbs only 
3.18 % of moisture at 90% RH. In the presence of 1.5 x sodium bicarbonate to 
that of citric acid content in the cocrystal, showed stable low moisture 
absorption up to 70% RH. Please see Table 5.24 and Figure 5.54. 
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Table 5.24 DVS of a single crystal of citric acid-L-cysteine monohydrate 
cocrystal. 
 
 
Figure 5.54 DVS of a single crystal of L-cysteine–citric acid-H2O cocrystal 
 
4.0 Scanning electron microscopy of L-cysteine-citric acid-monohydrate 
cocrystal 
Scanning electron microscopy (SEM) of L-cysteine-citric acid monohydrate 
cocrystal (single crystals) and its starting materials were carried out. The 
observed results are showed in the Figure 5.55 to 5.58. 
 
% RH Dm/Dt 
0.0 0.001 
10.0 0.015 
20.0 0.062 
30.0 0.394 
40.0 0.586 
50.0 0.677 
60.0 0.740 
70.0 0.813 
80.0 0.886 
90.0 3.184 
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Figure 5.55 SEM images of citric acid 40x and 250x magnification. 
SEM of citric acid showed a rough surface of crystalline material containing 
cavities which could contribute for moisture absorption. 
 
Figure 5.56 SEM images of L-cysteine 40x and 250x magnification. 
SEM of L-cysteine reveals that some triangular shaped long bars with smooth 
surface which could attribute to low moisture attraction. 
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Figure 5. 57Figure 5.57 SEM images of L-cysteine-citric acid LAG sample 
1:1 ratio 40x and 100x. 
SEM of LAG mixture of L-cysteine-citric acid shown an agglomerated material. 
 
Figure 5.58 SEM images of single crystal of L-cysteine-citric acid-
monohydrate cocrystal 100x and 250x. 
SEM images of L-cysteine-citric acid monohydrate (single crystals) reveals that 
many plates stacking arrangement of crystal with smooth surface could be 
attribute to low moisture attraction.  
5.0 Single crystal X-ray diffraction analysis  
The obtained good quality single crystals were subjected to single crystal X-ray 
crystallography (n=2). This involved the mounting of a single crystal on the 
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goniometer of Xcalibur Gemini EOS CCD diffractometer (Oxford Diffraction, 
Yarnton, UK). Reflections from the crystals were collected using Mo-Kα, 
radiation at 298K. CrysAlisPro (Version 1.171.33.55) software was used for 
data reduction. The reflection data and crystal structure were refined and solved 
using OLEX2-1.0 and SHELX-TL 97 software with the anisotropic refinement of 
non-hydrogen atoms. In a crystal, hydrogen atoms present in oxygen and 
nitrogen were located experimentally through difference electron density maps. 
The HFIX command in SHELX-TL was used for geometrical fixing of all C–H 
atoms. The final CIF file was checked using PLATON for any missed symmetry. 
The packing diagram was prepared using X-Seed program. 
The single crystal data showed the formation of L-cysteine - Citric acid co-
crystal hydrate in 1:1 stoichiometric ratio. Figure 5.59 shows ORTEP plot. 
Figure 5.60 shows the 1:1 stoichiometric ratio. Figure 5.61 reveals how these 
two molecules are bound to each other and the trapping of one water molecule 
in between them. Table 5.25 summarises the crystallographic parameters. 
 
Figure 5.59 ORTEP plot drawn at 50% probability level. 
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Figure 5.60 L-cysteine with citric acid co-crystal monohydrate in 1:1 
stoichiometric ratio. 
In Figure 5.60, the L-cysteine molecule bonded to the citric acid molecule 
through water molecule as C-H…H-O…H bonding. The bond between S-H…O 
observed is weak bonding. 
However, the main key interactions are revealed on the other side of bonding 
which is shown in Figure 5.61. 
 
Figure 5.61 Key interactions in the co-crystal of L-cysteine-citric acid-H2O 
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Figure 5.61 reveals the key interactions of this co-crystal, through which the 
other side of bonding was exposed.  There is bonding between the hydrogen of 
the amino group of L-cysteine and two molecules of citric acid and one 
molecule of L-cysteine. There is bonding between first L-cysteine molecules -
NH3+ group, as N-H…O-C with another L-cysteine molecule. The other two 
hydrogen bonding was also observed with the same -NH3+ molecule of first L-
cysteine molecule to the two citric acid molecules. This bonding occurred -N-
H…O-C of 1st citric acid and -N-H…O – H group of a 2nd citric acid molecule. 
However, the -COOH group of the 1st L-cysteine molecule connected to the 
water molecule as C-O….H bonding, which is another side bonded to the 3rd 
citric acid molecule. This 3rd citric acid molecule was bonded weakly to the 1st L-
cysteine molecule. Based on these various bonds, it can be predicted that, if 
tried carefully, L-cysteine-citric acid co-crystal can be formed without involving 
water molecule. However, here in this current study water was used in solvent 
evaporation method. It is well known that citric acid molecule has a strong 
affinity towards a water molecule. Thus, it was easier to adopt a water molecule 
in between the L-cysteine and citric acid crystal lattice. Other solvents were 
used, but they failed to work. 
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Table 5.25 Crystallographic data of citric acid-L-cysteine-H2O  
 citric acid-L-cysteine-H2O 
Crystal Shape Plate-like clear crystals 
Colour Colourless, clear  
Empirical formula 
(C3H7NO2S)· 
(C6H8O7).(H2O) 
Formula weight 331.29 
Crystal system Monoclinic 
Space group P 21 
T [K] 170(2) 
a [Å] 5.7524(NCBI) 
b [Å] 10.8433 
c [Å] 11.1221 
 [] 90 
 [] 102.285(2) 
 [] 90 
Z 4 
V [Å3] 677.86 
Dcalc [g cm-3] 1.623 
 [mm-1] 0.152 
Reflections used 9783 
Unique reflections 2259 
Observed reflections 2271 
Parameters 258 
R1[I > 2σ(I)] 0.0326 
wR2 [all]  0.0769 
GOF  1.153 
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Figure 5.62 shows the packing of citric acid-L-cysteine-H2O co-crystal 
monohydrate. 
 
Figure 5.63 Packing of citric acid-L-cysteine-H2O co-crystal monohydrate. 
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Thus, amino acids were screened for co-crystals formation, and five co-crystals 
with citric acid, four of L-proline-NSAIDs, and three of L-proline- carboxylic acid 
were successfully developed and characterised through PXRD, DSC, TGA, 
Raman and FT-IR. However, it is still a difficult task to obtain a single crystal 
from these. Only one single crystal was obtained in this study. 
The obtained single crystal and their ability to be less hygroscopic directed to 
further formulation studies. This improvement in effervescent tablet formulation 
process and their stability studies were carried out. Detailed information is 
presented in the next chapter. 
6 Summary 
Amino acids were successfully screened for the cocrystal formation with citric 
acid molecule through this study. Total five amino acids–citric acid cocrystals 
were obtained and confirmed through characterisation studies. However, as per 
the hypothesis design of this experiment to reduce the hygroscopicity of the 
citric acid molecule was not achieved with four cocrystals except one. After DVS 
studies of all obtained cocrystals, it was observed that only one citric acid-L-
cysteine cocrystal showed promising results where hygroscopic property of 
citric acid is reduced. Single crystal XRD examined the obtained single crystal 
and observed that there is the presence of one water molecule in the crystal 
lattice of 1:1, citric acid: L-cysteine. After careful observation, it was assumed 
that if carefully tried it could be possible to develop as an anhydrous cocrystal. 
The obtained cocrystal hydrate proved to be less hygroscopic. Thus, it could be 
used in the formulations as a physically stable component. 
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5.4 Application of co-crystals in effervescent tablet formulations 
5.4.1 Background 
This current study focuses on physical stability improvement of effervescent 
formulations by incorporating physically stable non-hygroscopic citric acid 
molecule. This citric acid non-hygroscopicity was achieved through successful 
cocrystallisation with the biologically safe amino acid molecule. The obtained 
co-crystal monohydrate of citric acid : L-cysteine (1:1) has shown good 
physicochemical characteristic improvement in stability. Therefore, it is selected 
to explore the stability in effervescent tablet formulation studies. This co-crystal 
has shown improvement in reducing the hygroscopicity of the involving 
molecules like citric acid.  Citric acid has excellent pharmaceutical relevance 
and it plays a vital role in effervescent formulations. Hence, obtained co-crystals 
of citric acid and L-cysteine amino acid can stand as a great influencing 
application in this field. 
As per the recent study, it was revealed that effervescent formulation had 
gained more popularity in Europe for decades as well as growth in the US also 
because they offer a new way for expansion to the pharmaceutical and 
nutraceutical companies (Lee 2000). 
At the production site of effervescent tablets, it was observed that effervescent 
tablets and powders are produced in much the same manner as conventional 
tablets and powders. However, there is a prerequisite that, production must 
occur in very low humidity conditions. This required controlled humidity 
condition maintenance could add a cost to the company. However, it could be 
reduced by the newly developed co-crystal based formula. Effervescent 
granulations can be mixed in conventional blending equipment, such as ribbon, 
twin-cone, and V-type blenders. All equipment should be well grounded and 
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should be allowed to make it entirely dry after wash-down. Any traces of 
moisture in the equipment will give erratic granulation results and most likely 
result in lost batches of product (Lee 2000).  
However, the in-house production of effervescent formulation using the newly 
formed co-crystal of L-cysteine-citric acid monohydrate bypasses all the 
problems mentioned above. It can be successfully scalable at an industrial 
level. 
5.4.1.1 Effervescent tablet formulations 
Below Table 5.26 and 5.27 represents the description of tablet formulation used 
in the present study. 
Effervescent tablet formulation carried out as per the formula 1 to 4, as (see 
Table 5.26 and Table 5.27) shown below.  
In this study, formula 1 and 3 are the general formula with pure chemicals as 
available as with Sigma-Aldrich standard. However, in the formula 2 and 4, 
instead of a pure form of citric acid, the citric acid co-crystal compound was 
used. All the ingredients were kept under vacuum at 600C temperature for 1 
hour before the tablet being pressed. As per the requirement, each ingredient 
was weighed carefully and transferred into a clean glass vial as per tablet 
formula and the airlock cap was placed on it. These vials were shaken 
thoroughly to mix the ingredients before the tablet was pressed. Six tablets of 
each formula (n=6) were pressed using Karnavati make Rimek mini press tablet 
machine (See Figure 5.64). 
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Table 5.26  Citric acid effervescent tablets 
Table 5.27 Ibuprofen (sodium salt) effervescent tablets 
 
 
Figure 5.64 Mini tablet press machine Rimek by Karnavati at CPES, 
University of Bradford. 
Citric acid-based tablets (Formula 1) Citric acid co-crystal-based tablets 
(Formula 2) 
Citric acid 400 mg 
(we took 800 mg) 
Cocrystal 
equivalent to 
400mg of citric 
acid 
652.25 mg 
(We took 
1304.5mg) 
Sodium 
bicarbonate 
600 mg (1200mg) Sodium 
bicarbonate 
600 mg (1200mg) 
Citric acid-based tablets  
(Formula 3) 
Citric acid co-crystal-based tablets 
(Formula 4) 
Ibuprofen sodium 
salt 
0.2213 gm Ibuprofen sodium 
salt 
0.2213 gm 
Sodium bicarbonate 0.6818 gm Sodium bicarbonate 0.6818 gm 
Polyvinylpyrrolidone 
(PVP K30) 
(In this study K-17)  
0.1 gm Polyvinylpyrrolidone 
(PVP K30) 
(In this study K-17) 
0.1 gm 
Mannitol  0.150 gm Mannitol  0.150 gm 
Citric acid 0.198 gm Cocrystal 
equivalent to 0.198 
gm of citric acid 
0.322 gm 
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Compact tablets were prepared for all the listed formulations and their stability 
was investigated using different standard stability conditions. The standard 
stability conditions used were 40°C/75% RH, 25°C/60% RH and 25°C/50% RH. 
The morphological stability of all the tablets was tracked at different time points 
ranging from day 0 to the 1month period. 
5.4.2 Results and Discussion 
Below Table 5.28 represents the tabular image format for all the stability tablets 
at different stability conditions. 
Table 5.28 Stability of tablets at day 0 (time T0) 
Time in Days 0 Day 
Citric acid tablet 
0 Day 
Ibuprofen tablet 
Experimental 
conditions 
compositions 
50 % RH at 
25°C, 
60% RH at 
25°C and  
75% RH at 40° 
C  
Conventional  
method 
1 3 
CA-L-Cyst 
cc hydrate 
new  
formula 
2 
4 
Results and comments 
At time T0 both 
conventional and 
newly developed 
formula citric acid 
tablets were stable 
under all experimental 
conditions. 
At time T0 both 
conventional and 
newly developed 
formula’s  ibuprofen 
salt citric acid tablets 
were stable at all 
experimental 
conditions 
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Table 5.29 Stability of tablet at day 8.  
Time in Days 8 Days 
Citric acid tablet 
8 Days 
Ibuprofen tablet 
Experimental 
conditions 
compositions 
50 % RH at 
25°C, 
 
 
Conventional 
method 
1 US 
3 US 
CA-L-Cyst 
cc hydrate 
new 
formula 2 S 4 S 
60% RH at 
25°C 
Conventional 
method 
1 US 
3US 
CA-L-Cyst 
cc hydrate 
new 
formula 
2 S 4 S 
75% RH at 40° 
C 
Conventional 
method 
1 US 3US 
CA-L-Cyst 
cc hydrate 
new 
formula 2 S 4 S 
Results and comments 
1,2,3 and 4: formula 
US: unstable 
S: stable 
1,2,3 and 4: formula 
US: unstable 
S: stable 
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Table 5.30 Stability of tablet at day 28. 
Time in Days 28 Days 
Citric acid tablet 
28 Days 
Ibuprofen tablet 
Experimental 
conditions 
compositions 
50 % RH at  
25°C, 
 
 
Conventional 
method 
1 US 
3 US 
CA-L-Cyst 
cc hydrate 
new 
formula 2 S 4 S 
60% RH at 
25°C 
Conventional 
method 
1 US 3US 
CA-L-Cyst 
cc hydrate 
new 
formula 2 S 4 S 
75% RH at 40° 
C 
Conventional 
method 
1 US 3US 
CA-L-Cyst 
cc hydrate 
new 
formula 2 S 4 S 
Results and comments 
1,2,3 and 4: formula 
US: unstable 
S: stable 
1,2,3 and 4: formula 
US: unstable 
S: stable 
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Based on the observations demonstrated in Table 5.28, 5.29 and 5.30, it is 
revealed that initially at T0 or day 0 time point all the tablets were stable and 
intact with a smooth surface. After 1-day it was identified that tablet of 
formulation 1 and 3 were became unstable at all stability conditions as the 
surface of the tablets started interacting with the moisture content and 
generating bubbled like rough surface. Under similar conditions tablet of 
formulation 2 and 4 were remained stable till day 8 at all stability condition. 
Whereas tablets at 40°C/75 % RH stability conditions were started interacting 
with moisture which states that they became unstable. The tablets of 
formulation 2 and 4 at 25°C/60% RH and 25°C/50% RH were remained stable 
after 8 days’ time point till 28 days stability studies. Slight decolouration of the 
formulation 4 tablets was observed at 25°C/60% RH after 18 days; this can be 
attributed to solid state degradation of actives in the formulation. Based on the 
images of the tablets of formulation 2 and 4 displayed minimum changes 
compared to formulation 1 and 3 at all the stability conditions. 
Thus, based on the stability studies, it is proved that formulation 4 displayed 
greater stability at 25°C/50% RH for one-month stability studies.  Thus, we have 
explored the application of cocrystallisation approach to enhance the 
hygroscopic stability of citric acid and further attenuate the cost of processing 
effervescent formulations. 
The other characteristic features of the newly developed formulation and 
original in-house formulation are shown in Table 5.31. 
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Table 5.31  Effervescent tablet studies 
Tablet 
formula 
number 
Thickne
ss 
in mm 
Average 
Hard
ness 
in KP 
pH 
after 
Disintegratio
n time in 
min. 
Complete 
solubilisatio
n in a min. 
Weight loss 
after 
solubilisatio
n 
1 3.658 1.15 5.83 0.32 0.38 0.14 
2 4.67 14.0 5.93 0.39 0.46 0.13 
3 2.796 1.17 6.58 2.07 5.35 0.04 
4 3.015 5.79 6.71 3.39 4.10 0.02 
 
The average size of the tablet was 20.59 mm in diameter. The pH of the distilled 
water was 6.89. All four formula tablets were checked for thickness (n=6) and 
the average thickness of tablets shown in Table 5.31. The hardness of each 
formula tablet was measured using 4M Hardness Tester (Schleuniger) (n=2) 
and the results are shown in Table 5.31. 
It was observed that the in-house developed formulation of effervescent tablet 
and the newly developed citric acid -L-cysteine monohydrate cocrystal based 
formulation tablets showed differences in their pH after disintegration. The time 
of disintegration, hardness, thickness, complete solubility time and weight loss 
were measured as 2 tablets (n=2) per formula and obtained results are noted in 
Table 5.31. As per the formulation, the amount of component varied, but still the 
obtained results are significant as compared with normal formulation. It proves 
the physicochemical properties have been changed due to the co-crystallisation 
process. 
5.4.3 Summary 
The obtained co-crystal of citric acid –L-cysteine-H2O monohydrate was 
successfully applied in the effervescent tablet formulations. Through this study, 
it was observed that the obtained cocrystal could be scalable to industrial level 
and has tremendous scope in the effervescent tablet productions. It improves 
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the stability of the product during processing as well as storage. It may be 
useful for the reduction in production and packaging costs of effervescent 
tablets. 
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Chapter 6 – Global Discussion and Conclusion 
6.1 Discussion 
The molecular interactions involved in the pharmaceutical preformulation limited 
to drug-PPB were studied through this current work. 
In this current study, high-performance liquid chromatography technique was 
utilised to carry out the structural properties governing drug-PPB. This is the 
first study to investigate and quantify the factors involved in the drug-PPB 
interaction by using the HPLC method. This method employs the stationary 
phases immobilised with plasma proteins (HSA and AGP). The drug-plasma 
protein binding was investigated for a set of compounds with a broad range of 
structural diversity. Based on the findings the LFER model was developed for it. 
The LFER model shows that for neutral compounds the structural parameters 
S, B and V are the prominent factors governing drug binding with HPLC 
stationary phases immobilised with HSA and AGP. Whereas E is less important, 
and A is not of statistical significance in both systems. For ionic compounds, 
electrostatic interactions play a major role in binding. The ionised acids, as 
anions, show very strong interaction with immobilised HSA stationary phase 
compared to immobilise AGP phase, whereas ionised basic compounds, as 
cations, interact with immobilised AGP phase stronger than the HSA phase. 
The structural diversity-based compounds showed different behaviours based 
on their molecular interactions like dipole-dipole moments, ionic behaviour at 
physiological pH conditions. Total hydrogen bond basicity and total hydrogen 
bond acidity are found to be essential to consider for the drug-PPB interaction. 
Drug displacement and strong or less affinity towards the plasma proteins play 
an important role in drug distribution, metabolism and concentration at the site 
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of action and excretion. Thus, the molecular behaviour in between drugs and 
plasma protein interaction was revealed by this study. 
Another area where such intermolecular interactions are widely observed is in 
the area of supramolecular complexes. The best example of it is the cocrystals. 
This study explores the molecular interactions involved in between two reacting 
molecules during the co-crystallisation process.  
Interestingly, in both cases, the interactions involve the hydrogen bonding, Van 
der Walls forces involvement and π-π interactions. In both cases, the 
interacting molecule has competent molecules. Like in drug-PPB interaction a 
strong affinity candidate and less affinity candidate compete to fulfil the binding 
site on the plasma proteins. It may be drug-protein, drug-drug or plasma protein 
with other serum components. However, in the co-crystallisation process, the 
coformer and solvent or hydrate molecule compete for binding with the APIs or 
the reacting molecule. 
This study reveals that amino acids are potent coformer molecules. These are 
biologically safe to a human being and thus necessary to be considered for 
coformer compared with other chemical coformers. As per FDA guidelines, 
amino acids are coming under the GRAS category and have excellent RDA 
(recommended dosage daily allowance) values.  
When amino acids entered the physiological condition, they become zwitterion 
and hence have more chances to develop better solubility and good 
permeability.  
The co-crystals synthesis of amino acids with various carboxylic acids, NSAIDs, 
and citric acid gives very good co-crystals. Single crystal obtaining process is, 
though, time-consuming and very much specific to solvent selection. However, 
this study has shown it is possible by using just water as a solvent that can 
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produce good single crystal of citric acid - L-cysteine monohydrate co-crystal. 
This hydrate formation is straight forward for the molecular interactions involving 
citric acid and amino acids and notably when there is water used as a solvent. 
The citric acid molecule has a greater affinity towards a water molecule. Hence 
once it encounters a water molecule, it changes physically and becomes a 
liquid deliquescent form. The used amino acid has good hydrogen bond donor 
capacity as well as accepting capacity.  
The single crystal X-ray diffraction analysis reveals that there is might be a 
possibility to develop anhydrous co-crystal from the same pair with using 
solvent system other than water. However, it requires time to selection of such 
system through range of polar and non-polar solvents in which both reacting 
molecules can be dissolved completely. The L-proline adipic acid and fumaric 
acid pairs have been already studied. However, succinic acid and L-proline 
showed very promising data of co-crystal formation. The Raman and FT-IR data 
revealed that there was no salt forming functional group peaks. It suggests that 
there is a formation of hydrogen bonds means co-crystals between L-proline 
and succinic acid. 
The L-proline and NSAIDs co-crystal screening also showed promising data. 
The data suggest that there may be the formation of co-crystals in between L-
proline and aspirin, ibuprofen, ketoprofen, flurbiprofen. However, L-proline -
ibuprofen co-crystal work was published by other researchers (Othman et al. 
from Malaysia) during this study. 
The obtained single crystal of L-cysteine and citric acid co-crystal monohydrate 
proves to be non-hygroscopic. It can tolerate the moisture absorption up to 28 
days (672 hrs at 25°C/60% RH). It has shown good improvement in the 
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effervescent tablet manufacturing process. It can be helpful in reducing the 
production cost. 
6.2 Conclusion 
Structural properties governing drug-plasma protein binding study was 
successfully carried out by using high-performance liquid chromatography. An 
HPLC method was utilised to quantify the factors involved in the drug-PPB 
binding interaction. The ionic behaviour which is responsible for the drug-PPB 
was quantified for the first time through this current study. LFER method has 
been used to develop a statistical equation for quantifying the drug-PPB 
interaction studies. The molecular interaction involved in the pharmaceutical 
preformulation limited to drug-PPB was studied successfully. 
Amino acid and citric acid co-crystals were developed, and one single crystal 
was successfully obtained through green synthesis process by using water as a 
solvent. Amino acids can be used as an alternative source for the chemical 
coformer which is more promising than the chemical coformer. The molecular 
interactions involved in preformulation and supramolecular complexes limited to 
the co-crystal study were explored and understood 
6.3 Recommended Future Work 
Based on the findings of this current study the following areas could be 
developed as future work: - 
1) LFER implementation in drug-drug interaction studies and quantification 
of commonly used drugs displacement studies. 
2) HPLC based techniques development for various interactions in 
biopharmaceutical applications for in-vivo and in-vitro analysis studies. 
3) To develop the amino acids co-crystals with BCS class II and IV drugs to 
draw them into mainstream drug development field. 
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4) To study the amino acid and NSAIDs cocrystals to improve their 
characteristic physicochemical properties. 
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Appendix-1 
Drug-plasma protein binding study: 
Preparation of stock solutions for HPLC analysis 
Each compound/drug molecule weighed adequately to get 10-2M (0.01M) stock 
solution in MeOH/ACN (Total stock 20ml) 
 For better UV detection and retention time prepare a solution from further stock 
dilution to get 0.001-0.00001M in Methanol. 
Column  
HSA 100.4       CHIRAL-HSA 4mm ID 100 x 4 mm 
Installation 
The column is filled with 10% propanol in distilled water. (Storage condition) 
Wash the column with distilled water 
Start the low flow rate and increase to 0.5 ml /min, maintain for 2min. 
Increase the flow rate to 0.8- 0.9 ml/min and continue the washing for 10min. 
Equilibrate the column with the mobile phase to be used and stable baseline to 
appear. 
Recommended flow rate with a 4.0 mm ID column is 0.8-0.9 ml/min. 
Mobile Phases 
Buffer 
Sodium or potassium phosphate buffers 
Ammonium or sodium acetate buffers 
Formate or citrate buffers 
Concentrations 
0.01– 0.1M 
Normally 10-20 mM (0.01-0.02M)  
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pH: 
Can be used in the range of 5-7. 
However, if used at pH>7 or <5 for a longer period, may decrease the column 
lifetime 
Organic modifier 
Recommended 1-Propanol,2-Propanol, methanol, ethanol, acetonitrile <10%  
Temp 
R.T. 
Samples injection volume 10-20microlitre 
Potassium phosphate buffer 
Compound Mol.wt    1M/1000ml           0.1M/1000ml               0.01M/1000ml 
K2HPO4 174.18 174.18gms 17.418gms 1.7418 gms 
KH2PO4 136.09 136.09gms 13.609 gms 1.3609 gms 
     .        
Add slowly second compound required molar solution into first until pH 
becomes7.0. 
First K2HPO4 buffer pH around 9.13. 
Second KH2PO4 buffer pH around 4.60. 
Calculations 
SP= c+eE+sS+aA+bB+vV 
SP= c+ eE+ sS + aA + bB + vV + j+J+ + j- J- 
Average of E = Em = [ E1+E2+E3+E4+……….E60]/ 60 
Similarly, S,A,B,V calculated. For 20% 15% and 25% IPA 
Relative contribution = %E = eE/ (eE+sS+aA+bB+vV) x 100 
Similarly, for % S, A,B and V calculated 
Using Minitab16 calculate the e.s.a.b.v values through MLR. 
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Regression Analysis: log kAGP versus E, S, A, B, V, J+, J-  
Method 
Rows unused 7 
Analysis of Variance 
Source      DF   Seq SS Contribution   Adj SS   Adj MS  F-Value  P-Value 
Regression   7  10.1263        79.65%  10.1263  1.44661    27.96    0.000 
  E          1   1.9050        14.98%   1.0071  1.00714    19.47    0.000 
  S          1   1.1069         8.71%   1.3589  1.35888    26.27    0.000 
  A          1   0.2328         1.83%   0.2399  0.23990     4.64    0.036 
  B          1   0.4326         3.40%   4.1650  4.16500    80.51    0.000 
  V          1   0.5819         4.58%   5.2455  5.24546   101.39    0.000 
  J+         1   0.2586         2.03%   0.0206  0.02056     0.40    0.531 
  J-         1   5.6086        44.12%   5.6086  5.60863   108.41    0.000 
Error       50   2.5867        20.35%   2.5867  0.05173 
Total       57  12.7130       100.00% 
Model Summary 
       S    R-sq    PRESS  R-sq(pred) 
0.227451  79.65%     76.80%  4.13625      67.46% 
Coefficients 
Term         Coef  SE Coef        95% CI        T-Value  P-Value    VIF 
Constant   -0.756    0.111  ( -0.979,  -0.533)    -6.81    0.000 
E          0.4274   0.0969  ( 0.2328,  0.6219)     4.41    0.000   2.33 
S         -0.3539   0.0691  (-0.4927, -0.2152)    -5.13    0.000  19.31 
A         -0.1566   0.0727  (-0.3026, -0.0105)    -2.15    0.036   6.58 
B          -1.254    0.140  ( -1.534,  -0.973)    -8.97    0.000  22.80 
V           1.279    0.127  (  1.024,   1.534)    10.07    0.000   9.77 
J+        -0.0511   0.0811  (-0.2139,  0.1117)    -0.63    0.531  10.40 
J-          1.562    0.150  (  1.261,   1.864)    10.41    0.000  13.05 
Regression Equation 
log kAGP = -0.756 + 0.4274 E - 0.3539 S - 0.1566 A - 1.254 B + 1.279 V - 0.0511 J+ + 1.562 J- 
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Amino acids cocrystals: 
Total experiment and characterisation studies carried out. 
Serial 
number 
Name of 
compound 
PXRD DSC TGA Raman FT-
IR 
DVS 
1 L-proline Yes Yes Yes Yes Yes Yes 
2 Adipic acid Yes Yes Yes Yes Yes Yes 
3 Fumaric acid Yes Yes Yes Yes Yes Yes 
4 Succinic acid Yes Yes Yes Yes Yes Yes 
5 L-proline-
Adipic acid cc 
Yes Yes Yes Yes Yes Yes 
6 L-proline-
Fumaric acid 
cc 
Yes Yes Yes Yes Yes Yes 
7 L-proline-
Succinic acid 
cc 
Yes Yes Yes Yes Yes Yes 
8 L-leucine Yes Yes Yes Yes Yes Yes 
9 L-isoleucine Yes Yes Yes Yes Yes Yes 
10 L-serine Yes Yes Yes Yes Yes Yes 
11 L-methionine Yes Yes Yes Yes Yes Yes 
12 L-cysteine Yes Yes Yes Yes Yes Yes 
13 Citric acid Yes Yes Yes Yes Yes Yes 
14 L-leucine-
Citric acid cc 
Yes Yes Yes Yes Yes Yes 
15 L-isoleucine – 
Citric acid cc 
Yes Yes Yes Yes Yes Yes 
16 L-serine-Citric 
acid cc 
Yes Yes Yes Yes Yes Yes 
17 L-methionine-
Citric acid cc 
Yes Yes Yes Yes Yes Yes 
18 L-cysteine- 
Citric acid cc 
Yes Yes Yes Yes Yes Yes 
19 Physical 
mixtures (1:1) 
Yes Yes Yes Yes Yes Yes 
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Amino Acids and reported cocrystals 
Name Short code structure Reported co-crystals 
non-polar, aliphatic residues  
L-Glycine Gly G 
 
Yes. L-gly-glutaric 
acid, L-gly-tartaric 
acid,L-gly-phthalic 
acid, L-gly-urea. 
L-Alanine Ala A 
 
L-ala-val-ala.H2O, L-
ala-mandelic acid, 
L-Valine Val V 
 
L-val-D-2 amino 
butanoic acid, L-val-
fumaric acid, D-val-L-
leu 
L-Leucine Leu L 
 
L-leu-D-val 
L-Isoleucine Ile I 
 
D-val-L-isoleucine 
L-proline Pro P 
 
L-pro-fumaric acid 
aromatic residues 
L-Phenylalanine Phe F 
 
No 
L-Tyrosine Tyr Y 
 
No 
L-Tryptophan Trp W 
 
No 
polar, non-charged residues 
L-Serine Ser S 
 
L-ser/pyridine-
2,4dicarboxilic acid 
L-Threonine Thr T 
 
L-thr/L-all-thr 
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L-Cysteine Cys C 
 
1) L-cys/S 
mandelic acid/R 
mandelic acid 
 
L-Methionine Met M 
 
No 
L-Asparagine Asn N 
 
2) L-asn / L tartaric 
acid 
 
L-Glutamine Gln Q 
 
No 
positively charged residues 
L-Lysine Lys K 
 
No 
L-Arginine Arg R 
 
No 
L-Histidine His H 
 
No 
negatively charged residues 
L-Aspartate Asp D 
 
No 
L-Glutamate Glu E 
 
No 
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A single crystal of citric acid - L-cysteine monohydrate co-crystal pattern 
 
Figure A 1 Crystal habit of single crystal citric acid-L-cysteine-H2O 
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Figure A2 Crystal pattern – the plate-like habit of a single crystal of citric 
acid-L-cysteine-H2O cocrystal hydrate. 
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Figure A3 L-proline-succinic acid cocrystal Raman spectroscopy  analysis  
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Figure A4 Raman spectroscopic  analysis of  L-leucine-citric acid  
cocrystal and starting material. 
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Figure A 5 L-isoleucine-citric acid cocrystal and their original material 
Raman spectroscopy. 
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Figure A 6 L-serine-citric acid and their starting material Raman 
spectroscopy. 
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Figure A 7 L-methionine-citric acid cocrystal and their starting material 
Raman spectroscopy. 
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Figure A 8 L-cysteine-citric acid cocrystal and their starting material 
Raman spectroscopy. 
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Figure A 9 L-leucine-citric acid cocrystal and their starting material FT-IR 
spectrum. 
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Figure A 10 L-isoleucine-citric acid cocrystal and their starting material 
FT-IR spectrum. 
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Figure A 11 L-serine-citric acid cocrystal and their starting material FT-IR 
spectra. 
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Figure A 12 L-methionine-citric acid cocrystal and their starting material 
FT-IR spectra. 
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Figure A 13 L-cysteine-citric acid cocrystal and their starting material FT-
IRspectra.
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The high-performance liquid chromatography (HPLC) method employing stationary phases immobilized 
with plasma proteins was used for this study to investigate the structural properties governing drug- 
plasma protein binding. A set of 65 compounds with a broad range of structural diversity (in terms of 
volume, hydrogen-bonding, polarity and electrostatic force) were selected for this purpose. The Abraham 
linear free energy relationship (LFER) analyses of the retention factors on the immobilized HSA (human 
serum albumin) and AGP (a1-acid glycoprotein) stationary phases showed that McGowan’s characteristic 
molecular volume (V), dipolarity/polarizability (S) and hydrogen bond basicity (B) are the three signiﬁcant 
molecular descriptors of solutes determining the interaction with immobilized plasma proteins, whereas 
excess molar refraction (E) is less important and hydrogen bond acidity (A) is not of statistical signiﬁcance 
in both systems, for electrically neutral compounds. It was shown that ionised acids, as carboxylate 
anions, bind very strongly to the immobilized HSA stationary phase and that ionised bases, as cations 
bind strongly to the AGP stationary phase. This is the ﬁrst time that the effect of ionised species on plasma 
protein binding has been determined quantitatively; the increased binding of acids to HSA is due almost 
entirely to acids in their ionised form. 
© 2017 Elsevier B.V. All rights reserved. 
 
 
1. Introduction 
 
The binding of drugs to plasma proteins is an important process 
that determines the activity and pharmacokinetics of many drugs 
in the body. After being distributed around the circulating system, 
drugs bind to plasma proteins in varying degrees. In general, such 
binding is reversible, and an equilibrium exists between bound and 
free molecular forms. In most cases, only the free drug molecules 
are able to cross membrane barriers, be distributed to tissues and 
then exert therapeutic effects [1,2]. Drug-plasma protein binding 
acts as a reservoir for free drug concentration and prolongs the 
duration of drug action. Therefore drug-plasma protein binding is 
considered as an important property and needs to be characterized 
in the early stage of drug discovery [3]. 
In  plasma,  two  major  proteins,  human  serum  albumin (HSA) 
and a1-acid glycoprotein (AGP) are present in relatively high quan- 
tities. They are able to bind a variety of drugs with considerable 
can bind acidic drugs with high association constants. AGP is an 
acidic protein with a lower concentration (0.9–2.2 10−5 mol/L). It 
exhibits a preference for binding basic and neutral drugs. Lipopro- 
teins which are macromolecular complexes of lipid and proteins 
also play a role to a lesser degree [5]. 
There are different techniques to determine drug-plasma pro- 
tein binding in vitro. Among these techniques, equilibrium dialysis, 
ultra-ﬁltration and ultra-centrifugation have been most widely 
used. However, these methods show a number of limitations such 
as a very low throughput and poor reproducibility [6]. In compari- 
son to these conventional methods, the HPLC method that employs 
stationary phases immobilized with plasma proteins appears an 
interesting approach because of the speed of analysis and automa- 
tion capability [7,8]. In this method, drugs with high afﬁnities 
interact strongly with the immobilized protein and are eluted later 
than drugs with no or less afﬁnities. The afﬁnity is expressed by the 
retention factor k, which is calculated through Eq. (1) 
afﬁnity [4]. It is found that HSA with the highest concentration (5–
7.5 × 10−4 mol/L) in plasma has two major binding sites and 
k = (tr − t0)/t0 (1) 
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where tr and t0 are the retention times of the solute and of an 
unretained compound, respectively. 
A number of studies have been carried out to investigate drug- 
plasma protein interaction by using special classes of drugs [9–13]. 
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